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ABSTRACT 
Introduction and aims: The prevalence of the metabolic syndrome (MetS) is increasing, 
both globally and in South Africa.  Albeit so, limited data have been published in the South 
African context. One of the factors that appear to influence the prevalence of the MetS is 
menopausal status, with both the MetS, and menopausal status influencing bone mineral 
density (BMD); however, the reported results are inconsistent.  Therefore, the aim of this 
study was to determine the prevalence of the metabolic syndrome, investigating bone health 
as well as the interactions between the MetS, menopausal status and bone health, in a farm 
working female population in the Western Cape. 
Methods:  A total of n=80 females were recruited and classified with the MetS, using the 
International Diabetes Federations’ definition.  The data collected included basic 
anthropometric measurements, blood pressure, BMD, and several questionnaires to obtain 
information regarding physical activity, demographic information, menstrual-, diet- and family 
health- history.  The blood parameters that were measured included alkaline phosphatase 
(ALP), vitamin D, parathyroid hormone (PTH), oestradiol (E2), fasting insulin (FI), fasting 
glucose (FG) and a lipid profile.   
Results: A relatively high prevalence of the MetS (55.0%) was reported in the current study.  
When investigating the separate MetS risk factors, most of the study participants had three 
risk factors (32.5%), with increased BP being the most prevalent MetS risk factor (72.5%).  
Factors that differed between MetS and Non-MetS sub-groups (according to menopausal 
status and age) included waist circumference (WC), high-density lipoprotein-cholesterol 
(HDL-c), systolic blood pressure (SBP) and diastolic blood pressure (DBP).  Significant 
associations between body mass (BM) and E2, and body mass index (BMI) and E2, were 
limited to the PreM (20-39 years) age group with the MetS (r=0.58, p=0.03, and r=0.60, 
p=0.02).  A total of 78.8% of the study participant had normal BMD.  When correlating BM 
and speed of sound (SOS), significant associations were limited to the PreM (≥40 years) 
group (MetS: r=0.56, p=0.04, Non-MetS: r=0.76, p=0.00), and significant associations 
between BMI and SOS were noted in both PreM groups (MetS PreM 20-39 years: r=0.53, 
p=0.05, Non-MetS PreM ≥40 years: r=0.73, p=0.00).  The significant correlations between FI 
and ALP (r=0.72, p=0.00), FG and ALP (r=0.89, p=0.00), and triglycerides with ALP (r=0.82, 
p=0.00) were limited to the PreM (≥40 years) group.  
Conclusion:  The prevalence of the MetS was higher than that reported by previous South 
African studies.  Irrespective of metabolic and menopausal status, most of the participants of 
the current study population had normal BMD.   
Key words: Metabolic syndrome, bone mineral density, menopause 
Stellenbosch University  https://scholar.sun.ac.za
 
 
xxii 
 
OPSOMMING 
Inleiding en doelwit:  Die voorkoms van die metaboliese sindroom (MetS) is beide globaal 
en in Suid Afrika toenemend.  Daarbenewens is daar beperkte data in die Suid-Afrikaanse 
konteks.  Een van die faktore wat die voorkoms van die MetS beïnvloed is die menopousale 
status, waar beide die MetS en menopousale status beenmineraaldigtheid (BMD) beïnvloed.  
Die resultate wat hier rapporteer word varieer egter.  Die doelstelling van hierdie studie was 
om die voorkoms van die MetS in ‘n plaaswerker vroue populasie in die Wes-Kaap te 
ondersoek, hulle been-gesondheid te bepaal asook te ondersoek of daar korrelasies is 
tussen die metabolise sindroom, menopousale status en been-gesondheid te korreleer. 
Metodes:  ‘n Totaal van n=80 vroue is gewerf en geklassifiseer deur gebruik te maak van 
die Internasionale Diabetes Federasie se kriteria vir die MetS.  Die data wat versamel was 
sluit onder andere in basiese antropometriese metings, bloeddruk, BMD, asook verskeie 
vraelyste om inligting oor fisiese aktiwiteit, demografiese inligting, menstruele-, dieet- en 
familie gesondheidgeskiedenis te versamel. Die bloedparameters wat bepaal was sluit in 
alkaliese fosfatase (ALP), vitamien D, paratiroïed hormoon (PTH), estradiol (E2), vastende 
insulien (VI), vastende glukose (FG), en ‘n lipiedprofiel.   
Resultate: ‘n Relatiewe hoë voorkoms van die MetS (55.0%) is in hierdie studie 
waargeneem.  Indien die individuele MetS risiko faktore in ag geneem word, het die 
meerderheid deelnemers drie risiko faktore gehad (32.5%), met verhoogde bloeddruk wat 
die mees algemene MetS risiko faktor (72.5%) was.  Sommige van die faktore wat tussen 
die MetS en Nie-MetS verskil het (volgens menopousale status en ouderdom) sluit in; 
middel-omtrek (MO), hoë digtheidslipoproteïen (HDL-c), sistoliese bloeddruk (SBD) en 
diastoliese bloeddruk (DBD).  Betekenisvolle verwantskappe is waargeneem tussen 
liggaamsmassa indeks (LMI) en E2, LMI en E2 is beperk tot die PreM (20-39 jaar) 
ouderdoms- en die MetS groepe (r=0.58, p=0.03 en r=0.60, p=0.02).  ‘n Totaal van 78.8% 
van die studie populasie het normale BMD gehad.  Wanneer liggaamsmassa (LM) en die 
spoed van klank (SvK) teenoor mekaar gekorreleer is, is betekenisvolle verwantskappe 
beperk gewees tot die PreM (≥40 jaar) groep (MetS: r=0.56, p=0.04, Nie-MetS: r=0.76, 
p=0.00), en betekenisvolle verwantskappe tussen LMI en SvK in beide PreM groepe (MetS 
PreM 20-39 jaar: r=0.53, p=0.05, Nie-MetS PreM ≥40 jaar: r=0.73, p=0.00).  Die 
betekenisvolle korrelasies tussen VI en ALP (r=0.72, p=0.00), FG en ALP (r=0.89, p=0.00), 
en trigliseriede met ALP (r=0.82, p=0.00) is beperk tot die PreM (≥40 jaar) groep. 
Gevolgtrekking:  Die voorkoms van die MetS was hoër as voorheen gerapporteerde Suid 
Afrikaanse studies.  Ongeag die metaboliese en menopousale status het meeste 
deelnemers normale BMD gehad.  
Sleutelwoorde: Metaboliese sindroom, beenmineraaldightheid, menopouse 
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Chapter 1                                                      Literature Review
 
1.1  Introduction 
The World Bank classified South Africa as a developing and upper middle-income country 
(World Bank, 2016).  South Africa is also part of a global population migration trend of 
epidemiological transition, known as urbanisation, describing people that migrate from rural 
to urban regions (Vorster et al., 2011; George et al., 2013).  Accompanying this transition, 
distinct and measurable changes in dietary intake habits, changes in levels of physical 
activity, as well as socio-psychological behavioural patterns also take place (Steyn et al., 
2012).  Collectively, these changes impact adversely on public health, resulting in the 
increased risk of developing chronic non-communicable diseases of lifestyle (NCDs) 
including type 2 diabetes mellitus (T2DM), obesity and hypertension, and the development of 
the metabolic syndrome (MetS) (Gill et al., 2009; Vorster et al., 2011; Erasmus et al., 2012; 
Steyn et al., 2012; Van Zyl et al., 2012).  
Obesity, which is considered one of the most important MetS risk factors, was originally 
believed to exert positive effects on bone health (from here on referred to as BMD) by 
protecting against osteoporosis-related fractures (Compston, 2013).  Several conflicting 
evidence exists where obesity actually exerts a negative effect on bone mineral density 
(BMD), warranting further investigation (George et al., 2013; Zillikens et al., 2010).  
Additionally, opposing results have also been reported on the effect of the individual MetS 
risk factors, as well as the MetS as a whole entity on BMD.  Here, findings suggest obesity to 
be protective against bone loss, whereas the low-grade inflammation that is associated with 
the MetS, promotes bone loss (Zillikens et al., 2010; Jeon et al., 2011; Cohen et al., 2013; 
Alissa et al., 2014; Nóbrega da Silva et al., 2014; Li et al., 2015).  
The natural transition from pre-menopausal (PreM) to post-menopausal (PostM) status is 
also believed to be related to an increased prevalence of the MetS in women (Ebrahimpour 
et al. 2010).  Evidence further suggests that menopausal status, or oestrogen deficiency, 
modifies BMD, with a decrease in BMD in PostM women (Alissa et al., 2014; Bączyk et al., 
2012; Jeon et al., 2011; You et al., 2014).  The abovementioned findings might therefore 
suggest a possible association between the MetS, menopausal status and BMD in women.  
However, limited South African studies report on the association between the MetS, 
menopausal status and bone health, which necessitates further investigation (Awotedu et al., 
2010; Hoebel & Malan, 2011; Kengne et al., 2012; Motala et al., 2011; Okafor, 2012; Peer et 
al., 2014). 
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1.2 The metabolic syndrome 
The MetS is defined as a cluster of cardio-metabolic risk factors which includes elevated 
blood glucose levels, dyslipidaemia, high blood pressure (BP) and central obesity, which in 
turn increases the risk of developing cardiovascular diseases (CVD), and lifestyle-associated 
diseases such as T2DM (Miranda et al., 2005; Hossein-Nezhad et al., 2009; Huang, 2009; 
Kim & Halter, 2014; Alissa et al., 2014; International Diabetes Federation, 2006).  
Furthermore, the cut-off values of the individual MetS-associated risk factors differ 
depending on the definition used for the diagnosis of the MetS.  
1.2.1 Definitions and classifications of the metabolic syndrome 
Several criteria and definitions aim to characterise individuals with the MetS; nevertheless, 
only the most widely used are summarised in Table 1.1.  The World Health Organization 
(WHO) describes the MetS as the presence of glucose intolerance, impaired glucose 
tolerance (IGT) or diabetes and/or insulin resistance (IR), together with two or more of the 
listed factors in Table 1.1.; whereas the National Cholesterol Education Program Adult 
Treatment Panel III (NCEP-ATP III) definition involves any three of the WHO risk factors 
(IDF, 2006).  According to the International Diabetes Federation’s (IDF) definition, an 
individual must present with central obesity (increased waist circumference (WC)), and at 
least two of the following risk factors: (i) raised triglycerides (TG), (ii) reduced high-density 
lipoprotein cholesterol (HDL-c), (iii) raised BP, or (iv) raised fasting plasma glucose (FPG).  
Since central obesity is the fundamental risk factor according to the IDF, gender and ethnic 
based cut-off values were subsequently compiled (Table 1.2).  However, since no current 
cut-off values are available for WC measurements for sub-Saharan African populations, the 
IDF recommended to use WC measures of Europeans until specific data are made available 
for these populations (Alberti et al., 2005; IDF, 2006; Akintunde et al., 2011; Ramli et al., 
2013).   
In an effort to link WC to the risk of developing T2DM and CVDs, the Joint Interim Statement 
(JIS) combined data from the IDF Task Force on Epidemiology and Prevention; National 
Heart, Lung and Blood Institute, American Heart Association, World Heart Federation; 
International Atherosclerosis Society; and International Association for the Study of Obesity.  
It was subsequently decided to remove abdominal obesity as the key risk factor from its 
definition, and  to include at least three risk factors for MetS classification, in order to 
possibly identify more MetS cases compared to all other definitions used (IDF, 2006; Alberti 
et al., 2009).
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Table 1.1: Different classification criteria for the MetS. 
Classification method World Health Organization 
(WHO) (1999) 
European Group on 
Insulin Resistance (EGIR) 
(1999) 
National Cholesterol 
Education Program’s 
(Adult Treatment Panel III, 
ATP III) (2002) 
International Diabetes 
Federation (IDF) (2006) 
Joint Interim 
Statement (JIS) (2009) 
Risk factors 
Abdominal obesity/  
Waist circumference 
BMI >30 kg/m2 and/or Males: ≥94 cm Males: >102 cm 
Ethnic-specific (Table 1.2) 
Males: ≥90 cm 
W:H: Males: >0.90   
W:H: Females: >0.85 Females: ≥80 cm Females: >88 cm Females: ≥80 cm 
Elevated TG ≥1.7 mmol/L >2.0 mmol/L ≥1.7 mmol/L 
≥1.7 mmol/L 
or specific treatment for lipid 
abnormality 
≥1.7 mmol/L or on 
treatment for elevated 
TG 
HDL-cholesterol 
(Reduced) 
Males: <0.9 mmol/L 
Males & females: <1.01 
mmol/L or treatment 
Males: <1.04 mmol/L 
Males: <1.03 mmol/L; 
or specific treatment for lipid 
abnormality 
Males: <1.0 mmol/L or 
on treatment for 
elevated HDL-c 
Females: <1.0 mmol/L Females: <1.29 mmol/L 
Females: <1.29 mmol/L 
or specific treatment for lipid 
abnormality 
Females: <1.3 mmol/L 
or on treatment for 
elevated HDL-c 
Blood pressure 
(Raised) 
≥140/90 mmHg ≥140/90 mmHg or treatment ≥130/85 mmHg 
SBP ≥130 mmHg 
or DBP ≥85 mmHg 
or treatment of previously 
diagnosed hypertension 
SBP: ≥130/85 
and/or 
DBP ≥85 mmHg 
or treatment of 
previously diagnosed 
hypertension 
Raised FPG  ≥6.1 mmol/L (non-diabetic) ≥5.6 mmol/L 
FPG ≥5.6 mmol/L, 
or previously diagnosed with 
T2DM 
If >5.6 mmol/L, oral glucose 
tolerance test is strongly 
recommended but is not 
necessary to define 
presence of the syndrome 
≥5.6 mmol/L or on 
treatment for elevated 
glucose 
Micro-albuminuria NA NA 
Urinary albumin excretion 
rate ≥20 g/min or albumin: 
creatinine ratio ≥30 mg/g 
NA NA 
(Alberti et al., 2005; Ramli et al., 2013). BMI: body mass index; DBP: diastolic blood pressure; FPG: fasting plasma glucose; NA: not applicable; SBP: systolic blood pressure; 
TG: triglycerides; W:H: waist-to-hip ratio. 
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Table 1.2: Ethnic-specific waist circumference cut-off values.  
(IDF, 2006). 
Additionally, several studies found that the IDF criteria identifies more individuals, especially 
women, with the MetS compared to the NCEP-ATP III definition (Kelliny et al., 2008; Kengne 
et al., 2012; Tran et al., 2011).  One particular study compared three different definitions 
(WHO, NCEP-ATP III and IDF) and reported that the higher prevalence according to the IDF 
definition was likely to be attributed to the low cut-off values of WC (Akintunde et al., 2011) 
(Table 1.1).  A South African and Malaysian study compared the MetS prevalence using 
three different definitions.  Here, they reported that the JIS definition (SA - 26.5%, Malay - 
43.3%) identified more individuals, followed by the IDF (SA - 23.3%, Malay – 37.4%), and 
then the NCEP-ATP III definition (SA - 18.5%, Malay - 26.5%) (Motala et al., 2011; Ramli et 
al., 2013).  Hoebel & Malan (2011) also found that the JIS definition identified more 
individuals with the MetS, whereas the IDF definition identified the least number of 
individuals when compared to the NCEP-ATP III definition, possibly due to the exclusion of 
abdominal obesity in the JIS definition. 
The TG values are similar in all definitions except the European Group on Insulin 
Resistance’ (EGIR) definition, which proposed a higher cut-off value of >2.0 mmol/L, 
compared to >1.7 mmol/L used by other definitions (Bloomgarden, 2004; Alberti et al., 2005; 
Huang, 2009).  The HDL-c cut-off values are similar across the IDF, NCEP-ATP III and JIS 
definitions (<1.3 mmol/L); whereas the WHO and EGIR definitions recommend a lower 
concentration (<1.0 mmol/L).  Likewise, the BP cut-off values are also similar across the IDF, 
NCEP-ATP III and JIS definitions (BP: ≥130, and ≥85 mmHg), whereas a higher cut-off value 
Country/Ethnic group Gender Waist circumference 
Europeans 
Male ≥94 cm 
Female ≥80 cm 
United States of America (ATP III)  
Male ≥102 cm 
Female ≥88 cm 
South Asians 
Based on a Chinese, Malay and Asian-Indian population 
Male ≥90 cm 
Female ≥80 cm 
Chinese 
Male ≥90 cm 
Female ≥80 cm 
Japanese 
Male ≥90 cm 
Female ≥80 cm 
Ethnic South and Central Americans 
Use South Asian recommendations until 
more specific data are available 
Sub-Saharan Africans 
Use European data until more specific 
data are available 
Eastern Mediterranean and Middle East (Arab) populations 
Use European data until more specific 
data are available 
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is used for BP according to the WHO and EGIR definitions (BP: ≥140 and ≥90 mmHg).  
Lastly, the FPG levels (≥5.6 mmol/L) are similar in the IDF and JIS definitions; however, the 
EGIR definition uses a higher cut-off value (≥6.1 mmol/L) (Alberti et al., 2005; Huang, 2009).   
Globally, many studies report on the prevalence of the MetS using different definitions, 
mainly because of the population diversity and differences in the definition criteria, as 
explained above.   
1.2.2 Incidence and prevalence of the metabolic syndrome 
The MetS is one of the most widespread chronic diseases in the world, and the fourth or fifth 
leading cause of death in the developed world (IDF, 2006).  When comparing the prevalence 
of the MetS in different world regions, an American study reported a total population 
prevalence of 34.5%, with a prevalence of 38.1% in the female participants (IDF definition) 
(Ford, 2005).  In an Australian and Danish population, a prevalence of 31.7% and 21.0% 
were reported respectively, when using the IDF definition (Cameron et al., 2007; Jeppesen 
et al., 2007).   
During 2010, an Indian study (using the IDF criteria) reported a prevalence of 40.0% (Table 
1.3) (Ravikiran et al., 2010).  When the JIS definition is used, a Nigerian population 
displayed an overall MetS prevalence of 86.0% (87.0% in females) (Ogbera, 2010), whilst a 
more recent Nigerian study reported an overall prevalence of 34.0% (62.0% in females), 
when the IDF definition was used (Iloh et al., 2014).  Other studies are summarised in Table 
1.3.  
When investigating differences in ethnic groups, Hoebel & Malan (2011) reported that the 
MetS prevalence was much higher in non-Caucasians vs. Caucasians, and Peer et al. 
(2014) reported a 74.3% prevalence rate in a Black population in Cape Town, with 
prevalence 43.5% in females.  Furthermore, when focussing on menopausal status, Goyal et 
al. (2013) reported a significant increase in the prevalence of the MetS from PreM (10.0%) to 
peri-Menopausal (PeriM) (41.7%), to PostM women (46.0%) (p<0.001 in both cases).  In 
agreement, other studies also reported an increased prevalence of the MetS in PostM 
women in comparison to PreM women (Maharlouei et al., 2013; Jesmin et al., 2013). 
From these studies, it is evident that differences in prevalence rates exist in different world 
regions, which could possibly be attributed to ethnicity, age, menopausal status and lifestyle 
differences.  Additionally, the use of different definitions of the MetS might also result in 
differences in prevalence reported (Cameron et al., 2004).  
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Table 1.3: Comparison of studies focussing on the prevalence of the MetS.  
Authors Country Definition Number of participants Conclusions 
Hoebel & 
Malan, (2011) 
South Africa 
(North West 
Province) 
JIS (2009), NCEP-
ATP III (2001), IDF 
(2005), 
Total: n=409 
Africans: males: n=101: females: n=99 
Caucasians: males: n=101; females: n=108 
The JIS definition included more people with the MetS, whereas the IDF 
has the lowest prevalence of the MetS. More Africans presented with the 
MetS than their Caucasian counterparts. 
Motala et al. 
(2011) 
South Africa 
JIS (2009), Modified 
NCEP-ATP III 
(2001), IDF (2005), 
n=947 participants 
 
n=758 females 
MetS: 22.1% overall, higher in females (25.0%) than males (10.5%). 
The optimal WC cut-off point to predict the presence of at least two other 
components of the MetS was 86 cm for males and 92 cm for females. 
MetS prevalence higher with the JIS definition (26.5%) 
than with the IDF (~23.3%), or the modified ATPIII (18.5%) criteria. 
Peer et al. 
(2014) 
South Africa JIS (2009) 
n=1099 participants: 
n=392 males, n=707 females 
Prevalence: significantly higher in females (43.5%) vs 
males (16.5%) (in a Black South African population group). 
Kengne et al. 
(2012) 
Sub-Saharan 
Africa 
IDF (2005), 
NCEP-ATP III 
(2001) 
n=308 participants with T2D: 
n=157 males, n=151 females 
Higher prevalence with IDF definition (71.7%) than NCEP-ATP III 
definition (60.4%). Significantly higher rates of the MetS in females than 
males (independent of definition). 
Ogbera, 2010 
Nigeria 
(Africa) 
JIS (2009) 
n= 973 patients with diabetes mellitus: 
n= 703 males, n=260  females 
MetS (n=834):  prevalence rate of 86.0%. 
Females with the MetS 87.0%; males with the MetS 83.0%. 
Iloh et al. 
(2014) 
Nigeria 
(Africa) 
IDF (2005) 
Total: n=365 
Males: n=187 
Females: n=178 
MetS present: n=124 (34.0%) 
MetS: males n=47 (37.9%); females n=77 (62.1%) 
Kelliny et al. 
(2008) 
Seychelles 
(Africa) 
NCEP-ATP (2005), 
WHO (1998), IDF 
(2005) 
n=1255 participants 
According to the ATP, WHO and IDF definitions, the prevalence of the 
MetS was, respectively, 
24.0%, 25.0%, 25.1% in males 
32.2%, 24.6%, 35.4% in females. 
Alkerwi et al. 
(2011) 
Luxembourg 
(Europe) 
JIS (2009), IDF n=1349 participants 
JIS definition diagnosed 28.0% of participants with the MetS and there 
was a high agreement between the definitions. 
Riediger & 
Clara, 2011 
Canada 
NCEP-ATP III 
(2001) 
n=1800 participants 
Overall MetS prevalence: 19.1% (±1.7) 
Males: 17.8% (±2.0) 
Females: 20.5% (±2.1). 
Lao et al. 
(2012) 
China IDF n= 6468 residents 
The prevalence of the MetS in this population was 7.3% 
Males: 5.3% 
Females: 9.0%. 
Ramli et al. 
(2013) 
Malaysia 
NCEP-ATP III 
(2005), 
IDF (2005), 
JIS (2009) 
Total: n= 8836 subjects 
n=3766 males; n=5070 females 
JIS had the highest overall prevalence (43.4%); IDF (37.4%); NCEP-ATP 
III (26.5%). 
Female participants were more likely to have the MetS compared to 
males according to the NCEP-ATP III and IDF definitions, but not with the 
JIS definition. 
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1.2.3 Pathophysiology of the metabolic syndrome 
All the individual MetS risk factors exert different, as well as associated pathophysiological 
effects in the different physiological systems.  The mechanisms and effects of the individual 
risk factors will be described subsequently. 
1.2.3.1 Obesity 
Adipose tissue (AT) consists of adipocytes, stromal pre-adipocytes, immune cells and 
endothelium (Kaur, 2014).  This metabolically active tissue can rapidly transform in response 
to excess caloric intake, or reduced caloric expenditure due to physical inactivity  (Hardy et 
al., 2012; Bays et al., 2013; Iyengar et al., 2015).  Adipocytes can either undergo 
hypertrophy due to increased storage of TG (Blüher et al., 2013) or hyperplasia  (Figure 1.1) 
(Hardy et al., 2012; Iyengar et al., 2015).  Excessive adipocyte hypertrophy leads to AT 
growth beyond vascular supply, inadequate angiogenesis, and AT hypoxia.  The latter is 
involved in increased inflammatory marker expression in AT, as well as ectopic fat 
deposition in the liver, muscle, and the pancreas.  In addition, excessive adipocyte 
hypertrophy also leads to mitochondrial and endoplasmic reticulum dysfunction, hormone 
dysregulation, impaired storage of fatty acids (FA) and increased circulating free fatty acids 
(FFAs) (Figure 1.1) (Bays, 2011; Bays et al., 2013).  
Both increased FFAs and altered adipokine production plays critical roles in the development 
of obesity-related metabolic complications (Lee et al., 2013).  Free fatty acids increase 
insulin secretion, and decrease insulin sensitivity in both skeletal muscle and the liver, 
leading to increased secretion of very low-density lipoprotein (VLDL), which are linked to 
endothelial dysfunction and atherosclerosis (Lee et al., 2013).  
Abdominal obesity has been linked to predictors of CVD, diabetes mellitus, and the 
development of conditions such as hypertension and atherosclerosis (Lu et al., 2010).  
Furthermore, abdominal obesity has also been associated with metabolic abnormalities such 
as IR, hyperinsulinaemia, elevated TG, hypertension and glucose intolerance (Jennings et 
al., 2009; Lu et al., 2010).  As previously mentioned, in states of obesity and adipocyte 
hypertrophy, blood supply to the adipocytes is reduced, causing hypoxia, tissue necrosis, as 
well as macrophage infiltration around the AT (Figure 1.2) (Kaur, 2014).  Figure 1.1 
illustrates how abdominal obesity may contribute to the development of dyslipidaemia and 
IR, via the increased release of pro-inflammatory markers and its downstream effects. 
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Figure 1.1: The development of metabolic complications via abdominal obesity.  
(Adapted from Cartier, 2010). 
Evidence suggests that macrophage infiltration in subcutaneous adipose tissue (SAT) lead 
to a state of chronic low-grade inflammation in individuals with the MetS.  This state 
activates pro-inflammatory markers such as interleukin-6 (IL-6) and tumour necrosis factor 
alpha (TNF-α), that leads to both increased lipolysis and mobilisation of FFAs (Figure 1.1) 
(Cartier, 2010; Bremer et al., 2011; Lee et al., 2013).  Other effects could be attributed to 
decreased insulin signalling in AT, as well as the liver, and decreased synthesis and 
translocation of glucose transporter type 4 (GLUT4), resulting in IR (Cartier, 2010; Lee et al., 
2013). 
Menopausal status also contributes to increased abdominal adiposity, as stated by Sapkota 
et al., (2015), that there is an increased in abdominal adiposity independent of the effect of 
age and total body adiposity.  The increased WC and FM during the menopausal transition is 
due to decreased  ovarian oestrogen secretion (Sowers et al., 2007; Carr, 2003; Goyal et al., 
2013).  
1.2.3.2 Insulin resistance 
Insulin resistance (IR) is defined by a chronically elevated plasma insulin concentration that 
fails to lower blood glucose levels (Han & Lean, 2014).  In the context of the MetS and 
obesity, the development of IR is primarily facilitated by increased abdominal obesity, which 
stimulates the secretion of the pro-inflammatory markers TNF-α, which is expressed by 
macrophages in the AT, and reduce both insulin secretion and sensitivity, further contributing 
to the development of IR (Figure 1.1 & 1.2) (Cartier, 2010).   
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Figure 1.2: The link between obesity and the development of insulin resistance.                       
(Adapted from Castan-Laurell et al., 2012). 
Tumour necrosis factor-alpha is also involved in initiating lipolysis, which increases 
circulating FFA levels (Cartier, 2010).  Interleukin-6 on the other hand, affects both glucose 
and lipid metabolism, and improves insulin sensitivity, as well as glucose tolerance (Piya et 
al., 2013).   
Jeon et al. (2011) reported that insulin levels were higher in both MetS PreM women 
(6.10±4.87 mU/L) compared to control PreM women (3.86±2.37 mU/L; p=0.000).  Post 
menopausal (PostM) women with the MetS showed higher insulin concentrations (5.88±2.95 
mU/L) compared to Non-MetS PostM women (4.62±6.40 mU/L; p=0.030).  Similarly, Alissa 
et al. (2014) reported that PostM women, serum insulin levels were significantly higher in the 
MetS group (17.68±18.15 μM/mL) than in Non-MetS group (12.15±9.38 μM/mL; p<0.01).  It 
is thus concluded that the MetS increases insulin concentration significantly, giving rise to 
glucose intolerance.  
In addition to the MetS altering insulin levels, the presence of menopause or oestrogen 
deficiency is also known to alter insulin levels (Matsui et al., 2013).  Accodring to Matsui et 
al. (2013), oestrogen might have a protective effect against insulin resistance in PreM 
women.  Matsui et al. (2013) reported higher levels of insulin in PreM women, although this 
was not significantly higher than in the PostM group.   
1.2.3.3 Glucose intolerance 
Most individuals that present with the MetS also experience some level of glucose 
intolerance (Aganović & Dušek, 2004).  Although there are many potential reasons for this, it 
is mostly associated with defects in the functioning of insulin and binding to the insulin 
receptor, i.e. failure to suppress gluconeogenesis in the liver, and the mediation of glucose 
uptake in insulin-sensitive tissues (muscle and AT) (Aganović & Dušek, 2004).  In such 
cases, and because of decreased GLUT 4 synthesis and translocation to the cell 
membranes, there is insufficient glucose uptake into tissue, resulting in hyperglycaemia 
(Aganović & Dušek, 2004; Cartier, 2010).  
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Heianza et al., (2013) reported that older age and menopausal status independently and 
additively influenced the high prevalence of dysglycemia in Japanese women.  Jeon et al. 
(2011) reported elevated glucose levels in PreM women with the MetS (5.69±1.96 mmol/L) 
compared to their Non-MetS (4.70±0.5 mmol/L; p=0.000) counterparts, with a similar 
observation for PostM MetS women (5.49±1.18 mmol/L) and PostM Non-MetS women 
(4.84±0.58 mmol/L; p=0.000).  In a study comparing only MetS and Non-MetS PostM 
women, fasting blood glucose (FBG) levels were reported to be significantly higher in the 
MetS (8.66 ±0.54 mmol/L) than Non-MetS women (6.0±0.93 mmol/L; p<0.0001) (Alissa et 
al., 2014).  It is therefore evident that irrespective of menopausal status, elevated glucose 
levels are present in individuals with the MetS.   
1.2.3.4 Dyslipidaemia 
Dyslipidaemia describes alterations in the structure, metabolism, and biological activities of 
atherogenic lipoproteins and anti-atherogenic HDL-c (Kaur, 2014).  Dyslipidaemia is further 
characterised by elevated levels of total cholesterol (TC), TG, low-density lipoprotein 
cholesterol (LDL-c), and low levels of HDL-c (Kaur, 2014; Mandal, 2015).  These blood lipid 
fractions are also associated with the MetS, where elevated LDL-c levels are more common 
in individuals with increased abdominal AT (Han & Lean, 2014).  There is also a strong 
correlation between IR and atherogenic dyslipidaemia (Han & Lean, 2014).  Under normal 
metabolic states, insulin suppresses lipolysis in adipocytes, but during IR there is impaired 
insulin signalling which results in higher levels of lipolysis and elevated FFA levels (Figure 
1.3) (Kaur, 2014; Jung & Choi, 2014).   
 
Figure 1.3: Pathway of increased adipose tissue contributing to dyslipidaemia.                       
(Adapted from Jung & Choi, 2014). 
Free fatty acids serve as a substrate for TG synthesis in the liver, and further stabilises the 
production of apolipoprotein B, which is the major lipoprotein of VLDL particles, resulting in 
higher VLDL concentrations (Lee et al., 2013; Kaur, 2014; Jung & Choi, 2014).  The TG in 
VLDL is exchanged for cholesteryl esters from LDL and HDL by cholesteryl ester transport 
protein, resulting in the production of TG-rich LDL and HDL.  Furthermore, the TGs in LDL 
and HDL are hydrolysed by hepatic lipases that produce small dense LDL and HDL (Jung & 
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Choi, 2014).  Therefore, both obesity and hyperinsulinaemia contribute to the altered lipid 
levels present in the MetS (Gierach et al., 2014; Jennings et al., 2009).  When considering 
menopausal status, Bade et al. (2014) reported increased levels of TG, LDL-c and 
decreased levels of HDL-c in PostM women in comparison to PreM women, possibly due to 
hormonal changes. 
1.2.3.5 Hypertension 
All of the MetS risk factors have been associated with the development of hypertension, with 
obesity, glucose intolerance and dyslipidaemia being the most commonly reported risk 
factors associated with the development hypertension (Kaur, 2014).  Central obesity, 
measured by an increased WC, contributes to the development of hypertension via the 
secretion of adipokines (TNF-α, IL-6, adiponectin) and dyslipidaemia (Bodea & Popa, 2015).  
Additionally, endothelial dysfunction, oxidative stress and vascular inflammation further 
promote the development of hypertension in the context of the MetS (Figure 1.4) (Bodea & 
Popa, 2015).   
Excess adipose tissue expresses all components of the renin-angiotensin-aldosterone 
systems.  The latter is activated by both hyperglycaemia and hyperinsulinaemia, which may 
contribute to the development of hypertension in individuals with IR (Ahima & Flier, 2000; 
Cassis et al., 2008; Kaur, 2014).  Some research suggested that IR and hyperinsulinaemia 
lead to the activation of the sympathetic nervous system (SNS) that plays a central role in 
the regulation of metabolic processes in the body (Da Silva, 2009; Horita et al., 2011).  Here, 
the kidneys are stimulated to increase sodium reabsorption, the heart to increase cardiac 
output, and vasoconstriction of the arteries, resulting in an increased peripheral resistance 
and ultimately hypertension (Kaur, 2014).   
 
Figure 1.4: The development of hypertension via increased AT.               
(Adapted from Bogaert & Linas, 2009). 
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Menopausal status is also known to contribute to the development of hypertension (Carr, 
2003; Goyal et al., 2013).  During menopause the changes in the oestrogen/androgen ratio 
leads to endothelial dysfunction, increased endothelin secretion and decreased nitric oxide 
production that contributes to increased oxidative stress, renal vasoconstriction and 
ultimately hypertension (Coylewright & Ouyang., 2008).   In addition, the changes in the 
oestrogen/androgen ratio also results in increased BMI that also contribute to oxidative 
stress that triggers renal vasoconstriction and hypertension (Coylewright & Ouyang., 2008).  
The increased BMI also leads to sympathetic activation, further increasing renin release and 
increased angiotensin II, renal vasoconstriction and the development of hypertension 
(Coylewright & Ouyang., 2008).    
1.2.4 The metabolic syndrome and menopause 
There appears to be a strong link between an increased prevalence of the MetS and ageing 
in women, specifically during the transition from PreM to PostM (Ebrahimpour et al., 2010).  
The oestrogen deficiency that occurs during this period exacerbates the MetS and appears 
to be associated with an increased risk for the development of most of the individual MetS 
risk factors (Ebrahimpour et al., 2010; Eshtiaghi et al., 2010).  Eshtiaghi et al. (2010) found 
that menopause was an independent predictor of the MetS, which may be due to oestrogen 
deficiency that alters lipid metabolism, causes changes in body fat distribution, and affects 
insulin action on the arterial wall (Eshtiaghi et al., 2010).  In agreement, Pandey et al. (2010) 
and Jesmin et al. (2013) reported a higher prevalence of the MetS in their PostM study 
participants (55.0% and 39.3% respectively) than in the PreM group (45.0% and 16.8%, 
respectively p<0.0001 and p<0.001).  Goyal et al. (2013) and Maharlouei et al. (2013) made 
similar conclusions.  
Apart from the association between menopause and the increased prevalence of the MetS, 
there also appear to be changes in bone health and BMD in women (AlDughaither et al., 
2015; Al-Safi & Polotsky, 2014).  
1.3 Bone 
Bone tissue provides mechanical support and protection to the structure of the body, as well 
as aiding in mineral homeostasis, and serves an important endocrine function in the body 
(Burr & Allen, 2013).  Since one of the most important focusses of this research entailed 
BMD and the possible associations with the MetS and menopausal status, a brief overview 
of the basic bone physiology and pathophysiology will be provided.   
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1.3.1 Basic bone physiology 
1.3.1.1 Composition of bone 
Bone tissue consists of specialised cells immersed in a mineralised extracellular matrix 
(ECM), which is composed of an inorganic matrix (±65%), providing density to bone (Figure 
1.5A).  The inorganic matrix mainly consists of calcium and phosphate as hydroxyapatite 
[Ca10(PO4)6(OH)2], while the organic matrix consists of a flexible type I collagen fibre 
framework, as well as an amorphous ground substance (Clarke, 2008; Ross et al., 2011; 
Sharp, 2011; Johnson, 2013; Burr & Allen, 2013). 
Eighty percent of bone tissue consists of a calcified cortical (compact/dense) component 
surrounding the marrow space, to provide both structural and protective support (Figure 
1.5B) (Clarke, 2008; Kini & Nandeesh, 2012; Walsh, 2014).  The remaining 20% constitutes 
the less calcified trabecular component that appears as a honeycomb network-like structure 
of trabecular plates with open cell-filled spaces (Clarke, 2008; Kini & Nandeesh, 2012; 
Walsh, 2014).  The cortical bone has a periosteal (outer) and endosteal (inner) surface 
(Clarke, 2008; Kini & Nandeesh, 2012).   
The periosteum consists of a fibrous connective tissue sheath, surrounding the outer cortical 
surface of the bone, except where joints are present.  Here, the bone is covered with an 
articular cartilage containing a blood vessel network, nerve fibres, osteoblasts and 
osteoclasts, and functions to protect, nourish and aid in bone formation (Kini & Nandeesh, 
2012).  The endosteum consists of a membranous structure covering the inner surface of the 
cortical and cancellous bone, as well as the Volkmann’s canals (Kini & Nandeesh, 2012). 
There are mainly three cell types present in mature bone; (i) osteoblasts, (ii) osteoclasts, and 
(iii) osteocytes (Johnson, 2013; Kini & Nandeesh, 2012).  Osteoblasts originate from the 
mesenchymal stem cells, or osteoprogenitor cells, of the bone marrow stroma (Kini & 
Nandeesh, 2012), after which they translocate to the surface of the bone tissue (Johnson, 
2013).  Osteoblasts are ‘specialised bone-forming’ cells, which produce enzymes and 
osteoid, a mixture of collagen and other proteins, providing a binding site for hydroxyapatite 
(Kini & Nandeesh, 2012; Silverthorn, 2013).  Osteoblasts deposit bone matrix and produce 
type 1 collagen, non-collagenous proteins and regulatory factors.  Osteoblasts further 
regulate osteoclasts, and mutually function to maintain homeostasis through continuous 
remodelling (Johnson, 2013).  This process is particularly important for calcium (Ca2+) and 
phosphate homeostasis, and the adaptation to external tensional forces (Johnson, 2013; 
Kini & Nandeesh, 2012).   
Osteoclasts are responsible for bone resorption via the secretion of hydrogen ions and the 
cathepsin K enzyme, by attaching around the periphery of a section of bone matrix 
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(Johnson, 2013; Kini & Nandeesh, 2012).  The acid acidifies the resorption compartment, 
which are located beneath the osteoclast to dissolve the mineral component of bone matrix, 
whereas the cathepsin K digests the proteinaceous matrix (Clarke, 2008).   
Osteocytes, the most abundant type of bone cell, develop when osteoblasts differentiate, 
and function in conjunction with osteoblasts to form bone matrix (Clarke, 2008; Johnson, 
2013; Walsh, 2014).  These cells also develop the ability to secrete bone matrix, and 
depending on the entrapment of some osteoblasts in the secreted bone matrix, the resultant 
osteoclasts will gradually stop secreting osteoid (Kini & Nandeesh, 2012).  
1.3.1.2 Bone mineral density 
Bone mineral density describes the health of an individual’s bones (National Osteoporosis 
Foundation, 2015; Osteogenesis Imperfecta Foundation, 2007; Office of the Surgeon 
General, 2004).  Bone mineral density is defined as the quantity of bone mass per unit 
volume, or per unit area, and is a measure of the concentration of calcium and phosphorus 
in a specified volume of bone (Office of the Surgeon General, 2004; Osteogenesis 
Imperfecta Foundation, 2007; Lee et al., 2010).  When referring to bone strength, a 
combination of two main features are involved, namely: (i) bone density, and (ii) bone 
quality, where the latter refers to the architecture (for example trabecular, connectivity and 
orientation), turnover, damage accumulation and mineralisation of bone (Lee et al., 2010).  
1.3.1.3 Bone growth  
Four distinct phases of bone growth exist.  The “growth phase” starts as a rapid phase 
lasting until late puberty (Office of the Surgeon General, 2004), followed by the consolidation 
phase, where the acquisition of bone mass occurs due to mechanical stresses, weight 
training and body weight (Office of the Surgeon General, 2004).  Peak bone mass (PBM) is 
reached during adolescence, and during the remodelling phase, bone mass is maintained for 
a few years (Figure 1.5) (Mosca et al., 2014; Velickovic et al., 2013).  Both testosterone and 
oestrogen are important sex hormones influencing skeletal growth, maturation and 
maintenance of bone (Karsenty, 2012).  Oestrogens specifically exert an inhibitory effect on 
osteoclasts and promote osteoclast apoptosis.  In contrast, male and female testosterone 
inhibits both osteoclast activity and osteoblast apoptosis and stimulates osteoblast 
proliferation and differentiation (Karsenty, 2012; Taie & Rasheed, 2014).  
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Figure 1.5: Different phases of bone growth throughout life, including the growth phase, consolidation 
phase which is followed by the rapid and gradual bone loss phases.                                                                  
(Adapted from Online: http://general.utpb.edu/fac/eldridge_j/kine3350/chapter_18_Review.htm). 
Bone remodelling is a homeostatic process where bone is renewed because of 
microdamage, and to help maintain strength and mineral homeostasis (Clarke, 2008; Walsh, 
2014).  In order to establish the rate and balance of bone remodelling, bone turnover 
markers are used (Walsh, 2014).  
1.3.1.4 Bone turnover markers 
Early changes in bone turnover, including both bone formation and bone resorption, can 
predict long-term changes in BMD.  The use of bone turnover markers is therefore 
considered a useful clinical tool for determining current, as well as future bone health 
(Schafer et al., 2010).   
Bone formation markers 
The process of bone formation is regulated by osteoblasts (Wheater et al., 2013).  Bone 
formation markers are either by-products of active osteoblasts, expressed during the various 
phases of osteoblast development, or by osteoblastic enzymes (Wheater et al., 2013).  
Alkaline phosphatase   
Alkaline phosphatase (ALP) is present in high concentrations in the liver, bone, kidney and 
intestines, although the ALP found in circulation primarily originates from either the liver or 
bone (Shipman et al., 2013).  Bone-specific alkaline phosphatase (BAP) is synthesised by 
osteoblasts and is involved in the calcification and mineralisation of bone matrix (Clarke, 
2008; Drechsler et al., 2011; Roudsari & Mahjoub, 2012).  
The reference levels of ALP are both age- and gender-specific, with a gradual increase in 
ALP between the ages of 40 and 65 years in women (Shipman et al., 2013).  Gossiel et al. 
(2014) provided evidence to support this, where serum BAP was reported to be lower in 
younger women (35.5±2.9 years, BAP: 10.9±4.2 ng/mL) compared to older women 
(67.1±7.1 years, BAP: 15.1±6.4 ng/mL).  Similarly, Chinese PreM women had significantly 
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lower BAP levels (17.3±6.4 U/L) than the PostM group (29.9±12.1 U/L; p=0.000) (Wang et 
al., 2013). 
Concerning the MetS, Kim et al. (2013b) reported that higher ALP levels were able to predict 
the development of the MetS in a middle-aged female Non-MetS population.  Here, it is 
postulated that ALP can act as a marker of visceral adiposity or hepatic steatosis, as well as 
low-grade inflammation.  During adipogenesis, ALP activity increases in pre-adipocytes with 
concomitant lipid accumulation (Lowe et al., 2011).  It is also thought that ALP is linked to 
vitamin D levels, since higher BAP levels were associated with vitamin D deficiency (<50 
nM) (Frost et al., 2010), and low vitamin D levels were reported in MetS individuals (Kim, 
2015).   
Procollagen type I N pro-peptide  
The most abundant protein in bone, procollagen type I N pro-peptide (PINP), is synthesised 
by osteoblasts and is deemed a precursor molecule of type I collagen (Vasikaran et al., 
2011; Wheater et al., 2013; Krege et al., 2014; Madar et al., 2015).  Concentrations of PINP 
differed significantly between PreM (36.4 ng/mL) and PostM women (43.3 ng/mL; p<0.01) 
(Niemann et al., 2013).  Furthermore, Gossiel et al. (2014) also indicated that older females 
(age 42.5±22 years) had higher PINP concentrations (67.1±7.1 ng/mL) than younger 
females (age: 35.7±18 years; PINP: 35.5±2.9 ng/mL).  
Osteocalcin 
Osteocalcin, bound to hydroxyapatite, is produced by osteoblasts, which influences osteoid 
mineralisation (Vasikaran et al., 2011; Marrone et al., 2012; Wheater et al., 2013).  A 
significant difference was reported in osteocalcin levels in Non-MetS PostM women with 
osteoporosis and osteopenia (Bączyk et al., 2012).  When the MetS was integrated in a 
PostM study, osteocalcin was more strongly associated with bone mass than any of the 
individual MetS components (Alissa et al., 2014).  Confavreux et al. (2014) found that 
osteocalcin concentrations were not significantly different between MetS and Non-MetS 
participants.  In another study comparing PreM and PostM women, osteocalcin levels 
differed significantly between these two groups (PreM: 15.40±6.00 μg/L; PostM: 21.69±8.58 
μg/L; p<0.001) (Jeong et al., 2014).  Therefore, menopausal, but not metabolic status seems 
to affect the osteocalcin levels. 
Bone resorption markers 
Most of the bone resorption markers are products of the degradation of bone collagen 
(Wheater et al., 2013).  Some of the most frequently used bone resorption markers include 
carboxy-terminal telopeptide x (CTx), N-terminal cross-linking telopeptide of type I collagen 
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(NTx), receptor activator of nuclear factor kappa beta ligand (RANKL), and osteoprotegerin 
(OPG) (Vasikaran et al., 2011; Wheater et al., 2013).  
Carboxy-terminal telopeptide x  
Carboxy-terminal telopeptide x (CTx) is used as the reference bone resorption marker, which 
is cleaved from the carboxy (C) terminal of type 1 collagen, which is then subsequently 
released into circulation (Vasikaran et al., 2011; Wheater et al., 2013).  It has been shown 
that CTx differed significantly between osteopenic and osteoporotic women, and is also 
associated with an increased fracture risk (Bączyk et al., 2012; Ivaska et al., 2010; Lee & 
Vasikaran, 2012; Marrone et al., 2012).  Furthermore, CTx was reported to be significantly 
lower in PreM compared to PostM women (309±172 μg/L vs. 546±256 μg/L; p<0.001) 
(Jeong et al., 2014).   
Amino-terminal cross-linking telopeptide of type I collagen  
Amino-terminal cross-linking telopeptide of type I collagen (NTx) is cleaved from the amino 
(N) terminal of type 1 collagen by cathepsin-K during the process of bone resorption 
(Wheater et al., 2013).  Wang et al. (2013) reported a significant difference between NTx 
levels in PreM (13.70±5.40 nmoL, bone collagen equivalents) compared to PostM women 
(17.29±8.1940 nmoL, bone collagen equivalents; p=0.000).  
Receptor activator of nuclear factor kappa beta ligand  
Receptor activator of nuclear factor kappa beta ligand (RANKL) is produced by osteoblasts 
and stimulates differentiation of osteoclasts by binding to receptor activator of nuclear factor 
kappa beta (RANK) (Azim et al., 2012; Wheater et al., 2013).  T-cells can also express 
RANKL, thereby influencing osteoclastogenesis, which explains the bone loss in diseases 
with persistent and active inflammatory states (Nagy & Penninger, 2015).  
Osteoprotegerin  
Osteoprotegerin (OPG) is secreted by osteoblasts and decreases bone resorption by binding 
to RANK, thus preventing osteoclastogenesis (Wheater et al., 2013).  Therefore, it is 
considered an entrapment substrate, competing with the binding of RANK to RANKL (Pérez 
de Ciriza et al., 2014; Wheater et al., 2013).  Jabbar et al. (2011) reported higher OPG in 
PostM osteoporotic women, and it was suggested that the higher OPG concentrations lead 
to increased bone turnover and lower BMD.  Similarly, Shinkov et al. (2014) reported 
significantly higher OPG levels in PostM vs. PreM women.   
In the context of the metabolic status, OPG concentrations were reported to be significantly 
higher in MetS individuals compared to Non-MetS individuals (1255±46 pg/mL vs. 1192±47 
pg/mL; p<0.05) (Pérez de Ciriza et al., 2014).  This was also confirmed by Bernardi et al. 
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(2014), where the MetS group also showed significantly higher OPG levels in comparison to 
controls (80.62±4.21 ng/L vs. 68.10±2.55 ng/L, p<0.0001).  Pérez de Ciriza et al. (2014) 
further reported an exponential increase in circulating OPG levels, with increasing numbers 
of MetS risk factors. 
1.3.2 Bone pathophysiology 
Scientific evidence thoroughly documents correlations between ageing and the increased 
prevalence of osteopenia and osteoporosis, although the prevalence of osteopenia is far 
greater compared to osteoporosis (Silva et al., 2015).  Additionally, menopause is emerging 
as a risk factor for the development of these conditions (Silva et al., 2015).  In order to 
describe BMD, T- and Z-scoring systems are used (Taie & Rasheed, 2014).     
The T-score aims to describe an individual’s BMD either as ideal or peak compared to a 
healthy 30-year old adult.  This score is expressed as standard deviations (SD) relative to a 
young adult population’s ideal BMD, and is both gender- and ethnic-specific (Equation 1) 
(Fogelman & Blake, 2000; National Institutes of Health, 2012).  
Equation 1: Calculation of T-score. 
T-score=Measured BMD -
young adult mean BMD
young adult SD
 
Table 1.4 presents the classification of the T-score into the different bone conditions 
according to the WHO definition (McComsey et al., 2010; WHO, 2015).  
Table 1.4:  Classification of T-scores: 
Condition T-score 
Normal Between +1 and -1 SD 
Osteopenia Between -1 and -2.5 SD 
Osteoporosis Below -2.5 SD 
(WHO, 2015). 
The Z-score is used in comparison with a typical, age-matched individual.  It is widely 
recommended to use the Z-score with children, adolescents and PreM women (Equation 2) 
(National Osteoporosis Foundation, 2015).  However, since low BMD is more common in 
older patients, this type of scoring can be distorted, and should therefore not be considered 
sensitive compared to the T-score.  As a result, the Z-score is not used to diagnose 
osteoporosis, but rather to detect whether or not other diseases or conditions (for example 
kidney failure, hyperparathyroidism or diabetes), or secondary osteoporosis might prevail 
that could affect bone loss (National Institutes of Health, 2012; National Osteoporosis 
Foundation, 2015).  The International Society for Clinical Densitometry (ISCD) recommends 
a normal Z-score to be above -2.0 (ISCD, 2015).  
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Equation 2: Calculation of Z-score. 
Z-score= Measured BMD - 
age-matched mean BMD
age-matched SD
 
1.3.2.1 Osteopenia 
Osteopenia is a well-known precursor of osteoporosis and is often described as a mild form 
of osteoporosis (Weissman, 2004).  It is characterised by a below normal BMD, with a T-
score ranging between -1 and -2.5 (WHO, 1994 & 2004).  Although numerous physiological 
factors contribute to the development of osteopenia, ageing and hormone deficiencies 
(oestrogen deficiency during menopause) are thought to be the main cause of the 
development of primary osteopenia and osteoporosis (Khosla et al., 2012).  Some lifestyle 
factors which influences BMD include long-term glucocorticoid use, diabetes mellitus, eating 
disorders (low dietary intake of Ca2+, as well as a vitamin D deficiency), smoking, and 
alcohol abuse (Taie & Rasheed, 2014).  Bolton et al. (2012) reported that exercise 
interventions targeting individuals with osteopenia might lower, delay or even prevent the 
risk for the development of osteoporosis. 
1.3.2.2 Osteoporosis  
Osteoporosis is characterised by decreased BMD, as well as decline of the skeletal 
microarchitecture, resulting in fragile bones and an increased fracture risk (WHO, 1994 & 
2004; Eastell, 2013).  There is a significant imbalance in bone turnover, which results in the 
inability of trabecular bone to remodel after constant micro-trauma, thereby resulting in the 
development of osteoporosis (Johnson, 2013). 
Osteoporosis can be classified as primary or secondary osteoporosis.  Primary osteoporosis 
usually develops as a result of ageing and/or menopause; whereas, hyperparathyroidism, 
hyperthyroidism, diabetes, vitamin D deficiency and/or the presence of osteoporosis in 
association with another chronic disease, are classified as secondary osteoporosis (WHO, 
1994 & 2004; McComsey et al., 2010).  
1.3.3 Physical bone mineral density assessment methods 
The assessment of BMD is a non-invasive, easy to use method that evaluates bone health 
status.  More advanced bone assessment methods rely on low dose radiation that can either 
be used to evaluate the whole-body, or a specific body section, i.e. the spine, hips, legs and 
arms (Osteogenesis Imperfecta Foundation, 2015).  Table 1.5 presents a summary and 
comparison of the different assessment methods used to quantify BMD.  
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Table 1.5: Comparison between different assessment methods used to quantify BMD. 
 Positive characteristics Negative characteristics 
DEXA 
 Highly accurate 
 Assessment of reference sites (spine 
and hip) 
- Uses X-rays (radiation exposure) 
- Expensive 
- Cannot distinguish between cortical 
and trabecular bone 
- Does not discriminate bone 
microarchitecture 
- Not useful as a screening tool 
QCT 
 Provides true density values 
 Discriminates between cortical and 
trabecular bone 
 High-resolution 
- Higher radiation dose than DEXA 
- Limited accessibility 
- Not useful as a screening tool 
QUS 
 Rapid 
 Inexpensive 
 Radiation free 
 Portable 
 Shorter analysis time than DEXA 
 Useful to investigate bone structural 
properties 
 Useful screening tool 
- Different guidelines for definition of 
osteoporosis 
- Measurements only possible at 
peripheral skeletal sites 
- Not directly comparable to DEXA 
MRI 
 Volumetric BMD calculations, without 
losing soft tissue signals 
 Ability to assess trabecular bone 
tissue 
 No exposure to ionising radiation 
- Expensive 
- Long duration to acquire the scan 
- Images tend to be less detailed 
(Adapted from Pisani et al., 2013). DEXA: dual-energy X-ray absorptiometry, QCT: quantitative 
computed tomography, QUS: quantitative ultrasound, MRI: magnetic resonance imaging. 
The major differences observed here are the radiation dose exposure, the discrimination 
between cortical and trabecular bone tissue, as well as the time and cost of each method.  
While dual-energy X-ray absorptiometry (DEXA) is considered the gold standard for BMD 
measurement and is currently the most sensitive tool for the prediction of future bone 
fractures, there is no clinical guarantee that it is 100% accurate (Heiss et al., 2012; The 
National Institutes of Health, 2012; Sohl et al., 2015).  At both a cross-sectional and 
longitudinal study level, a seven-year cohort study reported a strong positive correlation 
between quantitative ultrasound (QUS) and DEXA measurements (Trimpou et al., 2010).  
Another study also found a strong, and positive correlation between T-scores measured by 
DEXA and those measured using QUS (Beerhorst et al., 2013).  Furthermore, QUS was 
highly accurate and precise compared to DEXA, which deemed this method suitable for use 
in epidemiological studies (Fogelman & Blake, 2010; Beerhorst et al., 2013).   
1.3.3.1 Dual-energy X-ray absorptiometry (DEXA) 
Dual-energy X-ray absorptiometry (DEXA) is a two-dimensional scanning technique in which 
two X-ray energies are used to estimate the area of mineralised tissue at any skeletal site;  
however, it is mostly used at the lumbar spine or hip regions (Fogelman & Blake, 2010; 
Lorente-Ramos et al., 2013; Pisani et al., 2013; Suman et al., 2013).  In short, the X-ray 
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beam used in DEXA uses two different photon energies (constant and pulsed), selected to 
compensate for the different attenuation coefficients of the mineralised bone, as well as soft 
tissue of the bone area being analysed (Fogelman & Blake, 2010; Pisani et al., 2013).  The 
intensities of low-energy and high-energy photons passing through the bone and soft tissue 
are analysed separately, where after, the attenuation values of the soft tissue are then 
subtracted by an algorithm, providing only the attenuation values of bone mineral 
(hydroxyapatite, Ca10(PO4)(OH)2) (Fogelman & Blake, 2010; Pisani et al., 2013).  Since the 
mineral content is divided by the area, it only partially corrects for body size, and, therefore, 
cannot assess the depth or posterior-anterior width of the bone, and can also not distinguish 
between cortical and trabecular bone (Pisani et al., 2013; Suman et al., 2013).  Figure 1.6 
illustrates how the X-ray source (beneath the examination table) moves simultaneously with 
the X-ray detector system, scanning the patient’s body (Pisani et al., 2013).   
 
Figure 1.6: Dual-energy X-ray absorptiometry: Schematic representation of X-rays source and detector 
system, with an example of the type of image obtained by this measurement.              
(Adapted from Pisani et al., 2013). 
Some of the disadvantages of the DEXA include; a long time commitment during the scan; 
exposure to ionising radiation; costly, and being an immobile system.  These factors 
contribute negatively to the use thereof in developing countries (Lee et al., 2010; Heiss et al., 
2012; Louis et al., 2015; Silva et al., 2015; Sohl et al., 2015).  Additionally, a qualified 
radiographer is needed to operate the DEXA, since several factors including incorrect 
positioning of the patient, scan analysis or mistakes in interpretation, will lead to incorrect 
results and diagnosis (Pisani et al., 2013).  Irrespective of this, DEXA assessment is still 
regarded as highly accurate (Suman et al., 2013).  
1.3.3.2 Quantitative computed tomography (QCT) 
Quantitative computed tomography (QCT) is a specific type of bone scanning technique that 
measures the volumetric density of bones (Stewart & Sutton, 2012).  Both cortical and 
trabecular bone can be distinguished from one another, which is beneficial since the high 
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rates of bone turnover in trabecular bone can be detected.  If abnormalities are present in 
bone formation, early detection may prevent bone disease progression, and it is therefore 
highly sensitive to any change in bone composition (Stewart & Sutton, 2012).   
In QCT, the X-ray absorption profiles are normally obtained when the source and the 
detectors rotate around the bone of interest.  The absorption projections are then processed 
at different angles to construct a three-dimensional illustration of the imaged bone (Pisani et 
al., 2013).  Although this method seems advantageous, soft tissues exhibit little signal on 
QCT, which makes this type of measurement quite challenging when imaging or assessing 
bone and soft tissue (Ho et al., 2013; Louis et al., 2015).  Another disadvantage of using this 
technique is that it uses X-rays, and it is also more expensive compared to DEXA 
assessment (Stewart & Sutton, 2012; Pisani et al., 2013; Louis et al., 2015).  An alternative 
form of computed tomography is high-resolution peripheral quantitative computed 
tomography (HRPQCT), which provides additional information on the quality of bone 
microarchitecture (Madeira et al., 2014).   
1.3.3.3 Magnetic resonance imaging (MRI) 
This imaging technique uses the body’s natural magnetic properties to produce detailed 
images of the anatomical area of interest.  Body water, as well as AT contains hydrogen with 
a positive charge (Berger, 2002; Lindquist & Wager, 2014).  Under normal conditions, these 
protons are randomly orientated with respect to each other (Lindquist & Wager, 2014).   
The immense magnetic field generated by the magnetic resonance-magnets align the 
protons in cells in one direction (Figure 1.7).  Gradient coils produce radio waves that knock 
these protons out of its alignment.  After removal of these radio waves, the protons realign or 
return to equilibrium, thereby sending radio signals to the receivers (radio frequency coils), 
which can provide the exact location of the protons in the body.  Since protons in different 
tissues realign at different speeds, the signal can then distinguish between different tissue 
types in the body (Berger, 2002; Lindquist & Wager, 2014).  
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Figure 1.7: Schematic representation of a magnetic resonance imaging scanner with an example of the 
type of image produced by this technique.                                                                                                                                 
(Adapted from Alam, Willet & Ostlere, 2005 and http://io9.com/5495712/six-ways-science-can-see-into-
your-brain). 
The fact that BMD assessments can be made based on the volume of the bone, the 
absence of ionising radiation, and the ability to assess trabecular bone tissue, makes MRI an 
useful alternative to QCT and DEXA (Stewart & Sutton, 2012; Ho et al., 2013; Louis et al., 
2015).  Disadvantages of this technique include its costly nature and its lengthy scan 
procedure (Stewart & Sutton, 2012). 
1.3.3.4 Quantitative ultrasound method 
An alternative measurement of BMD is QUS, usually measured at the calcaneus bone, or 
other peripheral skeletal sites (Sohl et al., 2015).  This method is widely used due to the 
relatively low cost, simplicity of performance, mobility, non-invasive nature, no exposure to 
ionising radiation, and its provision of additional information on the quality of bone (Mergler 
et al., 2010; Trimpou et al., 2010; Chin et al., 2012; Sohl et al., 2015).  
The calcaneal bone is the only skeletal site recommended by the ISCD for BMD 
measurements with QUS.  The calcaneal bone is one of the weight-bearing bones of the 
body and therefore sensitive to changes in BMD due to mechanical loading (Pisani et al., 
2013; Chin et al., 2015; International Society for Clinical Densitometry, 2015).  Ultrasound 
uses high-frequency sound waves to measure the alteration of travelling vibrations when 
passing through a solid medium, as for example bone (Trimpou et al., 2010; Beerhorst et al., 
2013).  The generated sound wave released from the transmitter, passes through the 
calcaneal bone, and is received by the other transducer (Chin et al., 2012).  Figure 1.8A 
illustrates the principle of sound waves passing through different types of bone tissue, 
whereas Figure 1.8B illustrates the speed at which sound waves pass through cortical and 
trabecular bone.  
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Figure 1.8: The QUS method illustrating (A) the movement of ultrasound through a bone section, and (B) 
the corresponding ultrasound pulse wave generated for each type of bone (note that sound waves travel 
faster through the trabecular compared to cortical bone).                                                                                                
(Adapted from Pisani et al., 2013). 
There are several reasons why the calcaneal bone is considered the most suitable site for 
QUS measurement.  Firstly, it has very little soft tissue (makes it easy to measure the bone), 
secondly, it has relatively flat surfaces to ensure good contact between the calcaneus and 
transducer, and thirdly, it is similar in composition to the main fracture sites (90% trabecular 
bone).  Furthermore, it is easily accessible and requires very little patient preparation 
(National Osteoporosis Society, 2015).   
The right calcaneal bone is mostly used to assess BMD (Kim et al., 2013a).  Although QUS 
could vary between the right and left calcaneus, the right foot is dominant in most people 
and might therefore have a higher BMD than the left calcaneus.  However, some studies 
prefer to use the left heel to measure the lowest BMD (Mergler et al., 2010). 
Some QUS instruments are water-based (Figure 1.9A), where the heel is placed in a water 
bath (37°C) between two ultrasonic transducers, while other equipment uses a dry contact 
system (Figure 1.9B), where the transmitter and receiver are in direct contact with the 
calcaneus (National Osteoporosis Society, 2015).  Another method includes the use of “gel-
padded transducers” (Figure 1.9C) (National Osteoporosis Society, Australia and New 
Zealand Horizon Scanning Network).   
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Figure 1.9: Different quantitative ultrasound instruments, which includes a water bath system (A), dry 
contact system (B) and gel-padded system (C).                                                                                                                       
(Adapted from National Osteoporosis Society and Australia and New Zealand Horizon Scanning 
Network). 
One of the key features of the QUS system include its ability to measure bone quality index 
(BQI), by combining speed of sound (SOS) and broadband ultrasound attenuation (BUA).  
The SOS refers to the speed (m/s) at which ultrasound waves travel through the calcaneal 
bone (Beerhorst et al., 2013).  Speed of sound is directly associated with elasticity, quality 
and density of bone (Beerhorst et al., 2013).  The presence of soft tissue decreases the SOS 
transmitted through bone, and thus influences bone quality (Beerhorst et al., 2013).   
In participants with a history of fractures, Hernández et al. (2004) reported a lower SOS 
(1516.5±1.13 m/s) than in those with no history of fractures (1527.7±0.57 m/s; p<0.0001).  
When investigating both menopausal status and metabolic status, Sun et al. (2014) reported 
a lower SOS in PreM women with the MetS (1547.2±26.3) than those without (1549.8±28.6 
m/s; p=0.0198), and a similar observation was made in the PostM women (MetS: 
1531.7±28.0 vs. Non-MetS: 1533.7±28.0 m/s; p=0.030) (Sun et al., 2014).   
Ino et al. (1997) described BUA as the rate at which ultrasound waves are attenuated as 
they pass through bone.  Broadband ultrasound attenuation measures the pattern of 
attenuation of ultrasonic waves in bone tissue and is influenced by connectivity and 
trabecular separation (Lee et al., 2010; Mergler et al., 2010; Scheffler et al., 2014).  An 
osteoporotic bone will yield a BUA of 50 dB/Mhz compared to normal bone (100 dB/Mhz) 
(Burr & Allen, 2013).  In participants with a history of fractures, Hernández et al. (2004) 
reported a lower BUA (60.2±0.55 dB/Mhz) than in those with no history of fracture 
(66.4±0.28 dB/Mhz; p<0.0001).  Even though it was insignificant, PreM women with the 
MetS had a lower BUA than those without the MetS (MetS: 77.52±15.50 vs. Non-MetS: 
79.4±15.3 dB/Mhz; p=0.110) and a similar observation was noted in the PostM group (MetS: 
70.55±16.88 vs. Non-MetS: 71.38±16.85 dB/Mhz; p=0.137) (Sun et al., 2014).   
Stellenbosch University  https://scholar.sun.ac.za
 
 
26 
 
Bone quality index (BQI), or the stiffness index, is used to describe the overall bone quality 
derived from a linear combination of BUA and SOS (Mergler et al., 2010; Trimpou et al., 
2010).  Women in the PreM MetS group showed lower BQI, or quantitative ultrasound index 
(QUI) (MetS: 95.15±16.57 vs. Non-MetS: 96.86±17.48; p=0.184).  Similarly, PostM women 
with the MetS also had a lower BQI than those without the MetS (85.95±17.74 vs. 
87.00±17.60; p=0.072) (Sun et al., 2014).   
Although the abovementioned BMD assessment methods, as well as bone turnover 
markers, are widely used, and provide valuable information regarding bone health and 
fracture risk, additional information to contextualise these findings are needed.  Various 
other biochemical and nutritional blood markers that influence bone architecture must 
therefore be taken into consideration. 
1.3.4 Complimentary biochemical and nutritional assessment bone 
markers 
The three calcitropic hormones, Ca2+, vitamin D (calcidiol; calcifediol; 25-
hydroxycholecalciferol; 25(OH)D), and parathyroid hormone (PTH) are considered crucial in 
the regulation of BMD (Starup-Linde, 2013).  These elements affect several biochemical 
processes in bone, including alteration of bone structure, the rate of bone metabolism, the 
endocrine and/or paracrine system, as well as homeostasis of Ca2+ and other bone-active 
minerals (Cashman, 2007).  The following sections will discuss these calcitropic hormones 
including basic physiology, its correlation to the MetS, as well as the effect of ageing and 
menopause. 
1.3.4.1 Calcium 
Basic calcium physiology 
Calcium, which is either present in the form of phosphate complexes, albumin-bound, or in 
the free ionised form (Ca2+), plays a crucial role in assuring sufficient growth and 
development of the skeleton (Moe, 2008; Ross et al., 2011; Campbell, 2014).  Although 99% 
of the body’s total calcium exists in bone, it has several additional physiological functions 
(Ross et al., 2011; Campbell, 2014).  Since calcium plays such an important role in the body, 
serum calcium concentrations are one of the most rigorously controlled parameters in the 
body (Campbell, 2014).   
During hypocalcaemia, PTH stimulates maturation of osteoclasts and activity of osteoclasts 
to mobilise calcium from bone, with a simultaneous increase in gastrointestinal calcium 
absorption via the production of calcitriol (1,25-dihydroxycholecalciferol; 1,25(OH)2D) (Figure 
1.10A) (Campbell, 2014).  Conversely, during hypercalcaemia, the thyroid C-cells are 
activated to produce calcitonin, increasing the deposition of calcium in bone by inhibiting 
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osteoclast activity, which in turn, decrease serum Ca2+ levels (Figure 1.10B) (Davey & 
Findlay, 2013; Campbell, 2014). 
 
Figure 1.10:  Physiological interaction illustrating the role of PTH in the maintenance of serum calcium 
levels with key target organs and the feedback interactions with calcium (A).  Plasma calcium regulation 
via the parathyroid glands and thyroid C-cells (B).  (Adapted from Wimalawansa, 2012; Silverthorn, 2013 & 
Sherwood, 2010). 
Dietary Ca2+ is mainly present as a salt or associated with other dietary constituents in the 
form of calcium ions (Cashman, 2007; Pavone et al., 2015).  The recommended daily 
allowance (RDA) for women range between 1000 mg (19-50 years) and 1200 mg (51 – 70 
years), indicating that dietary Ca2+ intake should increase with ageing (Ross et al., 2011; 
Martini et al., 2013; National Institutes of Health, 2012).  Ageing, vitamin D deficiency and 
vitamin D resistance all affect the calcium homeostasis negatively (Oudshoorn et al., 2009). 
Circulating calcium and the metabolic syndrome 
Kim et al. (2010) reported a strong association between serum calcium levels and the 
prevalence of the MetS in participants with an age of ≥40 years (independent of age, BMI 
and gender).  Furthermore, in older study populations, both Cho et al. (2011) and Saltevo et 
al. (2011) reported that higher serum calcium (although still in the normal range) was 
associated with an increased risk of developing the MetS in healthy elderly women (47 to 75 
and 60 to 85 years respectively).  Both Kim et al. (2010) and Cho et al. (2011) reported 
significant associations between serum calcium levels and FBG, TC, HDL-c and TG, 
whereas Saltevo et al. (2011) reported associations between WC, BP, TG and FG and 
serum Ca2+ levels, but not HDL-c and serum calcium levels. 
Two possible mechanisms were proposed linking calcium and the MetS:  Firstly, intracellular 
calcium is a regulator of lipid metabolism, and increased concentrations will stimulate the 
expression and activity of lipogenic enzymes, reducing lipolysis and increasing the 
accumulation of adipocytes (resulting in obesity and the associated pathological 
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mechanisms described earlier) (Huang et al., 2011).  Lower dietary calcium intake will result 
in increased 1,25(OH)2D, which in turn will increase Ca2+ absorption and lipogenesis.  Huang 
et al. (2011) also reported a significantly decreased risk of abdominal obesity with each 
quartile increase in dietary calcium intake.  Secondly, high circulating calcium levels can 
reduce the absorption of dietary fat in the small intestine, since calcium increases the 
excretion of fats, by forming insoluble calcium FA soaps, or by the binding of bile acids 
(Huang et al., 2011).  Calcium is also essential for insulin-mediated intracellular processes in 
insulin-responsive tissues (Shin et al., 2015).  Therefore, abnormal regulation of calcium 
levels can affect both insulin sensitivity and insulin release, since insulin secretion is a 
calcium-dependent process (Kim et al., 2010). 
Calcium, ageing and menopause 
The majority of PostM women experience oestrogen deficiency, which can lead to calcium 
loss via the indirect effects on circulating calcium homeostasis (Qureshi et al., 2010; Drake 
et al., 2015).  During ageing, there is increased bone resorption, resulting in an increased 
loss of calcium from bone into the extracellular fluid (Drake et al., 2015).  To compensate for 
this loss, several mechanisms are at play: (i) the kidneys decrease renal calcium 
reabsorption, (ii) there is a decrease in intestinal calcium absorption, as well as (iii) a 
reduction in PTH secretion (Qureshi et al., 2010; Drake et al., 2015).  The combination of 
these physiological responses results in a net negative whole-body calcium concentration, 
ultimately leading to skeletal demineralization.   
Furthermore, menopausal women show a decrease in calcium absorption; however, the 
bone loss that occurs here cannot be prevented by increasing the consumption of dietary 
calcium, although it may help to decrease the rate of bone loss.  The use of hormone 
replacement therapy (oestrogen and progesterone) helps to increase calcium levels and 
prevent osteoporosis and fractures (National Institutes of Health, 2012).  Post-menopausal 
women showed significantly lower serum calcium levels compared to PreM women, which 
corroborates previous evidence (Qureshi et al., 2010; Bhattarai et al., 2013). 
1.3.4.2 Vitamin D 
Basic physiology 
Vitamin D, important in the development and maintenance of bone, is mainly found in two 
forms, (i) ergocalciferol (vitamin D2), and (ii) cholecalciferol (vitamin D3) (Péréz-López et al., 
2011; Campbell, 2014; International Osteoporosis Foundation, 2015; Pavone et al., 2015).  
Vitamin D2 is synthesised in plants or yeasts when exposed to ultraviolet (UV) light, and 
therefore needs to be included in the diet (Oudshoorn et al., 2009; Chen et al., 2010; Jäpelt 
& Jakobsen, 2013; Campbell, 2014).   
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Vitamin D3 (cholecalciferol) is synthesised in the epidermis of skin after the precursor of 
vitamin D, 7-dehydroxycholesterol, is exposed to ultraviolet-B (UVB) light (Figure 1.11) 
(Wimalawansa, 2012; Campbell, 2014; International Osteoporosis Foundation, 2015; 
Pavone et al., 2015).  An average daily sunlight exposure ranging between ten to fifteen 
minutes to the face or arms is recommended sufficient for synthesis of vitamin D3 in most 
individuals (International Osteoporosis Foundation, 2015). 
The liver is responsible for the conversion of cholecalciferol into calcidiol (25(OH)D), which is 
further converted to the active form, calcitriol (1,25(OH)2D) by the kidneys (Péréz-López et 
al., 2011; Wimalawansa, 2012) (Figure 1.11).  Due to the longer half-life (15 days) of 
25(OH)D, it is considered the best marker to determine vitamin D status (Saliba et al., 2011; 
Péréz-López et al., 2011).  
 
Figure 1.11: Production of 25(OH) D and 1,25(OH)2D, and conversion of vitamin D2 and D3, from dietary 
sources and supplements.                 
(Adapted from Wimalawansa, 2012; Silverthorn, 2013; Sherwood, 2010). 
Small deficiencies in 25(OH)D cause an increase in PTH that will result in increased bone 
turnover.  This might subsequently lead to the development of osteopenia, osteoporosis and 
an increased fracture risk (Chen et al., 2010; Saliba et al., 2011).  Depending on the 
concentration of 25(OH)D, individuals can be categorised as either having deficient, 
insufficient, sufficient or an overload of vitamin D; however, the cut-off values used differs 
between studies (Table 1.6).   
Table 1.6: Classification of Vitamin D levels. 
Vitamin D levels 
classification 
Gutiérrez et al. 
(2011) 
Holick et al. 
(2011) 
Sharp (2011) 
Park & Lee 
(2012) 
Deficient ≤20 ng/mL <20 ng/mL 
21-29 ng/mL 20-29 ng/mL 
Insufficient 21-30 ng/mL 21-29 ng/mL 
Sufficient - - ≥30 ng/mL >30 ng/mL 
Excess - - -  
Vitamin D deficiency is considered a global epidemic in which individuals are at a higher risk 
of developing osteoporosis (Conesa-Botella et al., 2010).  The International Osteoporosis 
Foundation reported that several countries, including South Africa, Russia, China, Italy, and 
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Germany had 25(OH)D levels between 10-20 ng/mL, whereas France, the United Kingdom, 
Saudi Arabia and Brazil had 25(OH)D levels between 20-29 ng/mL.  Furthermore, Sweden, 
Thailand, Vietnam and Taiwan were the only countries to have 25(OH)D levels above 30 
ng/mL (International Osteoporosis Foundation, 2016).   
In a study investigating 25(OH)D status in PreM and PostM women in relation to obesity and 
BMD, it was reported that the main risk factors for 25(OH)D deficiency was obesity, poor 
sunlight exposure, inadequate vitamin D supplementation, high W:H and age (Ardawi et al., 
2011).  Some other factors that are associated with altered vitamin D synthesis include 
latitude, the season of the year, air pollution, clothing, skin pigmentation, and use of 
sunscreen (Martini et al., 2013).  
The RDA for vitamin D is 15 μg (600 IU) for women between the ages of one and 70 years, 
and 20 μg (800 IU) for individuals older than 71 years (Ross et al., 2011; Martini et al., 2013; 
Pavone et al., 2015).  Older women require higher doses of vitamin D, and a study on 
supplementation in PostM women indicated that supplementing with both 800 IU 
cholecalciferol and 1000 mg calcium carbonate, exerted positive effects on BMD 
(Kärkkäinen et al., 2010).  In agreement, in a majority female study population, Bischoff-
Ferrari et al. (2012) reported similar results where ≥800 IU/d vitamin D supplementation 
showed positive effects in preventing hip and non-vertebral fractures in individuals older than 
65 years.   
It was also suggested that optimal levels of 25(OH)D differ by race and ethnicity (Van 
Ballegooijen et al., 2014).  Melanin absorbs radiation from 290 – 700 nm including the 
portion that is responsible for vitamin D3 synthesis, which takes place at 290 – 313 nm.  
Therefore, increased melanin pigmentation decreases the production of vitamin D3 and 
requires longer exposure to sunlight to produce the same amount of vitamin D3 than lighter-
skinned individuals (Holick et al., 2004; Chen et al., 2010).  Despite similar serum Ca2+ 
levels, Gutiérrez et al. (2011) reported differences between Caucasian and Black 
individuals for both serum 25(OH)D (25.6±0.4 ng/mL vs. 14.8±0.4 ng/mL), as well as PTH 
levels (39.9±0.4 pg/mL vs. 46.5±0.7 pg/mL).  Furthermore, in Caucasians, higher levels of 
25(OH)D were associated with higher BMD, but this was not true in Afro-American Black 
and Hispanic individuals (Van Ballegooijen et al., 2014).   
Vitamin D and the metabolic syndrome risk factors 
Vitamin D deficiency has been associated with some of the individual MetS risk factors 
(Alkharfy et al., 2013; Saedisomeolia et al., 2014).  Several studies, as listed in Table 1.7, 
reported significantly lower or inadequate levels of 25(OH)D in MetS individuals in 
comparison to Non-MetS individuals.  
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Table 1.7: Comparison between 25(OH)D concentrations between MetS and Non-MetS groups in different 
studies.  
 MetS Non-MetS p-value 
Hernández et al. (2011) 21.4±7.8 ng/mL 24.1±8.9 ng/mL p<0.0001 
Makariou et al. (2012) 11.8 ng/mL 17.2 ng/mL p=0.027 
Gagnon et al. (2012) 25±9 ng/mL 27±10 ng/mL p<0.001 
Barchetta et al. (2013) 13.5 ng/mL 17.4 ng/mL p<0.007. 
Gagnon et al. (2011) reported that the relationship between 25(OH)D and the MetS is 
mediated by IR in individuals with a BMI of ≥25 kg/m2.  Both Saedismeolia et al. (2014) and 
Bea et al. (2015) found increased FBG levels in 25(OH)D-deficient individuals, which was 
also corroborated by Alissa et al. (2015) and Kim et al. (2015) where an inverse correlation 
was made between 25(OH)D and FBG.  Here, it was shown that 25(OH)D supplementation 
can improve insulin sensitivity through stimulation of insulin receptor expression in peripheral 
tissues, and that low 25(OH)D concentration was associated with beta-cell dysfunction (Al-
Daghri et al., 2012; Baker et al., 2012; Alissa et al., 2015). 
Obesity has been linked to lower serum 25(OH)D levels, and/or decreased 25(OH)D 
bioavailability.  This is due to the sequestering effect of the high quantity of SAT on 
circulating 25(OH)D (Martini et al., 2013; Bea et al., 2015).  Ardawi et al. (2011) and George 
et al. (2013) reported an inverse association between serum 25(OH)D and BMI, suggesting 
that inadequate 25(OH)D levels might be a potential contributor to the development of the 
MetS.  It was also proposed that increased adiposity is associated with increased catabolism 
of 25(OH)D by the 24-hydroxylase enzyme, or that adiposity is responsible for a decreased 
hepatic synthesis of 25(OH)D (Martini et al., 2013).   
When investigating the association between WC and 25(OH)D levels, Martini et al. (2013) 
reported a positive association, with an increase of 0.20 nmol/L in 25(OH)D for each one 
centimeter increase in WC.  Gradillas Garcia et al. (2015) reported a negative and significant 
association between 25(OH)D and WC (r=-0.19, p=0.0014), which is in agreement with the 
statement made by Bea et al. (2015) who reported a significant association between low 
levels of 25(OH)D and a high WC.   
Inconsistent results have been published regarding the association of 25(OH)D and BP.  
Forman et al. (2013) found that supplementing individuals with 25(OH)D for three months, 
significantly and exponentially lowered SBP.  Vitamin D might reduce BP via improvement of 
endothelial function (Sugden et al., 2008; Tarcin et al., 2009) or reduce the activity of the 
renin-angiotensin-aldosterone system (Forman et al., 2010).  This is corroborated by Bea et 
al. (2015) who reported that 25(OH)D-deficient individuals tend to have higher BP. Gradillas 
Garcia et al. (2015) reported contrasting results, with a negative association between 
25(OH)D and mean BP (r=-0.19, p=0.002). 
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Makariou et al. (2012), Baker et al. (2012), Alissa et al. (2015), Bea et al. (2015) and Kim et 
al. (2015) found a significant inverse association between 25(OH)D and TG.  Evidence 
suggests a relationship between 25(OH)D deficiency and dyslipidemia, possibly due to the 
effects of 25(OH)D on hepatic lipid metabolism (Baker et al., 2012).  It is proposed that 
vitamin D increases intestinal Ca2+ absorption, with the latter binding to FA, forming insoluble 
complexes that inhibit lipid absorption.  Therefore, 25(OH)D deficiency may lead to abnormal 
lipid processing via alterations in Ca2+ availability (Baker et al., 2012).   
Kim et al. (2015) also reported a negative and significant association between 25(OH)D and 
TC, whereas, Saedisomeolia et al. (2014) reported only weak no-significant associations 
between these two measures.  Kim et al. (2015) reported that participants with 25(OH)D 
levels below 30 ng/mL have significantly higher levels of TC (186.5±38.1 mg/dL) than those 
with 25(OH)D levels of ≥30 ng/mL (174.9±30.3 mg/dL; p=0.021).  In contrast, a study by 
Saedisomeolia et al. (2014) reported no significant difference between TC levels in 
participants with 25(OH)D levels of ≥50 nmol/L and <50 nmol/L (p=0.44).    
Vitamin D, ageing and menopause 
A strong association exists between vitamin D3 deficiency, ageing and menopausal status, 
since the generation of vitamin D3 after sunlight exposure is less effective in the elderly due 
to a decline in the levels of cutaneous 7-dehydrocholesterol (Oudshoorn et al., 2009; Chen 
et al., 2010).  Supporting this evidence, Arabi et al. (2010) reported that 25(OH)D levels 
were significantly lower in older individuals (10.9±5.0 ng/mL) than in younger ones (14.2±8.1 
ng/mL; p<0.05).  A simultaneous decrease in sunlight exposure is also noted in the elderly, 
as these populations tend to be immobile and socially isolate themselves (Oudshoorn et al., 
2009).  Another factor contributing to 25(OH)D3 deficiency in the elderly is the increase in 
body fat with ageing, since this leads to a larger distribution volume for the fat-soluble 
25(OH)D3, thereby decreasing the bioavailability of 25(OH)D3 (Oudshoorn et al., 2009).   
Ageing is also associated with a decrease in the expression of the vitamin D receptors 
(VDR) in bone, gastro-intestinal tract, as well as muscle tissue (Oudshoorn et al., 2009).  
Oestrogen, growth hormone and 1,25(OH)2D are stimulators of VDR expression, and it is 
established that serum levels of these stimulators decrease with ageing (Oudshoorn et al., 
2009).  Ageing might also result in decreased binding of 1,25(OH)2D to the VDR receptor 
and cause VDR alterations leading to vitamin D resistance (Oudshoorn et al., 2009).  Two 
studies reported significant differences between 25(OH)D levels in PreM and PostM women, 
with PreM having significantly higher levels than the PostM women (17.22±12.21 ng/mL vs. 
13.34±9.96 ng/mL; p=0.000 and 30.21±4.20 ng/mL vs. 25.07±4.30 ng/mL; p=0.000 
respectively) (Ardawi et al., 2011; Wang et al., 2013).   
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1.3.4.3 Parathyroid hormone 
Basic physiology 
The four parathyroid glands, located posterior to the thyroid gland secrete parathyroid 
hormone (PTH) (Silverthorn, 2013).  This hormone functions as an efficient regulator of 
plasma Ca2+ levels, and maintaining bone health (Sharp, 2011), via the parathyroid 
endocrine cells, and the G-protein-coupled Ca2+ receptors on the membrane of the 
parathyroid endocrine cells (Silverthorn, 2013).  A decrease in plasma Ca2+ stimulates PTH 
secretion to release Ca2+ into the bloodstream via increased bone resorption, as well as 
increased reabsorption of Ca2+ in the small intestine and kidneys (Figure 1.12) (Walsh, 2014; 
Campbell, 2014).   
 
Figure 1.12: PTH regulating calcium levels.                                                                                                                                   
(Adapted from Silverthorn, 2013). 
Parathyroid hormone and the metabolic syndrome  
Parathyroid hormone can stimulate the development of hypertension in both a Ca2+-
dependent and -independent manner (Yagi et al., 2014).  The Ca2+-dependent manner is via 
receptors (calcium-sensing receptors) located in the parathyroid glands, the brain and 
kidneys that result in decreased sodium reabsorption, as well as a secondary decrease in 
Ca2+ reabsorption (Yagi et al., 2014).   
Parathyroid hormone receptors are also expressed in the endothelium and vascular smooth 
muscles of blood vessels (Garcia et al., 2013; Yagi et al., 2014).  Circulating PTH might 
affect intracellular signalling, resulting in intracellular Ca2+ overload.  This can lead to cell 
injury and cell death via promoting structural and functional modification to these cells, 
altering the mobility of the arteries, thereby altering BP (Garcia et al., 2013; Yagi et al., 2014; 
Van Ballegooijen et al., 2014).   
High serum PTH and Ca2+ levels are suggested to be risk factors for hypertension (Yagi et 
al., 2014; Van Ballegooijen et al., 2014), since PTH was positively correlated with BP 
(increased SBP and DBP) (Garcia et al., 2013).  Parathyroid hormone receptors are also 
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expressed in the myocardium and can therefore act on cardiomyocytes to promote left 
ventricular hypertrophy, vascular stiffness and chronotropic effects on the pacemaker cells of 
the heart, thereby producing an immediate and continuous increase in heart rate (Garcia et 
al., 2013; Yagi et al., 2014).  In addition, two separate studies reported significantly higher 
PTH in hypertensive participants, where hypertensive individuals had a higher mean PTH 
concentration compared to normotensive individuals (44.3±18.6 pg/mL vs. 37.7±17.7 pg/mL, 
p=0.006) (Garcia et al., 2013); and 109.3±81.4 pg/mL vs. 56.1±58.8 pg/mL, p<0.001) (Yagi 
et al., 2014).  
A statistically significant difference was also noted in the intact PTH levels between MetS 
and Non-MetS women (57.8±28.8 pg/mL vs. 51.2±18.0 pg/mL, p=0.001) (Hernández et al., 
2011).  In contrast, Guasch et al. (2012) found no association between PTH and the MetS 
and Alissa et al. (2014) reported no significant difference in PTH levels between MetS and 
Non-MetS, PostM women (54.52±2.82 pg/mL vs. 54.52±3.76 pg/mL).   
Parathyroid hormone was also positively associated with BMI, WC and percentage fat mass 
(% FM) (Garcia et al., 2013).  Higher serum PTH levels were associated with older age, 
Black and Hispanic race, higher BMI, SBP, lower 25(OH)D levels and phosphate 
concentrations (Van Ballegooijen et al., 2014). 
Parathyroid hormone, ageing and menopause 
Supporting evidence has shown a link between ageing, and an increase in PTH 
concentrations, due to vitamin D deficiency, renal insufficiency and low dietary calcium 
intake (Oudshoorn et al., 2009; Arabi et al., 2010; Kruger et al., 2011; Valcour et al., 2012).  
Joo et al. (2013), reported a significant difference in individuals between the age ranges 50-
59 years (64.4 pg/mL), and 60-69 years (69.1 pg/mL), and >70 years (78.1 pg/mL; p<0.001), 
and similarly Van Ballegooijen et al. (2014) found a positive association between PTH and 
older age.  
Studies by both Ardawi et al. (2011) and Wang et al. (2012) reported significant differences 
in the PTH concentrations between PreM and PostM women (47.10±27.55 pg/mL vs. 
54.64±31.55 pg/mL; p=0.000 and 35.59±23.25 pg/mL vs. 40.94±24.67 pg/mL; p=0.000, 
respectively) (Ardawi et al., 2011; Wang et al., 2012).   
1.3.5 Risk factors associated with bone mineral density 
In addition to the bone-specific, biochemical and nutritional markers, other factors also affect 
BMD.  These factors can either be modifiable or lifestyle-associated risk factors and non-
modifiable risk factors.  The presence of the MetS is another risk factor that can affect BMD 
that is of particular interest in this study.  
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There exists an unusual paradox between the MetS and BMD (Xue et al., 2012).  Studies by 
Hwang & Choi (2010) and Alissa et al. (2014) suggested that the MetS influences BMD 
negatively since women with the MetS had significantly lower BMD compared to Non-MetS 
women.  Jeon et al. (2011) also found that the MetS was negatively correlated with BMD of 
the lumbar spine and femoral neck in PostM women, as well as the lumbar spine of PreM 
women (Finkelstein et al., 2008; Jeon et al., 2011).  This difference observed here might be 
due to BMD loss that occurs at a more gradual rate at the femoral neck than the lumbar 
spine (Finkelstein et al., 2008; Jeon et al., 2011).  Additionally, both Hwang & Choi (2010) 
and Nóbrega da Silva et al. (2014) reported that the individual MetS risk factors, negatively 
affects BMD, with individuals having two or more risk factors showing significantly lower 
BMD compared to individuals with only one, or no MetS risk factors.  
In individuals with the MetS, a lower prevalence of osteopenia and osteoporosis were 
reported, even after adjustment for body weight and age (Alissa et al., 2014; El Maghraoui et 
al., 2014).  It was found that the MetS have the potential to increase BMD and reduce the 
risk of fractures, therefore not detrimental to bone health, but rather protective (Alissa et al., 
2014).  This was corroborated in a study by Muka et al. (2015), which reported that females 
with the MetS had significantly higher BMD than Non-MetS women.  
To summarise, it is apparent that there are various discrepancies of whether the MetS and 
its contributing risk factors have a positive or negative effect on bone health.  Reasons for 
the differences range from ethnicity, ageing, the presence of other pathological conditions, or 
treatments (Hwang & Choi, 2010).  Each of the individual MetS risk factors and their effects 
on BMD will follow. 
1.3.5.1 Blood pressure - hypertension 
Contrasting evidence have been reported on the association between BMD and 
hypertension (Javed et al., 2010; Alissa et al., 2014; Kaplan et al., 2010).  Although not 
significant, a weak positive correlation (r=0.150) was observed between DBP and BMD at 
the femoral neck in PostM women (Alissa et al., 2014).  Another study also reported DBP 
was associated with BMD at both the femoral neck and lumbar spine in PostM women (Jeon 
et al., 2011).  
In PreM women, SBP was significantly associated with BMD at the lumbar spine and DBP 
was significantly associated with BMD at the femoral neck (Jeon et al., 2011).  It is 
speculated that hypertension might be related to low BMD due an increase in the serum 
intact PTH concentration (Jeon et al., 2011).  The Ca2+ homeostasis abnormalities, present 
in hypertensive individuals, result in increased urinary excretion of Ca2+ (Nóbrega da Silva et 
al., 2014; Jeon et al., 2011).   
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Hypertension treatment 
There are many classes of anti-hypertensive treatment options, including; thiazide diuretics, 
beta-blockers, loop diuretics and Ca2+ channel blockers (CCB’s) (Ilić et al., 2013; Ghosh & 
Majumbar, 2014).  In a hypertensive, PostM female study population, those treated with 
thiazides had higher BMD and lower bone turnover marker (PINP and ß-CTx) levels than the 
controls (Olmos et al., 2010).  It is hypothesised that the effects of thiazide on BMD is 
mediated via reduced urinary Ca2+ excretion, increasing serum Ca2+ levels, that should 
decrease PTH secretion and decrease bone turnover (Olmos et al., 2010; Ruths et al., 
2015).  Furthermore, thiazide diuretics also possibly stimulate osteoblasts directly and 
thereby increases bone formation (Ghosh & Majumbar, 2014; Ruths et al., 2015).   
Beta-adrenergic blockers (BB’s) are a class of anti-hypertensive medications that act as an 
antagonist to the beta-adrenergic receptors in the heart and blood vessels (Hwang et al., 
2015).  In addition, beta-adrenergic receptors are also found on osteoclasts and osteoblasts 
and BB might possibly increase BMD via inhibition of the beta-adrenergic receptors in bone 
(Ghosh & Majumbar, 2014; Hwang et al., 2015).  Both Yang et al. (2011) and Song et al. 
(2012) confirmed this where they reported a decrease in hip fractures because of treatment 
with BB’s.  In contrast, Butt et al. (2012) reported an increased risk of fractures after initiation 
of BB treatment, but this might be due to the study population or differences in the 
adjustment of confounding factors.  
Loop diuretics increase urinary Ca2+ loss, thus negatively affecting BMD (Illic et al., 2013; 
Ghosh & Majumbar, 2014).  Here, it was hypothesised that there is an increased renal Ca2+ 
leak, as well as increased PTH and 1,25(OH)2D concentrations in the plasma (Illic et al., 
2013).  Calcium channel blockers decrease arterial stiffness, which is common during 
hypertension, specifically in the elderly (Hwang et al., 2015).  Calcium channel blockers 
might affect BMD via the inhibition of voltage-gated calcium channels, but ultimately seem to 
have no detrimental or beneficial effect on BMD (Ghosh & Majumbar, 2014).   
1.3.5.2 Dyslipidaemia 
Several studies have investigated the association between lipids and BMD; however, results 
have been inconsistent.  For example, Jeon et al. (2011) reported a positive correlation 
between HDL-c and BMD in the lumbar spine of PostM women, but Li et al. (2015) reported 
that higher levels of HDL-c were positively associated with a higher probability of having 
osteoporosis in a PostM Chinese population.   
Jeong et al. (2014) reported that the pathogenesis of osteoporosis might be associated with 
altered lipid metabolism.  Disorders of lipid metabolism may result in high levels of oxidised 
lipids, which is also considered to be the common trigger between these two conditions.  
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Oxidised lipids stimulates adipocyte differentiations and suppress osteoblast differentiation.  
(Wong et al., 2016; Jeong et al., 2014).  Oxidised lipids stimulate arterial wall mineralisation, 
which facilitates the development of atherosclerosis (Jeong et al., 2014).  It was suggested 
that HDL-c inhibits the osteogenic activity of vascular cells via the induction of inflammatory 
cytokines (IL-6 and IL-β) (Nóbrega da Silva et al., 2014).   
Joeng et al. (2014) reported no differences in HDL-c and TG between women with normal 
and low BMD, suggesting that HDL-c and TG might not be directly related to bone 
metabolism (Joeng et al., 2014).  In agreement, in Chinese PostM women, no association 
were evident between TC, TG and LDL-c and osteoporosis (Li et al., 2015).  
In a PostM study population, TC was however negatively associated with BMD at the 
femoral neck (Kim et al., 2010) and Joeng et al. (2014) reported a similar result in PreM 
women, but interestingly the opposite was true in PostM women, where higher TC was 
associated with higher BMD. 
Cholesterol lowering agents 
The use of statins has been associated with an increase in BMD and a decrease in fracture 
risk, indicating a positive effect on BMD (Jeong et al., 2014).  For example, a study 
investigating the effects of atorvastatin on BMD reported significantly higher total hip BMD 
(Chuengsamarn et al., 2010).  Similarly, daily treatment with fluvastatin for three years, 
resulted in moderately increased bone formation, and stability in PostM 
hypercholesterolaemic women (Gotoh et al., 2011).  The mechanism by which statins might 
increase bone formation and BMD is possibly via increased ALP activity and osteoblast 
differentiation or inhibition of osteoclast differentiation (Mandal, 2015). 
Some statins exert a similar effect as amino-bisphosphonates, a commonly used agent for 
the treatment of osteoporosis, that decreases the rate of bone turnover  (Chuengsamarn et 
al., 2010; Appelman-Dijkstra & Papapoulos, 2014).  Although another study reported that 
statin treatment did not change bone turnover makers (CTx, BAP, osteocalcin), it did 
significantly reduce the osteocalcin: CTx ratio (Jiang et al., 2007).   
1.3.5.3 Fasting plasma glucose and insulin concentrations 
Kim et al. (2010) found no significant association between FBG and BMD at the femoral 
neck (r=-0.037, p=0.220) and similarly, Alissa et al. (2014) also reported non-significant 
associations between FBG and BMD at the lumbar spine and femoral neck of PostM 
women.  However, in the same PostM study population, FBG was significantly associated 
with total body BMD (r=0.193, p<0.01) (Alissa et al., 2014).   
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Furthermore, Alissa et al. (2014) reported that circulating insulin concentrations were the 
main determinant of BMD at the femoral neck and lumbar spine; whereas Muka et al. (2015) 
reported that, the association between the MetS and higher BMD was due to elevated 
glucose levels.  A possible mechanism associated with the negative correlation between 
abnormal glucose levels and BMD, might be increased urinary Ca2+ excretion 
(hypercalciuria) and increases in inflammatory markers and cytokine levels (Nóbrega Da 
Silva et al., 2014). 
The low-grade inflammatory state present in IR individuals was proposed to be one of the 
common pathogenic mechanisms increasing fracture risk in these individuals (Jeon et al., 
2011; Alissa et al., 2014; El Maghraoui et al., 2014).  During this state there is increased 
secretion of pro-inflammatory cytokines (TNF-α, IL-1 and IL-6), inducing bone resorption with 
a resultant lower BMD.  It is further suggested that these pro-inflammatory cytokines can 
stimulate osteoclast activity through regulation of the RANKL-RANK system (Cao, 2011).   
Furthermore, in obese individuals, increased levels of plasma insulin result in the 
overproduction of ovarian androgen and oestrogens with an insufficient production of sex 
hormone-binding globulin (SHBG) by the liver (Taie & Rasheed, 2014).  These hormonal 
changes might result in elevated sex hormone levels and increased bone mass, due to 
reduced osteoclast activity and stimulation of osteoblasts (Taie & Rasheed, 2014).  
1.3.5.4 Obesity  
Studies investigating the relationship between BMD and fat distribution reported conflicting 
results (Zillikens et al., 2010; Cohen et al., 2013; Alissa et al., 2014).  Although obesity could 
be considered a protective factor against excessive bone loss during ageing, FM positively 
influenced BMD, possibly due to the increased conversion of androgens to oestrogens in AT 
(Zillikens et al., 2010; Jeon et al., 2011; Chantler et al., 2012; Alissa et al., 2014).  In 
addition, obesity might also lead to an increased BMD via the higher mechanical loading 
associated with obesity (Kruger et al., 2011; Xue et al., 2012; El Maghraoui et al., 2014). 
Several studies reported abdominal obesity might reduce BMD via the effect of elevated pro-
inflammatory cytokines in obese individuals (for example IL-6, interleukin-9 (IL-9) and TNF-
α), activating osteoclastic bone resorption (Kim et al., 2010; Migliaccio et al., 2011; Chantler 
et al., 2012; Cohen et al., 2013; Liu et al., 2013; El Maghraoui et al., 2014; George et al., 
2014).  Furthermore, studies investigating the effect of the MetS on BMD reported that the 
negative effect of the MetS on BMD was largely predicted by WC (Kim et al., 2010; Jeon et 
al., 2011), and that the only MetS risk factor that was significantly associated with BMD 
measurements was WC (Alissa et al., 2014).   
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In a study by Zillikens et al. (2010), the positive association between android fat distribution 
and BMD could largely be explained by the higher BMI, but when adjusted for BMI, android 
fat distribution had no or a negative association with BMD.  Additionally, a study by Sohl et 
al. (2015) indicated that not only BMI, but also FM influence QUS measurements, since a 
higher BMI was associated with higher BUA and SOS measurements, suggesting higher 
BMD’s.   
1.3.5.5 Lifestyle risk factors affecting BMD 
Physical activity 
Physical activity directly modifies bone remodelling via mechanical stimuli, resulting in 
increased mineralisation, as well as bone geometry (increased periosteal diameter and 
cortical thickness), thereby protecting against bone fractures (Langsetmo et al., 2012).  
Weight-bearing physical activities are more beneficial to bone health than non-weight-
bearing physical activities (Braun et al., 2015).  Therefore, it is recommended that individuals 
participate in weight-bearing endurance exercises, three to five times a week, and jumping 
and/or resistance exercise, two to three times a week for about 30 to 60 minutes per day in 
order to maintain bone health throughout adolescence (Braun et al., 2015). 
In contrast to the abovementioned findings, a study on skeletal robustness and bone 
strength, have shown that daily total steps as a measure of physical activity in young adults, 
did not significantly influence BQI (Scheffler et al., 2014).  Similarly, Sritara et al. (2015) 
reported that different types of physical activities had no significant effect on the lumbar 
spine, femoral neck or hip BMD in women. 
Breastfeeding 
During lactation, hyperprolactinemia and hypoestrogenemia levels promote bone resorption, 
as a result of increased plasma Ca2+ levels, allowing an increased Ca2+ uptake by mammary 
tissue, to provide Ca2+-rich milk to the infant (Lovelady et al., 2009; Bjørnerem et al., 2011; 
Prentice, 2013).  It is evident that there are marked changes in Ca2+ metabolism during 
lactation where significant Ca2+ is lost from the mother, depending on the quantity of breast 
milk produced, the diet of the mother, and duration of breastfeeding (Canal-Macias et al., 
2012).  The loss of BMD seems to be the greatest in the first five months of lactation 
(Lovelady et al., 2009). 
In contrast to the abovementioned statements, a study on PostM Turkish women found no 
relationship between the duration of breastfeeding and BMD, and this study further 
concluded that longer duration (up to 220 months) of breastfeeding did not affect bone mass 
later in life (Yazici et al., 2011).  Greater losses in trabecular vs. cortical bone was also 
reported during lactation, although the BMD returns to normal levels once breastfeeding is 
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ceased and is completely restored in the medium to long-term (Canal-Macias et al., 2012).  
A proposed mechanism for the return of BMD to normal levels is that weaning will allow 
oestrogen repletion that will increase osteoblast activity.  This will increase Ca2+ uptake into 
bone, that will decrease serum Ca2+, resulting in increased PTH and 1,25(OH)2D.  The 
resultant increase in PTH and 1,25(OH)2D will increase renal Ca2+ reabsorption and increase 
intestinal Ca2+ absorption respectively (Prentice, 2013). 
Bjørnerem et al. (2011) reported that breastfeeding was associated with a lower risk of hip 
fracture.  Similarly, Canal-Macias et al. (2012) reported that in PreM women with a history of 
breastfeeding, a higher total BMD, higher BMD at the lumbar spine, as well as cortical bone 
were present.  It is therefore evident that breastfeeding had no deleterious effects on BMD, 
and in fact, may provide modest protection against fractures.  
Smoking 
Previous smokers and/or snuff users might have a higher risk of developing osteoporosis, 
with heavy smokers being at an even higher risk of hip fractures (Ayo-Yusuf & Olutola, 
2014).  Smoking might affect BMD via decreasing Ca2+ absorption and decreasing 
circulating levels of PTH and 25(OH)D (Øyen et al., 2014).  Smoking is a known factor that 
leads to increased production of free radicals, which may result in increased bone 
resorption.  Elements present in tobacco, decrease oestrogen production, which affects the 
intestinal absorption of Ca2+ (Kruger et al., 2011).  
It was also suggested that smoking causes a decrease in FM, which results in decreased 
bone formation and an increased fracture risk (Shahab, 2012).  Others reported that the 
lower BMD commonly seen in smoking individuals might be due to lower body weight or FM, 
rather than the direct effect of smoking (Øyen et al., 2014; Ayo-Yusuf & Olutola, 2014).   
Nicotine has also been stated to have anti-oestrogenic effects and might lead to the 
development of early menopause and osteoporosis in female smokers (Ayo-Yusuf & Olutola, 
2014).  Shahab (2012) suggested that smoking increases oestradiol clearance and SHBG, 
which leads to lower levels of free oestradiol, leading to increased bone resorption.   
In smokers, ascorbic acid deficiency is common due to a greater turnover of this antioxidant, 
since it becomes depleted due to smoke-derived oxidant species (Varvadas et al., 2008; 
Sørensen et al., 2010; Shah et al., 2015).  This is detrimental to bone health since ascorbic 
acid is essential for the development of collagen, an important component of connective 
tissue (Peterkofsky, 1991; Sørensen et al., 2010).  This water-soluble vitamin increases the 
rate of bone healing (Bsoul & Terezhalmy, 2004), reduces bone loss, and acts as a 
protective factor against fractures (Shen et al., 2013).  It was also found that ascorbic acid is 
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essential for the proliferation and differentiation of mesenchymal stem cells into bone tissue 
(Shen et al., 2013).   
Alcohol consumption 
Several studies have shown that moderate alcohol consumption, which some studies report 
to be up to three drinks and other up to two drinks per day, increased BMD, possibly due to 
increased calcitonin levels that inhibit bone resorption (Kruger et al., 2011; Maurel et al., 
2012; Marrone et al., 2012; Sritara et al., 2015).  A study on women aged between 50 and 
62 years found that those who consumed more than one drink per day had significantly 
higher BMD at the lumbar spine and femoral neck than non-drinkers (Mclernon et al., 2012).  
In agreement, Marrone et al. (2012) also reported that moderate alcohol consumption may 
reduce the rate of bone loss in PostM women by diminishing increased bone turnover 
(Marrone et al., 2012).  In a study by Sommer et al. (2012), consuming more than three 
alcoholic drinks per week, was positively associated with BMD at the femoral neck and 
lumbar spine. 
On the contrary, chronic alcohol consumption can result in decreased serum vitamin D levels 
that will decrease Ca2+ absorption in the small intestine and cause low serum Ca2+ levels in 
circulation that will ultimately stimulate bone resorption (Maurel et al., 2012).  Chronic 
alcohol abuse was also linked to decreased BMD, decreased osteoblast number and 
function, possibly due to increased bone resorption and elevated PTH levels (Kruger et al., 
2011; Marrone et al., 2012).  To summarise, it is evident that moderate alcohol consumption 
seems to have a positive effect on BMD, but chronic alcohol intake (abuse) generally 
resulted in decreased BMD. 
Medications 
Contraceptives 
Hormone oral contraceptives (OC) can be classified as either combined contraceptives 
containing both oestrogen and progestin (synthetic progestogens), or a progestin-only 
contraceptive, containing only progestin (WHO, 2016).  A study comparing the use of 
combined oral contraceptives (COC) and progestin-only contraceptives, found that women 
(26-36 years old) using COC, had significantly higher BMD than those using the progestin-
only contraceptives (Wei et al., 2011).  Differences in the effect of OC on BMD have also 
been reported by Elkazaz & Salama (2015), were the absence or previous use of OC had a 
positive effect on BMD, in comparison to current OC users.  
The injectable contraceptive, depot medroxyprogesterone acetate (DMPA), suppress 
ovarian oestrogen synthesis via the hypothalamic pituitary ovarian axis (Pitts et al., 2012).  
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Using DMPA has been linked to a decrease in bone mass, although this effect was reversed 
once DMPA was discontinued (Chantler et al., 2012; Pitts et al., 2012; Biason et al., 2015).  
The progestin-only injectable contraceptives are mostly used up to the age of 50 years; 
however, it should be discontinued thereafter, since its use significantly increases the risk for 
osteoporosis (National Contraception Clinical Guidelines, 2012; Lambert, 2014).  Treatment 
with OC increases BMD in both PeriM and PreM women due to hypoestrogenic conditions.  
This positive association might suggest that the beneficial effect of using OC’s during the 
reproductive years may persist even after OC cessation, and continue into the PostM years.  
This could be due to optimising PreM bone mass and/or the prevention of bone loss in the 
years prior to menopause (Wei et al., 2011).  
Glucocorticoids 
Elevated levels of glucocorticoids (GC) are detrimental to bone health (Hardy & Cooper, 
2010; Lane & Yao, 2010; Lau & Adachi, 2010).  The main naturally occurring GC in the 
body, cortisol, is produced by the adrenal glands, with receptors in almost all tissue types 
(Hardy & Cooper, 2010; Ragnarsson et al., 2015).  Cortisol, for example, has a major impact 
on protein, fat, and carbohydrate metabolism, the skeletal, cardiovascular and immune 
system (Ragnarsson et al., 2015).  Furthermore, GC’s are widely used to treat chronic 
inflammatory conditions since they exert potent anti-inflammatory effects (Klein, 2015).  
In PostM women, bone formation and bone resorption are usually coupled and up-regulated; 
however, during GC treatment, these processes are uncoupled (Lems & Saag, 2015).  
Prolonged use of GC’s, can lead to a decreased BMD, increased fracture risk, and also an 
increased risk to develop CVD (Ragnarsson et al., 2015).   
Furthermore, the increased levels of GC’s in the body may result in the development of 
glucocorticoid-induced osteoporosis (Hardy & Cooper, 2010; Lane & Yao, 2010; Lau & 
Adachi, 2010).  This is possibly due to GC increasing osteocyte apoptosis or increasing 
skeletal fragility via a decrease in muscle mass and decreased mechanosensing (Hardy & 
Cooper, 2010).  The effects on osteoblasts include a decrease in their proliferation, which 
then leads to a decrease in bone formation and increased apoptosis of these cells (Lane & 
Yao, 2010; Lau & Adachi, 2010).  Conversely, the effects on osteoclasts seem to be 
multifactorial as decreases in growth factors, sex steroids and Ca2+ absorption and 
resorption all affect the osteoclasts (increasing PTH levels).  All this contributes to the 
increased levels of RANKL and decreased OPG (Lau & Adachi, 2010).  The decreased OPG 
levels and increased RANKL levels result in increased osteoclast absorption and survival, as 
well as decreased apoptosis of osteoclasts (Lau & Adachi, 2010).   
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Supplements 
Both vitamin D2 and D3 can be given as supplements to increase circulating levels of 
25(OH)D, although vitamin D3 generally produce higher levels of circulating vitamin D due to 
its longer retention time in the body (Wimalawansa, 2012).  A study investigating the use of a 
combination of calcium and vitamin D supplements found these supplements to be 
associated with a better maintenance of bone health when BMD was measured at several 
anatomical sites (Zhou et al., 2013).  Another report suggested that vitamin D 
supplementation alone, might not be as sufficient to treat osteoporosis, and it is therefore 
recommended to take both vitamin D3 and calcium supplements (Madar et al., 2015). 
1.3.5.6 Non-modifiable risk factors 
Genetics (Familial bone health and disease history) 
According to Sedó Sarkis et al. (2011), genetic factors account for 75-80% of the variation in 
PBM.  A study indicated that parental history of bone fractures (amongst other factors) was a 
predictor of lower BMD in the offspring (Bączyk et al., 2012).  Although this relationship exist, 
the correlation between parental history of fractures and reduced BMD in the offspring was 
very weak (Bączyk et al., 2012).  
A South African study found that adolescents had a decreased risk of fracture in the 
presence of increased maternal bone mineral content (BMC) at the lumbar spine.  A 24% 
reduction in fracture risk with every SD increase in maternal lumbar spine BMC was noted.  
Despite the above-mentioned finding, maternal history of fractures was not associated with 
fractures in the offspring (Thandrayen et al., 2014). 
Ethnicity 
Since high concentrations of melanin in Black or African-American individuals reduce the 
skin’s ability to generate vitamin D3 from sunlight, vitamin D deficiencies are more common 
in African-Americans than in Caucasians (Sharp, 2011; Johnson, 2013).  Research indicated 
that the Black population requires larger doses of UVB exposure to achieve a maximal 
cutaneous synthesis of vitamin D (Ardawi et al., 2011).  The vitamin D deficiency in Black or 
African-American individuals might result in a lower BMD in these population groups than in 
Caucasians. 
Contrasting to the above mentioned, a South African study reported higher BMD in Black 
African women (age according to BMI <25 kg/m2: Black: 35±9, Caucasians: 39±6; p<0.01); 
BMI ≥25 kg/m2: Black: 37±8, Caucasians: 37±7).  In this study, it was hypothesised that the 
increased BMD in Black African women were likely due to the higher body mass in these 
participants compared to the Caucasian participants (Conradie et al., 2014).  This is quite 
likely since a study comparing African-Americans, Caucasians, Chinese and Japanese 
Stellenbosch University  https://scholar.sun.ac.za
 
 
44 
 
women also reported that the differences in the rates of bone loss during the menopausal 
transition was largely due to the differences in body mass between the ethnic groups 
(Finkelstein et al., 2008).  In addition, Sowers et al. (2013) and George et al. (2014) also 
reported differences in BMD between ethnic groups due to body mass.   
A South African study reported that the femoral neck and total hip BMD, but not lumbar 
spine BMD, was significantly higher in Black compared to Caucasian women (Chantler et al., 
2012).  At the femoral neck and total hip, bone consists mainly of cortical bone, which is 
more responsive to weight-bearing and mechanical loading than trabecular bone.  In this 
specific study, the Black women had higher body masses than the Caucasian group, and the 
mechanical loading effect of increased body mass might be the reason for differences 
between these two groups (Chantler et al., 2012).   
Therefore, although studies reported differences in the 25(OH)D levels between different 
ethnic groups (Sharp, 2011; Johnson, 2013; Ardawi et al., 2011), the results still indicated 
that BMD was higher in Black individuals, but this was likely due to higher body masses in 
these groups (Conradie et al., 2014; Sowers et al., 2013; George et al., 2014). 
Hormonal status (menopause) 
The three forms of oestrogen include 17β-oestradiol (E2), oestrone and oestriol, with E2 
being the most physiological active form (Pradhan, 2014).  In PreM women, oestrogen is 
primarily released from the ovaries, but aromatization in AT also produces oestrogen 
(Pradhan, 2014).  It is well known that oestrogen plays a major role in bone development 
and health, as well as bone mass accrual up to PBM (Khosla et al., 2012; Karsenty, 2012).  
Decreases in oestrogen concentrations will therefore result in decreased BMD (Khosla et al., 
2012; Karsenty, 2012). 
Age-related bone loss commences immediately after PBM is reached, although the largest 
portion of bone loss occurs after the age of 65 years (Silva et al., 2015).  Bone loss initially 
occurs at a rapid rate, but the rate of bone loss gradually decreases after about five to ten 
years into menopause.  Oestrogen replacement therapy has the ability to protect against 
decreases in BMD during menopause, which is normally reached between the ages of 45 
and 56 years (Al-Safi & Polotsky, 2014; AlDughaither et al., 2015).  During menopause, the 
menstrual cycle stops due to the termination of ovarian hormone production, and common 
side effects or symptoms develop, which includes hot flushes, sleeping disturbances, joint 
and muscular discomfort, fatigue and joint stiffness (AlDughaither et al., 2015).  
Menopause is also associated with increased FM, which has a positive effect on BMD, due 
to higher levels of oestrogen (Zillikens et al., 2010; Migliaccio et al., 2011; Al-Safi & Polotsky 
2014).  In PostM women, oestrogen is synthesised via the enzyme aromatase from 
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androgen precursors, situated in AT; therefore, oestrogens synthesised in AT is one of the 
major sources of oestrogen in PostM women (Migliaccio et al., 2011).  After the age of 50, 
weight loss increases the risk of hip fractures, whereas weight gain results in a lower risk of 
hip fractures (Silva et al., 2015). 
In PostM women, bone loss occurs as a result of increased and unbalanced bone turnover, 
where bone resorption dominates over bone formation (Marrone et al., 2012).  Loss of BMD 
during menopause occurs in two stages.  During Stage one, there is an oestrogen-
dependant exponential decrease in BMD continuing for approximately five to ten years 
(Figure 1.13).  Stage two is considered more constant, where bone loss occurs as a function 
of ageing  (Bączyk et al., 2012) (Figure 1.13).  Prior to menopause, oestrogen facilitates the 
maintenance of bone strength through its diminishing effect on oxidative stress in bone and 
bone marrow; however, this effect is lost after menopause (You et al., 2014).  The presence 
of oestrogen deficiency during menopause causes the up-regulation of RANKL in bone 
marrow cells, resulting in increased bone resorption (You et al., 2014).  
 
Figure 1.13:  Variation of the bone density of women at different ages.                                                                        
(Brown & Duncan, 1999). 
In PostM women with hypo-oestrogenism, bone loss occurs at a rate of about 0.5 - 1.5% per 
year, and a small percentage of women classified as “fast bone losers”, can lose up to 3-5% 
bone mass per year.  Although these rates are dependent on hormonal, environmental and 
genetic factors (Silva et al., 2015), bone loss during menopause is due to the increased 
resorption by osteoclasts, nevertheless during ageing, there is reduced bone formation due 
to low number and function of osteoblasts (Bermeo et al., 2014).  From the evidence 
provided here, it is clear that age and menopausal status causes a decrease in BMD. 
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1.4 Summary 
From the cited literature, it can be argued that the MetS is not only a global problem, but 
there also seem to be some evidence linking this problem to the South African population.  
The literature provides sufficient reason to further explore this hypothesis.  The metabolic 
abnormalities seem to affect BMD; however, the current literature remains controversial 
regarding its potential positive or negative effects.  Abdominal obesity appears to be the 
main MetS factor affecting BMD.   
However, ageing and/or menopausal status are also known risk factors that negatively affect 
BMD.  Various assessment methods exist to determine BMD, and even though DEXA is 
regarded as the gold standard, this method is not easily accessible in South Africa; therefore 
the use of QUS might be a more practical method to assess BMD in a South African field 
setting.  To date, no reference values are available for BMD of the South African population, 
more specifically for the mixed (Coloured/Black) populations of South Africa.  There are also 
limited data on BMD in the context of the MetS and menopausal status of female farm 
workers in South Africa.  
1.4.1 Problem statement 
Little evidence exists investigating the combined effect of menopausal status and the MetS, 
on BMD.  There are also limited data available on the prevalence of the MetS in South 
Africa, specifically the Western Cape Province.   
Research questions 
We formulated the following research questions based on the problem statement: 
 What is the prevalence of the MetS and osteopenia and osteoporosis in a Western 
Cape female farm worker population? 
 Is there an association between menopausal status, MetS status, and BMD in a 
female farm worker community? 
1.4.2 Hypothesis 
From the second research question, this study hypothesises that there will be a difference in 
the BMD between PreM vs.PostM, and MetS vs. Non-MetS females. 
1.4.3 Aims  
The aims of this study were to: 
 establish the prevalence of the MetS in a selected female farm worker population in 
the Western Cape Province  
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 describing the risk factors associated with BMD in this female farm worker 
population  
 determine the interaction between BMD (bone health), menopausal status, and the 
MetS. 
1.4.4 Objectives 
 To categorise the female volunteers into groups according to their menopausal 
(PreM and PostM) and metabolic status (presence or absence of the MetS); 
 To assess BMD using the SONOST 3000 (OsteoSys Ultrasound Bone Densitometer) 
 To assess serum vitamin D, ALP, and PTH levels; 
 To obtain information on the bone health history of the participants; 
 To assess body composition using anthropometric measurements; 
 To determine the physical activity level of the participants with the Global Physical 
Activity Questionnaire 
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Chapter 2            Materials and Methods 
 
This chapter describes the materials and methods used to collect and analyse data for this 
research project.   
2.1   Ethical considerations 
Ethical clearance was obtained from the Human Research Ethics Committee (HREC) of 
Stellenbosch University, Protocol Nr (N13/04/052) (Appendix A).  Prior to the data collection, 
information sessions were held with potential volunteers at each of the different data 
collection sites, where they were informed about the study aims in an easily understood 
manner, and also had an opportunity to ask questions.  During these sessions, individuals 
had the opportunity to indicate whether they would be interested to participate, after which 
appointments were scheduled with volunteers. 
Before volunteers were recruited, the researcher made sure participants were still prepared 
to be part of the study.  After they volunteered, each participant signed a “Participant 
information and consent form” (Appendix B) prior to data collection.  Each participant 
received an unique study code, which was used on all questionnaires, as well as blood 
samples, ensuring privacy and anonymity.  In addition, participants were given the autonomy 
to withdraw their consent and participation at any time during data collection.  All hard copies 
of the consent forms were kept separate from the raw data, which were kept in a locked file 
drawer in a lockable office.  The data were entered using the Microsoft Office Excel 2010 
package, password protected and backed-up daily on the Stellenbosch University network 
server. 
2.2   Study design and sample population characteristics 
A cross-sectional study design was followed in which the association between the MetS and 
BMD in PreM- and PostM farm working women from the Boland wine district, Western Cape, 
South Africa were described.  The participants were recruited from three selected farming 
districts, including the Villiera Wine Estate (Owethu Clinic - Stellenbosch), Neethlingshof 
Wine Estate (Stellenbosch), and Solms-Delta Wine Estate (Franschoek).  
From the total sample population (including men), a total of n=191 participants (n=42 men, 
and n=149 women) between the ages of 20 and 60 years were recruited.  A total of two 
women withdrew their consent due to time constraints, where after the remaining women 
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(n=147) were subsequently divided into two main groups according to their metabolic status 
(MetS and Non-MetS).   
These women were further categorised according to age and menopausal status into (A) 
PreM - between the ages of 20 and 39 years, (B) PreM - older than or equal to 40 years of 
age, and (C) PostM.  Specific to this study, menopause or PostM was defined as the 
absence of menstruation for at least 12 consecutive months (Alissa et al., 2015; 
Ebrahimpour et al., 2010).  
A random sample of n=80 women were selected from the total sample (n=147), and 
subsequently categorised into the different study groups. Since there were relatively few 
PostM women with, and without the MetS, all the women in these specific groups were 
included.   
The final groups used for all data analyses are described as follows: 
 Group 1: n=14 PreM women with the MetS (between the ages of 20–39 years) (PreM 20-39 years) 
 Group 2: n=15 PreM women with the MetS (age ≥40 years) (PreM ≥40 years) 
 Group 3: n=15 PostM women with the MetS (PostM) - [All participants in this group were selected (no 
randomization)] 
 Group 4: n=14 PreM women without the MetS (between the ages of 20–39 years) (PreM 20-39 years, 
Non-MetS) 
 Group 5: n=14 PreM women without the MetS (age ≥40 years) (PreM ≥40 years, Non-MetS) 
 Group 6: n=8 PostM women without the MetS (PostM, Non-MetS) - [All participants in this group were 
selected (no randomization)] 
2.2.1 Inclusion and exclusion criteria 
Before recruitment, all eligible participants were selected based on the following inclusion 
and exclusion criteria:  
 Inclusion criteria: 
 All participants had to be women between the ages of 20-60 years; 
 All women had to be permanent South African residents, currently residing in 
the Western Cape Province (from the three selected districts); 
 Exclusion criteria  
 Any woman younger than 20, or older than 60 years of age; 
 Not a permanent resident of South Africa, or residing in the Western Cape 
Province. 
 Pregnant or lactating women 
 Any known bone disease 
 Human Immunodeficiency Virus and the use of Antiretroviral Therapy  
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2.2.2 Definition of the metabolic syndrome 
The IDF definition is one of the most widely used definitions in South African studies and 
therefore suitable for the classification of the MetS in this study population, to allow direct 
comparisons between studies.  This specific definition also includes a set range of optimal 
WC levels that are gender- and ethnic-specific.  Although there are no specific WC cut-off 
values for South Africans, the IDF suggested that the values for Europeans be used for 
populations in South Africa and Sub-Saharan Africa (IDF, 2006).  
Using the IDF definition, women were classified as having the MetS if they presented with an 
increased WC according to their ethnic group (Table 1.1), plus any two of the following 
criteria: increased TG (≥1.7 mmol/L), reduced HDL cholesterol (<1.29 mmol/L for women), 
increased BP (SBP ≥130 mmHg, or DBP ≥85 mmHg) and elevated FPG (≥5.6 mmol/L) (IDF, 
2006). 
2.3 Data collection  
After written informed consent was obtained, a registered HPCSA and GCP qualified 
medical biological scientist assessed BP and heart rate, followed by blood sampling.  Basic 
anthropometric measurements were recorded by the researcher on a proforma sheet 
(Appendix C), followed by BMD assessment.  Participants were then asked to complete a 
demographic questionnaire, a global physical activity questionnaire (GPAQ), and a bone 
health questionnaire.  
2.3.1 Blood pressure and heart rate 
Prior to BP and heart rate assessments, participants were allowed to remain in a relaxed, 
seated position for approximately five to ten minutes.  Blood pressure measurements were 
performed using an appropriately sized ERKA blood pressure cuff (Perfect Aneroid Clinic 48, 
Germany), and a Littmann 3M™ stethoscope (G13L 12829, Littmann 3M™ USA).  In cases 
where participants presented with very high, or low BP, repeated BP measurements were 
taken and the results averaged.  In cases where the second measurement also showed a 
potentially, critically elevated BP, the participant was immediately referred to medical staff.  
The heart rate was measured using a finger plethysmography heart rate monitor (Contec 
medical systems, China).   
2.3.2 Haematology 
Blood was drawn from the cubital vein in the right arm, under aseptic conditions and 
collected into a plasma fluoride tube (4 ml), an ethylenediaminetetraacetic acid tube (EDTA, 
4 ml) and two serum separating tubes (SST, 4 ml each).  The blood tubes were immediately 
inverted (eight times), where after the plasma fluoride tube was placed on ice for fasting 
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glucose analysis by PathCare laboratory (Stellenbosch).  The EDTA tube was immediately 
centrifuged (MRC Laboratory Centrifuge) for ten minutes at 4000 revolutions per minute 
(rpm), where after the plasma was aliquoted into 1.5 ml Eppendorf tubes and placed on dry 
ice until storage in a -80 ˚C bio-freezer.  The two SST tubes were allowed to clot at room 
temperature (22 °C) for ten minutes and subsequently centrifuged.  One SST tube was 
placed on ice for fasting insulin and lipogram analyses, performed by the local PathCare 
laboratory (Stellenbosch).  These blood parameters, together with WC and BP 
measurements, were then used to classify participants into either the MetS or Non-MetS 
groups respectively.  
Serum obtained from the remaining SST tube was aliquoted into 1.5 ml Eppendorf tubes and 
placed on dry ice until return to the Department of Physiological Sciences’ molecular 
laboratory, where the samples were stored in a bio-freezer (-80°C) for later analysis.  Serum 
samples were used to analyse vitamin D and serum alkaline phosphatase (sALP), while 
plasma samples were used for parathyroid hormone (PTH) analyses.  With the exception of 
sALP, which was also determined by the local PathCare laboratory (Stellenbosch), all 
remaining biochemical parameters were analysed by the researcher in-house, using an 
enzyme-linked immunosorbent assay (ELISA).  The reference levels of the different blood-
specific bone markers are provided in Table 2.1.   
Table 2.1: The reference levels of the bone-specific markers. 
Biochemical 
parameters 
Reference values Diagnoses 
Alkaline phosphatase 40 –120 units per litre (U/L) Normal 
Vitamin D 
< 20 nmol/L Deficient 
> 50 nmol/L Sufficient 
> 75 nmol/L No additional change in p-PTH levels 
> 125 nmol/L Excess 
Parathyroid Hormone  
15-65 pg/mL Normal 
>65 pg/mL High 
(Garcia et al., 2013; Saliba et al., 2011; ARUP Laboratories, 2014). 
2.3.2.1 Enzyme-linked immunosorbent assay 
The ELISAs that were used are classified as ‘sandwich’ ELISA assays.  Briefly, the 96-well 
plates were pre-coated with an immobilised capture antibody that binds to the target protein 
and captures it from the added testing sample. Hereafter, detection antibodies were added, 
Stellenbosch University  https://scholar.sun.ac.za
 
 
52 
 
allowing the formation of complexes with the captured target protein.  This step catalyses the 
appearance of a colour reaction via activation of a covalently-linked enzyme.  The colour 
produced here is then representative of the quantity of the target protein present in the 
sample.  
a) Parathyroid Hormone  
For the analysis of p-PTH, a BioVendor Human Parathyroid Hormone ELISA (Appendix D), 
(RIS003R) was used.  All procedures were done according to the manufacturer’s protocol.  
Samples and reagents were equilibrated at room temperature (22 °C) prior to analysis.  In 
order to establish whether the samples needed to be diluted, literature on similar populations 
were consulted, which revealed that PTH levels were relatively low and that no dilution is 
needed (Alissa et al., 2014; Ardawi et al., 2011; Batchetta et al., 2013; Garcia et al., 2013; 
George et al., 2013; Guasch et al., 2012; Guitierrez et al., 2011; Hernandez et al., 2011; Joo 
et al., 2013; Makariou et al., 2012; Reis et al., 2007; Van Ballegooijen et al., 2014; Yagi et 
al., 2014).  
For assay procedures, the calibrators (standards) and controls were reconstituted according 
to the datasheet provided by the supplier.  The following range of standards was supplied: 
1400 pg/mL; 666 pg/mL; 224 pg/mL, 70 pg/mL, 22 pg/mL and 0 pg/mL (blank).  Fifty 
microliters of incubation buffer was added to all wells, followed by 50 μL of the standards, 
controls and samples in duplicate.  The plate was incubated for two hours at room 
temperature (22 °C), followed by a thorough wash step (4 x 400 μL wash buffer).  Anti-PTH-
horseradish peroxidase (HRP) was added and left for an hour at room temperature (22 °C).  
The plate was repeatedly washed (three times), followed by the addition of a chromogenic 
solution containing 3,3’,5,5’-tetramethylbenzidine (TMB).  The plate was incubated for 30 
minutes, where after a stop solution was added. Absorbencies were recorded at 450 and 
490 nm using a plate reader (EL800 Universal Microplate Reader).  The quantity of substrate 
turnover was determined by measuring the absorbance, which was proportional to the p-
PTH concentration (Biovender ELISA).  
b) Vitamin D 
The vitamin D ELISA kit (Elabscience, E-EL-0012) with all its constituents, as well as the 
serum samples, were equilibrated to room temperature (22 °C) prior to analysis (Appendix 
E).  The standards were prepared to generate a standard curve with the following 
concentrations: 400 ng/mL, 200 ng/mL, 100 ng/mL, 50 ng/mL, 12.5 ng/mL, 6.25 ng/mL, and 
0 ng/mL.  Briefly, 50 µL of the standard solution and samples were added in duplicate to 
each well, followed by the addition of 50 μL of biotinylated detection antibody.  The plate was 
then allowed to incubate for 45 minutes at 37 °C on a shaker (Orbital Shaker Incubator, 
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MRC), followed by a triple wash step.  After this, a 100 μL HRP-conjugate was added and 
the plate incubated for 30 minutes at 37 °C, followed by washing the plate five times.  This 
was followed by adding 90 μL of substrate reagent, after which the plate was incubated for 
15 minutes at 37 °C until a stop solution, containing sulphuric acid, was added.  The 
absorbencies were recorded spectrophotometrically at a wavelength of 450 nm using a plate 
reader (EL800 Universal Microplate Reader). 
2.3.3 Anthropometry: base measurements 
All anthropometric assessments were done by the researcher according to the standard 
methodology from the International Society for the Advancement of Kinanthropometry (ISAK) 
and noted on the data collection sheet. 
2.3.3.1 Body mass 
Body mass was measured to the nearest 0.01 kg using a Seca 634 calibrated scale (Seca, 
United Kingdom, Birmingham, England).  Participants were instructed to remove their shoes 
and excess clothing, and remain in a still-standing position on the scale with their weight 
evenly distributed.  
2.3.3.2 Stretched stature 
Stretched stature was measured to the nearest 0.1 cm with a portable LeicesterTM 
stadiometer (Leicester, England).  Each participant was asked to stand upright against the 
stadiometer, with their heels together, also ensuring that their buttocks and scapulae were in 
contact with the stadiometer.  Participants were positioned in the “Frankfurt Plane”, and the 
Broca plane of the stadiometer moved downwards until it made contact with the vertex of the 
skull.  Participants were then asked to inhale and hold their breath, where after the 
researcher applied a slight upward pressure from the mastoid process in order to assess the 
stretched stature of the participant (Stewart & Sutton, 2012).  
2.3.3.3 The body mass index 
The base measurements, weight and height, were used to calculate the body mass index 
(BMI) (Equation 3). Table 2.2 provides the different classifications for the BMI.   
Equation 3: Calculation of BMI in kg/m2 
 BMI=
weight (kg)
height (m)
2  
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Table 2.2: Classification of BMI according to the WHO. 
WHO classification of BMI 
BMI (kg/m2) Classification 
<18.50 Underweight 
18.50-24.99 Normal 
≥ 25.00 Overweight 
30-34.99 Obese (class I) 
35.00-39.99 Obese (class II) 
≥40 Obese (class III) 
(WHO, 2015). 
2.3.3.4 The waist circumference 
Waist circumference was defined as the circumference of the abdomen at the narrowest 
point between the lower costal (10th rib) border, and the superior aspect of the iliac crest, 
perpendicular to the long axis of the trunk (Stewart & Sutton, 2012).  The point between the 
iliac crest and lower rib is the generally accepted level for this measurement.  Waist 
circumference (WC) was measured using a Lufkin® executive thin line tape measure (Lufkin 
W606PM) (Apex Tool Group, USA).  The measuring tape is passed around the body and 
tightened at the required level ensuring that the level is horizontal and that the soft tissue is 
not compressed.  The reference values for WC are given in Table 2.3.  
Table 2.3: Reference values per gender for waist circumference.  
Waist circumference 
≤80 cm for women  
≤94 cm for men 
(IDF, 2006). 
2.3.3.5 The hip circumference 
The hip circumference (HC) was defined as the circumference of the buttocks at the level of 
their greatest posterior protuberance, perpendicular to the long axis of the trunk (Stewart & 
Sutton, 2012).  The HC measurement was recorded whilst the participant stood erect with 
their feet together.  The tape is passed around the body and tightened at the required level, 
ensuring that compression of the soft tissue does not take place and the measurement is 
noted. 
2.3.3.6 The waist to hip ratio 
The waist to hip ratio (W:H) (Equation 4) is considered an important predictor for the 
development of cardiovascular diseases, the MetS, as well as altered BMD (Aghaei Meybodi 
et al., 2011; Ardawi et al., 2011; Seo et al., 2008; Zillikens et al., 2010).   
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Equation 4: Calculation of Waist to hip ratio 
W:H =
WC
HC
 
2.3.4 Ultrasound bone densitometry measurement 
Bone mineral density was assessed using the SONOST 3000 Ultrasound Bone 
Densitometer (OsteoSys, Korea) (Figure 2.1).  The date of birth, gender, ethnic background, 
foot supporter number, height and weight of each participant were recorded on the SONOST 
3000 prior to BMD analysis in order to accurately estimate the T- and Z-scores (Appendix F). 
The calcaneal bone is considered a validated anatomical site for the measurement of BMD 
and furthermore considered to be highly predictive of fracture risk (Seo et al., 2008).  The 
right calcaneus bone was used for all BMD assessments.  Measuring the BMD took 
approximately one minute, after which an ultrasonic wave image (graph) was generated on a 
liquid crystal display of the bone densitometer.   
 
Figure 2.1: The SONOST 3000 Ultrasound Bone Densitometer (OsteoSys 3000).  
2.3.4.1 Questionnaires 
Additional supplementary information was obtained from participants through standard and 
validated questionnaires, including demographics, physical activity level (GPAQ), overall 
bone health, and dietary habits.   
a) Demographic questionnaire 
To contextualise the participants’ socio-demographic status, a structured basic demographic 
questionnaire was used focussing on age, home language, monthly or weekly income, the 
type of house, and specifics regarding the age and number of people in the household 
(Appendix G).   
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b) Physical activity questionnaire  
The Global Physical Activity Questionnaire (GPAQ), (Appendix H), developed by the WHO in 
2002, formed part of the WHO STEPwise Approach to Chronic Disease Risk Factor 
Surveillance (STEPS).  This questionnaire described physical activity during work, as well as 
for transport and recreational activities.  The frequency and duration of the activity were 
recorded, and the energy required for these activities was either classified as vigorous, 
moderate or intense (Bull et al., 2009).  
c) Bone health questionnaires  
The bone health questionnaire was used to assess bone health in participants.  This 
questionnaire focussed on questions such as bone health history, menstrual history, diet 
history, sunlight exposure, smoking and drinking habits, family health history, and physical 
activity (Appendix I).  
d) Bone health history 
The bone health section of the questionnaire included questions regarding the participant’s 
history of fractures or broken bones, stress fractures and any medications that could affect 
bone physiology.  
e) Menstrual history 
Since menses play a crucial role in general bone health, questions focussed on the women’s 
age of first menstrual cycle, date of recent menstrual cycles, and presence of 
oligomenorrhea, menorrhagia or amenorrhea.  Participants were asked about birth control 
methods such as use of pharmacological or medical devices, as well as number of 
pregnancies and past breastfeeding practices.   
f) Diet history 
This section of the bone health questionnaire concentrated on specific questions related to 
past practices of dieting, and whether participants had taken any appetite-suppressing 
medication.  The participants were asked whether they engaged in any eating disorder 
behaviour such as inducing vomiting or binge eating, as well as their perception of body 
weight changes over the past five years.  
g) Sunlight exposure and other contributing factors 
Assessing participant’s sunlight exposure aimed to quantify the average daily sunlight 
exposure in minutes.  Participants were also questioned about their medical history (past 
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and present), including medication and supplement intake that could provide any possible 
links between interacting pharmacological agents and vitamin D status.  Smoking and 
alcohol consumption were also included as part of other contributing factors that could affect 
bone health.  For the purpose of this study moderate alcohol consumption was classified 
here as consuming up to two drinks per day (grouped as “current” alcohol consumers), and 
heavy alcohol consumption was classified as having three or more drinks per day (Marrone 
et al., 2012).   
h) Family health history 
The questions raised here aimed to gather information on whether close family members 
(maternal, paternal or siblings) had any history of specific diseases that may be related to 
bone health, e.g. any bone disease, osteoporosis, or kidney stones.  
2.4 Data handling 
Each data sheet was coded with a unique study code for every participant.  The hard copies 
were kept in a lockable filing cabinet in an office at the Department of Physiological 
Sciences, Stellenbosch University.  Consent forms were kept in a separate folder, and 
locked in the office of the principle investigators since these forms contained the names and 
personal details of participants.  Raw data were entered into an MS Office Excel 2010 
spreadsheet, where after the data were independently cross-checked over separate days to 
ensure data capture accuracy.  The MS Excel file was imported into Statistica® Version 12.0 
(StatSoft Inc. 2014, USA) for statistical analyses. 
2.5  Statistical analysis 
After the data were organised, a normality test was performed, followed by basic descriptive 
statistical analysis.  A student t-test was employed to determine differences between two 
groups, provided the data were normally distributed.  All results were reported as means ± 
standard error of the mean (SEM), and medians and interquartile ranges (IQR) in cases 
where the data was not normally distributed.  For multiple groups, data were analysed using 
a factorial analysis of variance (ANOVA) with a Bonferroni post hoc test.  Pearson 
correlations were used to describe associations between selected physiological parameters.  
Statistical significance was set at p<0.05.   
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Chapter 3        Results
 
This chapter illustrates and narrate the results obtained for this study.   
3.1 Basic description of the sample population 
The participant characteristics for the sample population are provided in Table 3.1.  A total of 
n=80 women were recruited in this study, with a mean age of 42.2±1.1 years.  The mean 
BMI for the sample population was 31.4±0.9 kg/m2, and the mean WC was 87.9±1.6 cm, 
which is indicative of an overweight/obese population.  All other variables were within normal 
physiological ranges, with the exception of vitamin D levels which were below the detection 
limit in more than half the population (Appendix J), although sunlight exposure data indicated 
that participants were exposed to sunlight for approximately two hours (129.71 minutes) per 
day (data not presented).  The LDL-c concentrations as well as FI concentrations were 
higher than normal (3.0±0.0 mmol/L; 25.6±4.4 mIU/L).   
Table 3.1: Description of the characteristics of the total sample population. 
Characteristic 
Mean±SEM 
(n=80) 
Age (years) 42.18±1.12 
Body mass (kg) 79.13±2.22 
Height (m) 1.59±0.01 
BMI (kg/m2) 31.44±0.87 
Blood pressure 
Systolic blood pressure (mmHg) 139.18±2.48 
Diastolic blood pressure (mmHg) 84.70±1.49 
Circumferences 
Waist circumference (cm) 87.86±1.61 
Hip circumference (cm) 109.78±1.83 
W:H 0.80±0.01 
Blood parameters 
Fasting glucose (mmol/L)*  5.44±0.26 
Fasting Insulin (mIU/L)* 25.61±4.43 
HDL-c (mmol/L)* 1.22±0.04 
LDL-c (mmol/L)* 2.98±0.12 
Triglycerides (mmol/L)* 1.62±0.14 
Stellenbosch University  https://scholar.sun.ac.za
 
 
59 
 
Vitamin D (pg/mL) 0.74±0.11 
Parathyroid hormone (pg/mL) 3.63±0.18 
Alkaline phosphatase (U/L) 79.99±3.37 
E2 (pmol/L) 261.70±29.81 
Bone status 
T-score -0.33±0.12 
Z-score 0.37±0.17 
SOS (m/s) 1525.42±2.30 
BUA (dB/MHz) 107.58±1.99 
BQI  97.41±2.21 
*Normal ranges: Fasting glucose: 3.5-5.5 mmol/L, Fasting insulin: 2.1-10.4 mmol/L, HDL-c: >1.2 mmol/L, LDL-c: 
<3.0 mmol/L, Triglycerides: <1.7 mmol/L   
3.2 The prevalence of the metabolic syndrome, and descriptive 
characteristics of the population 
Using IDF criteria (IDF, 2006), two groups from the n=80 sample were identified based on 
their metabolic status.  More than half (55.0%; n=44) of the participants were classified with 
the MetS, whereas 45.0% (n=36) did not present with the MetS (Non-MetS) (Figure 3.1).   
 
Figure 3.1: The prevalence of the MetS in the sample population. 
Table 3.2 presents the characteristics of metabolic and bone-related variables between the 
MetS and Non-MetS groups.  Here, it is shown that neither group had any age difference, as 
well as bone-related parameter differences.  The following metabolic profile parameters 
differed significantly between the two groups: SBP (p<0.001), DBP (p<0.001), WC 
(p<0.001), FG (p<0.01), FI (p<0.01), HDL-c (p<0.001) and TG (p<0.01).  Other 
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anthropometric parameters which also differed significantly, included BM (p<0.001), BMI 
(p<0.001), HC (p<0.001), and W:H (p<0.001).  
Table 3.2: Descriptive characteristics of the MetS vs. Non-MetS individuals. 
Description 
MetS 
(mean±SEM) 
n=44 
Non-MetS 
(mean±SEM) 
n=36 
p-value 
Age (years) 43.48±1.55 40.58±1.61 NS 
Body mass (kg) 87.80±2.41 68.53±3.20 p<0.001 
Height (m) 1.58±0.01 1.59±0.01 NS 
BMI (kg/m2) 35.12±0.92 26.95±1.16 p<0.001 
Blood pressure 
Systolic blood pressure (mmHg) 148.55±3.14 127.72±3.05 p<0.001 
Diastolic blood pressure (mmHg) 90.23±1.91 77.95±1.81 p<0.001 
Circumferences 
Waist circumference (cm) 95.94±1.69 77.99±1.91 p<0.001 
Hip circumference (cm) 115.74±2.01 102.48±2.83 p<0.001 
Waist-to-hip ratio 0.83±0.01 0.77±0.01 p<0.001 
Blood parameters 
Fasting glucose (mmol/L)* 6.18±0.43 4.55±0.09 p<0.01 
Fasting insulin (mIU/L)* 35.90±6.92 13.03±2.36 p<0.01 
HDL-c (mmol/L)* 1.06±0.03 1.42±0.07 p<0.001 
LDL-c (mmol/L)* 3.15±0.12 2.77±0.18 NS 
Triglycerides (mmol/L)* 2.01±0.22 1.15±0.12 p<0.01 
Vitamin D (pg/mL) 0.70±0.13 0.84±0.24 NS 
Parathyroid hormone (pg/mL) 3.76±0.25 3.48±0.25 NS 
Alkaline phosphatase (U/L) 83.70±4.79 75.44±4.63 NS 
E2 (pmol/L) 214.61±28.75 319.25±55.16 NS 
Bone status 
T-score -0.38±0.16 -0.31±0.18 NS 
Z-score 0.43±0.26 0.26±0.26 NS 
SOS (m/s) 1523.62±3.01 1526.98±3.55 NS 
BUA (dB/MHz) 108.44±2.61 105.79±3.09 NS 
BQI 96.46±2.86 97.79±3.49 NS 
NS: Non-significant, *Normal ranges: Fasting glucose: 3.5-5.5 mmol/L, Fasting insulin: 2.1-10.4 mmol/L, HDL-c: 
>1.2 mmol/L, LDL-c: <3.0 mmol/L, Triglycerides: <1.7 mmol/L   
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3.3 Prevalence of the different metabolic syndrome risk factors 
In order to quantify the MetS risk factors in the sample population, each participant in their 
respective MetS and Non-MetS groups were listed as having zero, one, two, three, four or 
five risk factors (Figure 3.2).  In the MetS group, 60.0% of the participants presented with 
three MetS risk factors, followed by 25.0% with four risk factors and 15.9% with all five MetS 
risk factors (Figure 3.2A).  In the Non-MetS group, 52.8% of the participants had two MetS 
risk factors, followed by 25.0% with one risk factor, and 22.2% of the participants with zero 
risk factors (Figure 3.2B).  From Figure 3.2C, which included the total sample population 
irrespective of metabolic status, it is apparent that most of the participants presented with 
three risk factors (32.5%), followed by two risk factors (23.8%), and four risk factors (13.8%).  
Only one MetS risk factor was present in 11.3% of the participants, 10.0% had zero risk 
factors, and 8.8% had all five MetS risk factors.  
 
Figure 3.2: The proportion of participants with zero, one, two, three, four, and five MetS risk 
factors in (A) the MetS group, (B) the Non-MetS group, and (C) the total sample population. 
In order to establish which of the MetS risk factors were more prevalent, the individual risk 
factors for each participant were ranked according to frequency (Figure 3.3).  In the total 
sample population (Figure 3.3A), increased BP was the most prevalent MetS risk factor 
(72.5%, n=58), followed closely by increased WC (68.8%, n=55), and low levels of HDL-c 
(42.5%, n=34), increased TG (27.5%, n=22) and increased FG (25.0%, n=20).  From Figure 
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3.2B, it is evident that all of the MetS participants had higher WC’s (100.0%), followed by 
elevated BP (90.9%), HDL-c (81.8%), FG (45.5%) and TG (40.9%).  In contrast, elevated BP 
(50.0%) was found to be the predominant risk factor in the Non-MetS group, followed by low 
HDL-c (38.9%), and WC (30.6%).  Although only 11.1% of the participants had elevated TG 
levels, none of the participants displayed elevated FG levels.  
 
Figure 3.3 Prevalence of specific MetS risk factors in (A) the total sample population and in (B) 
the MetS and Non-MetS groups. 
3.4 Bone health status of the total sample population, and between 
the MetS and Non-MetS groups 
One of the aims was to describe the bone health status of the total sample population, 
irrespective of the metabolic status.  In total, 78.8% (n=63) of the individuals presented with 
normal BMD, whereas 18.8% (n=15) presented with osteopenia, and only two and a half 
percent (n=2) had osteoporosis (Figure 3.4). 
 
Figure 3.4: Classification of the bone health of the total sample population. 
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Considering the metabolic status, 79.6% (n=35) of the MetS participants displayed a normal 
BMD, whereas 18.2% (n=8) were classified as osteopenic (Figure 3.5). In the Non-MetS 
group, 77.8% (n=28) had a normal BMD, compared to 19.4% (n=7) who had osteopenia.  
Only one individual in each of the MetS and Non-MetS groups presented with osteoporosis 
(2.3%, and 2.8% respectively) (Figure 3.5). 
 
Figure 3.5: Classification of the bone health status in the MetS and the Non-MetS groups. 
To further describe and compliment bone health status, information regarding fracture 
history was obtained through a questionnaire.  From the total population, 23.8% of the 
participants reported previous fractures, compared to 15.0%, which reported previous stress 
fractures (not shown).  When metabolic status was considered (Figure 3.6), fractures and 
stress fractures were found to be more prevalent in the MetS group.   
 
Figure 3.6: Prevalence of fractures and stress fractures in the MetS vs. Non-MetS groups. 
In the participants with the MetS, 52.3% of the participants indicated that they had never 
smoked, compared to 29.6% who were current smokers, and 22.7% who had been previous 
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smokers (Figure 3.7A).  It is important to note that some participants were both classified as 
previous and current smokers, since some of them reported to have stopped for a certain 
time period.  In the Non-MetS group, 44.4% of the participants had never smoked before, 
30.6%, were current smokers, and 25.0% had been previous smokers (Figure 3.7B).  
Overall, almost half of the participants never smoked (48.8%), 30.0% were current smokers, 
and 23.8% were previous smokers (Figure 3.7C). 
 
Figure 3.7:  Frequency of participants who were previous, current and non-smokers in (A) the 
MetS group, (B) the Non-MetS group, and (C) the total population. 
In the MetS group, 54.6% (n=24) indicated they are current alcohol consumers, 25.0% 
(n=11) had never consumed alcohol, 22.7% (n=10) were previous alcohol consumers, and 
6.8% (n=3) were heavy alcohol consumers (Figure 3.8A).  In the Non-MetS group, 61.1% 
(n=22) were current alcohol consumers, 30.6% (n=11) had never consumed alcohol, 19.4% 
(n=7) were previous alcohol consumers, and 11.1% (n=4) were heavy alcohol drinkers 
(Figure 3.8B).  Figure 3.8C reported that more than half the participants consumed alcohol 
daily (57.5%, n=46), followed by 27.5% (n=22) who had never used alcohol before, 21.3% 
(n=17) who were previous alcohol consumers, and 8.8% (n=7) who are heavy alcohol 
consumers.  
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Figure 3.8: Frequency of participants who were previous, current, non-consumers and heavy 
consumers of alcohol in (A) the MetS group, (B) the Non-MetS group, and (C) the total 
population. 
Basic information was also obtained regarding the menstrual history of the participants.  The 
average age of the women at their first menstrual cycle was 14 years of age.  A total of 
86.3% (n=69) of the participants reported having previous pregnancies, and the average 
period of breastfeeding was 40.5 months.  A total of 77.5% (n=62) of the participants also 
indicated that they had regular monthly menses, whereas 28.8% (n=23) reported a history of 
irregular menses (Appendix K).  A comparison between the MetS and Non-MetS groups 
regarding the use of several types of medication is also shown in Appendix K.  
Figure 3.9A illustrates previous, current and non-contraceptive users in the total population.  
A total of 37.5% (n=30) of the participants previously used contraceptives, while 33.8% 
(n=27) were current users of contraceptives, and 30.0% (n=24) indicated that they had never 
used contraceptives before.  In Figure 3.9B the frequency of previous, current and non-
contraceptives between the MetS and Non-MetS groups is compared.  In the MetS group, 
38.6% (n=17 each) were both previous, or current contraceptive users, and 18.2% (n=8) had 
never used contraceptives before.  In the Non-MetS group, 44.4% (n=16) had never used 
contraceptives before, whereas 36.1% (n=13) were previous users, and 27.8% (n=10) were 
current users of contraceptives.  
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Figure 3.9: The frequency of previous, current and non-contraceptive users in (A) the total 
sample population, and (B) the MetS and Non-MetS groups. 
The results obtained from the GPAQ questionnaire indicated that 47.7% of individuals with 
the MetS, and 41.7% of participants without the MetS performed moderate-intensity work-
related activities, whereas 20.5% and 16.7% performed vigorous-intensity work-related 
activities respectively (Figure 3.10A).  A total of 75.0% (n=33) of participants with the MetS 
took part in moderate-intensity recreational, or sport activities, compared to 61.1% of the 
participants in the Non-MetS group (n=22).  Only 6.8% (n=3) and 13.9% (n=5) of the MetS 
and Non-MetS individuals participated in vigorous-intensity sport, or recreational activities, 
respectively (Figure 3.10B).  In the total population, 45.0% (n=36) of the participants 
reported to have work that required moderate-intensity physical activity, and 68.8% (n=55) 
participated in moderate-intensity sport, or recreational activities (Figure 3.10C).  
 
Figure 3.10: The proportion of participants engaging in vigorous- and moderate-intensity 
activities at work, as well as in sport, or recreational activities in (A) the MetS group, (B) the 
Non-MetS group, and (C) the total sample. 
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In the MetS group, 68.2% (n=30) compared to 55.6% (n=20) in the Non-MetS group 
engaged in walking, or cycling for more than ten minutes per day for travelling purposes 
(Figure 3.11A & B).  In the total sample population, 62.5% (n=50) of the participants walked 
or cycled for travelling purposes (not shown).  
 
Figure 3.11: The percentage of participants who walked or cycled for more than ten minutes 
per day for travelling purposes in (A) the MetS group, and (B) the Non-MetS group. 
3.5 Description of participants according to menopausal status 
Participants were further classified according to their menopausal status into either PreM, or 
PostM, in order to determine the association between menopausal status, and various 
metabolic and physiological parameters, irrespective of metabolic status (Table 3.3).  Firstly, 
to provide a general illustration of bone health in PreM vs. PostM women, Figure 3.12 
indicates that 75.4% of the PreM women had normal BMD, whereas 87.0% of the PostM 
women had normal BMD.  Osteopenia was present in 21.1% of the PreM women and  in 
13.0% of the PostM women.  None of the PostM women had osteoporosis, whereas 3.5% of 
the PreM women had osteoporosis.  
 
Figure 3.12: Frequency of occurrence of normal BMD, osteopenia and osteoporosis in PreM 
and PostM women. 
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In Table 3.3 the participants in the PreM group are compared to the PostM group.  Here, 
significant age differences were reported between the PreM and PostM groups (38.21±1.16 
years vs. 52.0±1.01 years; p<0.001).  Furthermore, only SBP (135.88±2.87 mmHg vs. 
147.35±4.56 mmHg; p<0.05), PTH (3.29±0.16 pg/mL vs. 4.51±0.45 pg/mL; p<0.001), E2 
(299.30±36.40 pmol/L vs. 168.52±46.74 pmol/L; p<0.05), and the Z-score (0.14±0.22 vs. 
0.89±0.18; p<0.05) differed significantly between the different menopausal groups.  Trends 
towards significance were noted for height (p=0.066), W:H (p=0.063), and ALP (p=0.056) 
measurements between the PreM and PostM groups.  Some additional graphs comparing 
PreM and PostM groups are shown in Appendix L.  
Table 3.3: Descriptive characteristics of the PreM vs. PostM individuals. 
Description 
Pre-Menopausal 
(Mean±SEM)  
n=57 
Menopausal 
(Mean±SEM) 
n=23 
p-value 
Age 38.21±1.16 52.00±1.01 p<0.001 
Body mass (kg) 78.86±2.87 79.80±3.11 NS 
Height (m) 1.60±0.01 1.56±0.11 p=0.066 
BMI (kg/m2) 30.92±1.09 32.74±1.27 NS 
Blood pressure 
Systolic blood pressure (mmHg) 135.88±2.87 147.35±4.56 p<0.05 
Diastolic blood pressure (mmHg) 84.42±1.74 85.39±2.91 NS 
Circumferences 
Waist circumference (cm) 86.45±2.00 91.35±2.53 NS 
Hip circumference (cm) 109.39±2.33 110.74±2.77 NS 
Waist-to-hip ratio 0.79±0.01 0.83±0.02 p=0.063 
Blood parameters 
Fasting glucose (mmol/L)* 5.20±0.26 6.04±0.60 NS 
Fasting Insulin (mIU/L)* 25.98±3.85 24.67±10.95 NS 
HDL-c (mmol/L)* 1.20±0.04 1.28±0.08 NS 
LDL-c (mmol/L)* 3.0±0.10 2.95±0.27 NS 
Triglycerides (mmol/L)* 1.49±0.14 1.97±0.34 NS 
Vitamin D (pg/mL) 0.65±12 0.92±25 NS 
Parathyroid hormone (pg/mL) 3.29±0.16 4.51±0.45 p<0.001 
Alkaline phosphatase (U/L) 75.91±4.21 90.09±4.88 p=0.056 
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E2 (pmol/L) 299.30±36.40 168.52±46.74 p<0.05 
Bone status 
T-score -0.30±0.16 -0.46±0.12 NS 
Z-score 0.14±0.22 0.89±0.18 p<0.05 
SOS (m/s) 1525.94±3.06 1523.12±2.48 NS 
BUA (dB/MHz) 108.15±2.51 105.00±3.07 NS 
BQI 98.01±2.96 94.70±2.34 NS 
NS: Non-significant, *Normal ranges: Fasting glucose: 3.5-5.5 mmol/L, Fasting insulin: 2.1-10.4 mmol/L, HDL-c: 
>1.2 mmol/L, LDL-c: <3.0 mmol/L, Triglycerides: <1.7 mmol/L   
 
3.6 Description of participants according to menopausal and 
metabolic status 
In order to describe the association between menopausal and metabolic status, participants 
in their respective metabolic groups (MetS and Non-MetS) were sub-divided into either: A) 
PreM (between the ages of 20-39 years), B) PreM (≥40 years), and C) PostM.  Figure 3.13 
illustrates the distribution of participants according to both menopausal and metabolic status.  
An almost equal distribution of participants in all three sub-groups was noted for the MetS 
group (34.1%, 34.1% and 31.8% respectively) (Figure 3.13A).  In the Non-MetS group, 
participants were equally distributed in both the PreM (20-39 years) and PreM (≥40 years) 
groups (39.0%, n=14) respectively, whereas only 22.0% (n=8) of participants formed part of 
the PostM group (Figure 3.13B). 
 
Figure 3.13: Classification of participants in (A) the MetS, or (B) Non-Mets groups according to 
menopausal status. 
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No significant differences were observed for age and W:H between the MetS and Non-MetS 
groups (Figure 3.14A & B).  Women in the PreM (20-39 years) MetS group showed a 
significantly higher BM compared to those in the PreM (20-39 years) Non-MetS group 
(p<0.001) (Figure 3.14C).  A similar pattern was observed for BMI (p<0.01) (Figure 3.14D), 
where only the PreM (20-39 years) MetS vs. Non-MetS group indicated significant 
differences.  
The WC (Figure 3.14A) differed significantly between the PreM (20-39 years) MetS, PreM 
(≥40 years) MetS, and their respective Non-MetS groups (p<0.001 and p<0.01 respectively).  
A similar finding was observed for HDL-c, although here, the Non-MetS groups presented 
with an elevated HDL-c level (>1.29 mmol/L) compared to their MetS counterparts (p<0.05 
for PreM 20-39 years, and p<0.01 for PreM ≥40 years) (Figure 3.14B)
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Figure 3.14: Descriptive characteristics for (A) age, (B) W:H, (C) BM, and (D) BMI between the MetS and Non-MetS groups with respect to 
menopausal status (*p<0.05; **p<0.01; ***p<0.001
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Figure 3.15: Metabolic syndrome risk factors for women grouped according to their menopausal and metabolic status for (A) waist circumference, 
(B) HDL-c, (C) systolic blood pressure, (D) diastolic blood pressure, (E) fasting glucose, and (F) triglycerides. Solid lines represent the normal cut-
off values (IDF, 2006) (*p<0.05; **p<0.01; ***p<0.001).
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Similar, significant differences were observed between the MetS and Non-MetS participants 
in the PreM (20-39 years) groups for SBP (p<0.001), and DBP (p<0.001) (Figure 3.15C & 
D).  No differences were observed for FG and TG between any of the subgroups (Figure 
3.15E & F).  Both FI and LDL-c (Figure 3.16A & B) were not significantly different between 
any of the groups. 
 
Figure 3.16: The fasting insulin (A), and LDL-c (B) concentrations between groups. The solid 
line represents the normal cut-off values (IDF, 2006; Pathcare). 
For the bone-specific markers (PTH and ALP) (Figure 3.17A & B), no significant differences 
were noted.  The female-specific hormone, oestradiol, also did not differ significantly 
between any of the respective groups (Figure 3.17C). 
 
 
 
 
   
 
 
 
 
 
Figure 3.17: Parathyroid hormone (A), alkaline phosphatase (B), and oestradiol (C) levels 
between groups with respect to metabolic and menopausal status. 
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No significant differences were noted with regards to bone health status, as expressed by 
the T-scores (Figure 3.18A), Z-scores (Figure 3.18B), SOS (Figure 3.18C), BUA (Figure 
3.18D), and BQI (Figure 3.18E) 
 
Figure 3.18: The different measures of bone health, including (A) T-score, (B) Z-score, (C) SOS, 
(D) BUA, and (E) BQI between the different menopausal and metabolic syndrome groups.
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3.7 Correlation analysis 
Pearson correlations were performed in order to establish possible associations between 
selected parameters.  In order to contextualize the interpretations of these correlations, the 
following was considered; (i) no or negligible relationship was reported if r=0.01 to 0.19, (ii) 
correlations were classified either as positive or negative, with a weak (r=0.20 to 0.29), 
moderate (r=0.30 to 0.39), strong (r=0.40 to 0.69), or very strong correlation coefficient 
(r=>0.7) (Scally, 2014).  The level of significance was accepted if p<0.05.  Furthermore, a p-
value between 0.051 and 0.075 was regarded as a statistical trend. 
For most of the correlations, where more than one correlation is discussed per group, A and 
B will indicate the PreM (20-39 years) groups, C and D the PreM (≥40 years) groups, and E 
and F the PostM groups.  In cases where three correlations are described, the PreM (20-39 
years) groups will be indicated by the graph labelled A, B and C, the PreM (≥40 years) 
groups by those labelled D, E and F, and the PostM groups by the graph labelled G, H and I.  
3.7.1 Correlation analysis between BM, BMI and E2 
Positive correlations were observed for all groups when BM and E2 were correlated with 
each other (Figure 3.19A, C & E), with the exception of the PostM, Non-MetS group, which 
showed a strong negative correlation (Figure 3.19E).  The only strong, significant and 
positive correlation between BM and E2 was evident for the PreM (20-39 years) MetS group 
(r=0.58, p=0.03) (Figure 3.19A).  All other correlations between BM and E2 were weak to 
moderate (Figure 3.19A, C & F).   
The correlation between BMI and E2 (Figure 3.19B, D & F) also indicated a positive strong 
and significant correlation in the PreM (20-39 years) MetS group (r=0.60, p=0.02) (Figure 
3.19B).  All other correlations between BMI and E2 were weak and moderate, and some 
negative, but insignificant. 
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Figure 3.19: The association between BM and E2, and BMI and E2 in the PreM (20-39 years) 
groups (A, B), the PreM (≥40 years) groups (C, D), and the PostM groups (E, F), respectively. 
3.7.2 Correlation analysis between BM, BMI and SOS 
When BM and SOS were correlated with one another (Figure 3.20A, C & E), the PreM (20-
39 years) MetS group revealed a strong, positive association with a trend towards 
significance (r=0.51, p=0.06) (Figure 3.19A).  Significant and positive correlations were 
present in the PreM (≥ 40 years) participants in both the MetS (strong, r=0.56, p=0.04) and 
Non-MetS (very strong, r=0.76, p=0.00) groups (Figure 3.20C).  In the PostM, MetS and 
Non-MetS groups, weak and moderate positive correlations were noted, respectively (Figure 
3.20E). 
 
 
 PostM 
PreM 
(≥40 years) 
PreM 
(20-39 years) 
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The correlations between BMI and SOS (Figure 3.20B, D & E) indicated a significant and 
strong positive correlation in the PreM (20-39 years) MetS group (r=0.53, p=0.05), whereas 
the Non-MetS group indicated no association (r=-0.08, p=0.78) (Figure 3.20B).  In the PreM 
(≥40 years) Non-MetS group, a significant, and very strong positive correlation was present 
(r=0.73, p=0.00) (Figure 3.20D).  The other correlations between BMI and SOS were 
moderate and positive (Figure 3.20D & F).  
Figure 3.20: The association between BM and SOS, and BMI and SOS in the PreM (20-39 years) 
groups (A, B), the PreM (≥40 years) groups (C, D), and the PostM groups (E, F), respectively. 
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3.7.3 Correlation analysis between FI, FG, TG and ALP 
The association between FI and ALP (Figure 3.21 A, C & E) indicated only one significant, 
and very strong correlation in the PreM (≥40 years) MetS group (r=0.72, p=0.00) (Figure 
3.21C).  All other correlations were noted to be negligible to moderate.  
Correlation analysis between FG and ALP (Figure 3.21B, E & H) also showed a significant 
and very strong association in the PreM (≥40 years) MetS group (r=0.89, p=0.00) (Figure 
3.20E).  All other correlations between FG and ALP were non-significant.  
Correlations between TG and ALP (Figure 3.21C, F & I) revealed only that the PreM (≥40 
years) MetS group displayed a very strong, significant (positive) correlation (r=0.82, p=0.00), 
(Figure 3.21F).  In the PostM MetS group, a moderate positive correlation was noted 
(r=0.38, p=0.17), whereas the PostM Non-MetS group displayed a strong negative 
association (r=-0.62, p=0.10) (Figure 3.21I).  No associations were evident in the PreM (20-
39 years) Non-MetS and MetS groups (Figure 3.21C), as well as the PreM (≥ 40 years) Non-
MetS groups (Figure 3.21F).  Some additional correlation analyses are shown in appendix 
M.  
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Figure 3.21: The association between FI and ALP, in the PreM (20-39 years) (A), PreM (≥40 years) (D), and PostM (G) groups; the association 
between FG and ALP, in the PreM (20-39 years) (B), PreM (≥40 years) (E) and PostM (H) groups; the association between TG and ALP in the PreM 
(20-39 years) (C), PreM (≥40 years) and PostM groups (I), respectively.     
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Chapter 4                                                                 Discussion 
 
4.1  Introduction 
This chapter will discuss the major findings of the study and integrate these findings with 
relevant literature.  The aim of the first part of this study was to report on the prevalence of 
the MetS in a female farm worker population in the Western Cape of South Africa, while the 
second aim was to describe bone health and possible associations between bone markers, 
metabolic- and menopausal status in the selected population.   
4.2 Basic description of the study population 
4.2.1  The study population was largely overweight 
The participants used in the current study were predominantly overweight, or obese, since 
both the mean BMI (31.4±0.9 kg/m2) and WC (87.9±1.6 cm) were higher (Table 3.1) than the 
normal ranges reported by the WHO for BMI (18.5-24.99 kg/m2) and the IDF for WC (≤80.0 
cm).  With the exception of FI (25.6±4.4 mmol/L) and LDL-c (3.0±0.1 mmol/L), none of the 
clinical markers describing metabolic and cardiovascular health, including BP, FG, HDL-c 
and TG were abnormally elevated or decreased.     
The increased FI levels might be due to the increased abdominal AT and IR, which is 
commonly reported in obese individuals due to the increased levels of TNF-α and IL-6 as a 
consequence of low grade inflammation (Cartier, 2010; Han & Lean, 2014).  Furthermore, 
the increased LDL-c observed here, is part of the dyslipidemia or lipid abnormalities noted in 
obese individuals and it is commonly seen in individuals with increased abdominal adipose 
tissue (Franssen et al., 2011).  During obesity there is remodeling of these lipoproteins by 
enzymes such as cholesteryl ester transfer protein and hepatic triglyceride lipases (Tchernof 
& Despres, 2013).  Furthermore, it is stated that the increased LDL-c in obesity is driven by 
the increased concentrations of TG (Klop et al., 2013).  Although TG were not abnormally 
elevated, it was borderline normal, thus TG might help explain the elevation in LDL-c as 
observed here.  The presence of IR also worsens the clearance of LDL by reducing the 
ability of insulin to stimulate the expression of the LDL receptors (Tchernof & Despres, 
2013).  
4.3 The metabolic syndrome: More than half of the study 
participants presented with the MetS 
South Africa, as well as smaller African countries, reported varied results regarding the 
prevalence of the MetS.  Some of the South African studies include the study by Motala et 
al. (2011) who reported a MetS prevalence of 21.2% in women (age-adjusted), using the IDF 
definition.  A study by Erasmus et al. (2012), which also used the IDF, reported a 
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significantly higher prevalence of 67.8% in a female mixed-race population in the Cape Town 
Metropole.  Two more recent studies used the JIS definition, and reported an overall (men 
and women) prevalence of 29.0% (George et al., 2013), and 43.5% in women (Peer et al., 
2014).   
A higher prevalence of the MetS was observed in smaller African countries.  For example, 
Kengne et al. (2012) described a prevalence of 86.1% in Cameroon (IDF), and a more 
recent study conducted in Nigeria reported a prevalence of 62.1% (Iloh et al., 2014).  Both 
these studies made use of the IDF definition and only included female participants.  
However, Kengne et al. (2012) also included T2DM individuals, which could help 
contextualise the high prevalence observed in their study.  
Data from the current study indicated that the farm working women, from mixed ancestry, 
have a comparatively high prevalence of the MetS (55.0%; Figure 3.1).  This prevalence is 
relatively higher than that reported by Motala et al. (2011), George et al. (2013) and Peer et 
al. (2014), even though the last two studies made use of the JIS definition.  Although the JIS 
makes use of similar cut-off values as the IDF definition, it does not consider WC as an 
obligatory MetS risk factor as compared to the IDF definition.   
The study specific population, being from a variety of ethnic backgrounds, sample size, age 
distribution, as well as level of urbanisation could account for the differences observed with 
regards to the MetS prevalence.  All of the studies mentioned thus far had much larger 
sample sizes, as well as participants from different age groups compared to the current 
study.  Motala et al. (2011) included a total of n=758 women (age of 46.6±18.2), compared 
to n=454 women over the age of 51 years in the study by Erasmus et al. (2012).  George et 
al. (2013) used a female population of n=375 and Peer et al. (2014) included n=707 women 
between the ages of 25 and 74 years.  Irrespective of the small sample size in the current 
study (n=80), and the average age of the females which were 42.2±1.1 years, the MetS 
prevalence was still one of the highest reported thus far for a South African population. 
4.3.1 There was no age difference between the MetS and Non-MetS groups 
In several studies, the prevalence of the MetS was correlated with age (Hernández et al., 
2011; El Maghraoui et al., 2014; Peer et al., 2014).  Two different studies indicated that 
participants characterised as having the MetS were significantly older than those without the 
MetS (66±9 vs. 61±9, p<0.0001, and 63.3±8.4 vs. 60.1±7.5; p=0.013 respectively) 
(Hernández et al., 2011; El Maghraoui et al., 2014).  It was proposed that ageing and the 
accompanying physical inactivity might play a predominant role in this occurrence 
(Hernández et al., 2011; El Maghraoui et al., 2014).  A study on a Black urban population 
from the Cape Town Metropole also concurred, but further reported a peak in the MetS 
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prevalence (74.3%) between the ages of 55-64 years in women (Peer et al., 2014).  Despite 
these findings, the same conclusion could not be made in the current study population, as 
there was no significant difference in the mean age between the MetS and Non-MetS groups 
(43.5±1.6 years vs. 40.6±1.6 years) (Table 3.2).  Although a larger sample size might have 
confirmed the results of Hernández et al. (2011); El Maghraoui et al. (2014); Peer et al. 
(2014), the MetS-specific risk factors may possibly be better predictors of the MetS 
prevalence as observed in the current study.  
4.3.2 The MetS group had significantly higher WC, FBG, BP and TG, and 
significantly lower HDL-c than the Non-MetS group 
All five of the MetS risk factors (WC, FBG, BP, low HDL-c, and TG) differed significantly 
between the MetS and Non-MetS groups (Table 3.2).  These results were expected, since 
three or more of these risk factors (using IDF criteria) needed to be present in order to 
classify a participant as having the MetS, and several other studies have also reported 
similar findings (Motala et al., 2011; Alissa et al., 2014).  The increased WC, as a result of 
increased AT, is hypothesised to be responsible for the development of IR, which in turn, 
decrease HDL-c and increase TG levels, leading to the development of arterial hypertension 
(Jennings et al., 2009; Gierach et al., 2014).  Since increased WC is considered the key 
contributing MetS risk factor, the abovementioned statement regarding increased AT might 
explain the increased FBG, BP, TG and low HDL-c observed in the MetS participants 
compared to the Non-MetS participants in the current study. 
4.3.3 The majority of the MetS participants had three MetS risk factors, 
whereas the Non-MetS group’ participants had mostly two MetS risk 
factors 
The clustering of zero, one, two, three, four and five MetS risk factors was clearly distinct 
between the MetS and Non-MetS groups.  The Non-MetS participants displayed zero, one 
and two risk factors, whilst the MetS group displayed three, four and five risk factors (Figure 
3.2A & B).  In the current study population, just over half the population in the Non-MetS 
group had two risk factors (52.8%), whilst the majority of the MetS group displayed three risk 
factors (59.1%) (Figure 3.2A & B).  Bihn et al. (2014) reported that 39.1% of their participants 
had one MetS risk factor, followed by 25.8% with two risk factors and 15.9% having zero risk 
factors.  Furthermore, 14.9% had three risk factors and 3.9% four risk factors and only 0.8% 
had five MetS risk factors.  Although this clustering of risk factors is important to predict 
possible future cases of the MetS and allow early detection and treatment, the prevalence of 
the specific MetS risk factors are more beneficial to determine specific treatment options 
(Bihn et al., 2014). 
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4.3.4 Increased BP was the most prevalent MetS risk factor in the total sample 
population 
The prevalence of hypertension was the most predominant risk factor in the total population 
(72.5%; Figure 3.3).  This was also the most frequent MetS risk factor according to O’Neill & 
O’Driscoll (2014), which increases the risk for the development of kidney damage and heart 
failure.  It is thought that hypertension may develop via hyperinsulinemia causing an 
increased retention of sodium and increase SNS stimulation, which will both lead to the 
development of hypertension (Fujita, 2007; Horita et al., 2011).  Insulin induces a 
vasodilatory action via the stimulation of vascular endothelial cells to release nitric oxide, 
which in turn increase blood flow to enhance glucose uptake in skeletal musculature; 
however, this vasodilatory effect is attenuated in insulin-resistant states (Muniyappa et al., 
2008; Tziomalos et al., 2010; Emanuela et al., 2012; Bodea & Popa, 2015).  It is therefore 
suggested that the high prevalence of increased BP might be partially due to the increased 
insulin concentration, which was also observed in this study population (25.6±4.4 mIU/L) 
(Table 3.1).  
The second, and third most prevalent MetS risk factor in this sample population was 
increased WC (68.8%) and low HDL-c (42.5%) respectively (Figure 3.3).  An increase in 
abdominal obesity, as noted in the current study, is associated with dyslipidaemia, including 
increased TG, VLDL, LDL-c, and decreased HDL-c levels (Franssen et al., 2011; Bodea & 
Popa, 2015).  The obese participants of the current study presented with increased LDL-c in 
the total population (3.0±0.1 mmol/L) (Table 3.1), as well as in the specific MetS (3.2±0.1 
mmol/L) and Non-MetS (2.8±0.2 mmol/L) groups, whilst HDL-c levels were decreased in the 
MetS group only (1.1±0.0 mmol/L) (Table 3.2).  Another South African study by Peer et al. 
(2014) also reported a high prevalence of increased WC (86.0%), decreased HDL-c (75.0%) 
and increased BP (47.6%), however this was not in the same order as observed here for the 
total study sample population.   
4.3.5 The clustering of increased WC, increased BP and decreased HDL-c was 
the most prevalent in both the MetS and Non-MetS groups 
Considering the metabolic status, the current study found a high prevalence of increased 
WC (100.0%) in the MetS group (Figure 3.3B), which is not unexpected, since it is a 
compulsory risk factor according to the IDF (IDF, 2006).  The increased WC is suggested to 
contribute to the development of hypertension via the secretion of adipokines and lipid 
abnormalities (Bodea & Popa, 2015).  This might explain why increased BP (90.9%) and low 
levels of HDL-c (81.8%) was the second and third most prevalent MetS risk factors (Figure 
3.3).  A South African study by Motala et al. (2011) also found a high prevalence of WC 
(96.9%), HDL-c (90.4%) and BP (89.5%) in female participants with the MetS, albeit not in 
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the same order as in the current study (WC, BP and HDL-c).  Although Motala et al. (2011) 
used the JIS definition, the only difference in the cut-off values between the JIS and IDF 
definition is the reduced HDL-c levels of <1.29 mmol/L according to the IDF definition and 
<1.30 mmol/L according to the JIS definition (Alberti et al., 2005; Ramli et al., 2013).  In 
addition, the average HDL-c levels of the female participants were 1.2±0.4 mmol/L in the 
study by Motala et al. (2011) in comparison to the slightly lower 1.2±0.0 mmol/L in the 
current study.  
Similar to the clustering of the MetS risk factors in the MetS group (WC, BP and HDL-c), BP 
(50.0%), HDL-c (38.9%), and WC (30.6%) was also found to be more prevalent in the Non-
MetS group, but not in the same order as in the MetS group (Figure 3.3B).  Even though 
Motala et al. (2011) used the JIS definition, the clustering of low HDL-c, increased WC and 
increased BP was also the most prevalent three risk factors in their Non-MetS group.  
Our study found that 45.5% of the individuals with the MetS presented with increased FG 
(Figure 3.3B), which might be indicative of IR.  Peripheral target tissues, such as skeletal 
muscle, AT and the liver can also become insulin resistant, resulting in a decreased 
peripheral uptake of glucose, leading to hyperglycaemia (Bodea & Popa, 2015).  Fasting 
insulin concentrations (Table 3.2) was significantly higher in the MetS group compared to the 
Non-MetS group (35.9±6.9 vs. 13.0±2.4; p<0.01) (Table 3.2) of the current study, which 
could explain the increased prevalence of increased FG levels in the MetS group vs. Non-
MetS group (Figure 3.3B).   
Insulin resistance is also frequently associated with abdominal obesity and is considered a 
consequence of increased production of lipoproteins by the liver and skeletal muscle, and 
the inability of the AT to store the excess produced lipoproteins (Bodea & Popa, 2015).  
Therefore, the increased insulin levels in the MetS group might also explain the increased 
TG levels (MetS: 2.0±0.2 mmol/L vs. Non-MetS: 1.2±0.1 mmol/L) (Table 3.2) observed, and 
consequently the increased prevalence of increased TG levels (40.9%) in the MetS group 
(Figure 3.3B).  
4.4 The majority of the study population had normal BMD 
Bone health results in the total sample population revealed that the majority (78.8%) of the 
participants presented with normal BMD (Figure 3.4), followed by 18.8% with osteopenia, 
and only 2.5% had osteoporosis.  This finding accounts for the normal levels found in all five 
measures of bone status (T-score, Z-score, BQI, SOS, and BUA), as well as the bone-
related markers, PTH and ALP (Table 3.1).  The only biochemical marker that was not within 
the normal ranges was the relatively low levels reported for 25(OH)D (0.7±0.1 pg/mL), 
despite participants reporting sufficient time exposed to sunlight necessary for vitamin D3 
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synthesis.  Vitamin D is known to be an important regulator of bone health (Pérez-Lopez et 
al., 2011), and according to the International Osteoporosis Foundation (2015), an average of 
ten to fifteen minutes of exposure to sunlight to the face or arms daily, is considered 
adequate for the synthesis of vitamin D3 in most individuals.  However, even though the 
participants in the current study reported a daily average of two hours of sunlight exposure, 
more than half of the sample population still had serum 25(OH)D levels lower than the 
detectable limit.  This result was anticipated, since most of the participants in the current 
study were of African descent, and studies have shown that black individuals tended to be 
25(OH)D deficient (Gutiérrez et al., 2011; Van Ballegooijen et al., 2014).  For example, the 
study by Gutiérrez et al. (2011) reported a mean concentration of 14.8±0.4 pg/mL in Black 
individuals and stated that 81.0% of their Black participants were vitamin D deficient, 
whereas Van Ballegooijen et al. (2014) reported that 43.0% of the Black individuals had 
vitamin D levels below 20 pg/mL and 14.0% had levels between 20-30 pg/mL.  It has also 
been reported that much longer sunlight exposure (about six times longer) is necessary to 
reach sufficient conversion of pre-vitamin D to vitamin D in these individuals (Hall et al., 
2010; Ardawi et al., 2011).   
In a study comparing 25(OH)D supplementation levels, Black individuals required a mean 
intake of 3916 IU/d in comparison to the 3040 IU/d in the Caucasians to achieve a serum 
25(OH)D concentration of 75 nmol/L (Aloia, 2008).  A study by Hall et al. (2010) reported a 
daily vitamin D intake of between 2100 and 3100 IU/d for African ancestry individuals with 
low sunlight exposure, and between 1000 and 2500 IU/d for European ancestry individuals 
to reach 75 nmol/L serum 25(OH)D, depending on the season.  It is therefore evident that 
Black individuals require higher concentrations of vitamin D supplementation.  Since only 
6.3% (n=5) of the current study population reported on the use of calcium or vitamin D 
supplements, and considering the low vitamin D levels even after sufficient sunlight 
exposure time, supplementing the diet of all the study participants with vitamin D might be 
beneficial.   
4.4.1 Other factors influencing BMD 
Modifiable (physical activity, alcohol consumption, smoking, contraceptive use and 
breastfeeding), or non-modifiable factors (genetic susceptibility to fractures) can also 
influence BMD (Abrahamsen et al., 2014; Mgodi et al., 2015).  Participants in the current 
study reported a relatively low history of stress fractures (15.0%), and bone fractures 
(23.8%).   
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4.4.1.1 Smoking 
Smoking causes an increase in fractures and/or decrease in bone mass (Shabab, 2012; 
Ayo-Yusuf & Olutola, 2014).  Three possible mechanisms could link smoking and decreased 
BMD.  Firstly, smoking decreases PTH, thereby decreasing Ca2+ absorption and oestrogen 
levels.  It also concurrently increases cortisol and adrenal androgen levels, thus contributing 
to an increased risk for the development of osteoporosis.  Since PTH and oestradiol 
concentrations were within the normal ranges in the current study population, and only 
30.0% of the population were current smokers and 23.8% were previous smokers (Figure 
3.7C), this could partly explain the normal BMD overall.  Secondly, smoking reduces vitamin 
D levels, which is a prerequisite for high BMD and healthy bones.  However, vitamin D levels 
were very low in the current study population, which is probably because of the ethnicity of 
the participants (mentioned earlier), rather than smoking per se.  Lastly, smoking is a major 
contributor of increased free radicals and oxidative stress, leading to increases in bone 
resorption (Shahab, 2012).  However, since free radicals and oxidative stress were not 
measured in any of the participants, it is still debatable whether this mechanism could 
potentially have influenced the results obtained.  A follow-up study is needed in order to 
make a full conclusion.  
4.4.1.2 Alcohol consumption 
Heavy alcohol consumption is deleterious to bone health, since it was previously linked to 
increased bone resorption (Kruger et al., 2011; Marrone et al., 2012).  Fortunately, only a 
small proportion of participants were grouped as heavy alcohol consumers (8.8%), 
compared to 57.5% who were current, but moderate alcohol consumers (Figure 3.8C).  The 
classification used here to determine heavy and moderate alcohol consumption was adopted 
from a study by Marrone et al. (2012), which stated that having up to two drinks per day 
were regarded as moderate alcohol consumption, whereas having more than two drinks per 
day were considered heavy alcohol consumption.  Alcohol can directly affect BMD by (i) 
impairing proliferation and functioning of osteoblasts, (ii) causing malabsorption, (iii) 
increasing renal excretion, and (iv) disrupting the Ca2+-regulating hormones, PTH, calcitonin 
and vitamin D metabolites (Sommer et al., 2012).  In the current study, PTH levels were 
within the normal physiological range (3.6±0.2 pg/mL), therefore corroborating the results of 
a normal BMD overall, even though 25(OH)D levels were very low (Table 3.1).   
4.4.1.3 Contraceptive use 
Apart from physical activity, alcohol consumption and smoking, the use of contraceptives 
also affects BMD (Wei et al., 2011; Elkazaz & Salama, 2015).  Oestrogens, or the 
oestrogenic effects of oral contraceptives, have beneficial effects on BMD via remodelling of 
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the bone in several ways: (i) it promotes osteoclast apoptosis, (ii) it decreases the RANKL, 
and (iii) it reduces cytokine activity, thereby reducing osteoclast functioning (Scholes et al., 
2011).  Approximately 37.5% of the population were previous users of contraceptives, 
whereas 33.5% were current contraceptive users (Figure 3.9A).  This, in combination with 
the normal E2 levels (26.7±29.8 pmol/L) could potentially have contributed to bone health 
overall.  Irrespective, it is not known whether the women who were either current or previous 
contraceptive users started using these treatments to regulate abnormal hormone profiles.  
This is of particular importance, since contraceptives have also been shown to exert 
negative effects by increasing hepatic production of SHBG, and thereby decreasing the 
availability of oestrogens (Scholes et al., 2011).   
Wei et al. (2010) reported an association between the duration of OC use and total body and 
spine BMD, most notable in women using OC for more than ten years.  The participants of 
the current study indicated an average previous use of contraceptive of seven years and 
current use of about five years, suggesting that OC use would potentially not have 
contributed to BMD in these study participants.  
4.4.1.4 Physical activity 
The low prevalence of osteoporosis and fractures in our study population could be attributed 
to their physical activity levels, either at work or during sport or recreational activities.  
Approximately 45.0% of the participants indicated that their daily work included moderate-
intensity physical activity, whereas 68.8% participated in moderate-intensity sport or other 
recreational activities (Figure 3.10).  Furthermore, more than half of the total study 
population (62.5%) indicated that they commute by either cycling or walking for longer than 
ten minutes daily (Figure 3.11).  Since physical activity is known to increase BMD (Janssen 
& Ross, 2012; Langsetmo et al., 2012; Braun et al., 2015), and the participants in the current 
study were physically active overall, a normal BMD should be anticipated.  Although the 
exact mechanism linking physical activity and increased BMD is yet largely undiscovered, it 
was hypothesised that osteocytes detect the mechanical stimuli and direct it to osteoclasts 
and osteoblasts for bone resorption and remodelling (Kelley et al., 2013).  This may explain 
the link between the high levels of physical activity and subsequent normal BMD overall. 
4.4.1.5 Breastfeeding 
Mgodi et al. (2015) reported that breastfeeding for longer than five years was associated 
with lower BMD, whilst another study reported that longer duration (for up to 220 months) did 
not affect BMD later in life (Yazici et al., 2011).  An average duration of only three years of 
previous breastfeeding was recorded in the current study, which could also have contributed 
towards a normal BMD, since BMD levels were shown to return to normal after cessation of 
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breastfeeding (Canal-Macias et al., 2012).  Although Åkesson et al. (2004) reported that the 
speed of recovery of BMD may vary by skeletal site, Karlsson et al. (2001) reported that 
BMD was not fully restored within five months, and therefore, a longer period is needed for 
recovery of BMD after breastfeeding.  Unfortunately, the time since cessation of 
breastfeeding was not recorded in the current study and a definite conclusion cannot be 
made regarding the return of BMD to normal levels. 
4.5 Bone health and the metabolic syndrome 
Studies investigating the relationship between the MetS and BMD reported inconsistent 
results, since some studies suggest that BMD increases due to the MetS and is therefore 
protective to bone health (El Maghraoui et al., 2014; Muka et al., 2015), whilst others report 
contrasting evidence (Hwang & Choi, 2010; Jeon et al., 2011; Nóbrega da Silva et al., 2014).  
In the current study, almost 80.0% of the participants with the MetS presented with normal 
BMD whereas 18.2% had osteopenia (Figure 3.5).  Literature suggests that osteoporosis is 
less prevalent in individuals with the MetS, and in the current study only 2.3% were identified 
with osteoporosis (El Maghraoui et al., 2014; Alissa et al., 2014).  However, we cannot rule 
out the possibility that a larger sample size may have yielded different results. 
4.5.1 Body mass, body mass index and BMD 
The inconsistencies in the association between the MetS and BMD revolve around 
abdominal obesity.  Increased BM and BMI is associated with higher BMD due to increased 
mechanical loading in these individuals (Silva et al., 2015; Sohl et al., 2015).  Osteocytes 
detect mechanical loading to the skeleton, and it is possible that in response to greater 
mechanical loading, increased signals are sent to osteoblasts to increase bone formation, 
and/or neighbouring osteoclasts to reduce bone resorption (Finkelstein et al., 2008).  
Interestingly, Cvijetic et al. (2010) reported that increased BMD was present in individuals 
with the MetS, but this positive effect disappeared after adjustment for BMI.  However, 
Zillikens et al. (2010) reported contrasting results and attributed the positive effect of android 
fat distribution on BMD to increased BMI. 
Although both the BM and BMI of the MetS group was significantly higher (BM: 87.8±2.4 kg; 
BMI: 35.1±0.9 kg/m2) than the Non-MetS group (BM: 68.5±3.2 kg; BMI: 27.0±1.2 kg/m2; 
p<0.001 in both BM and BMI), (Table 3.2), both groups presented with normal BMD (Table 
3.2; Figure 3.5).  Therefore, the current study cannot corroborate or disagree with the results 
found by Cvijetic et al. (2010) and Zillikens et al. (2010).  Despite this, and even though no 
differences were observed for any of the BMD measures (T-score, Z-score, BUA, SOS & 
BQI) between the MetS and Non-MetS groups, the majority of individuals with the MetS still 
had normal BMD (MetS: 79.6%, Non-MetS: 77.8%; Figure 3.5).  This result can however 
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possibly be attributed to the difference in sample distribution between the MetS (n=44) and 
Non-MetS group (n=36), (Figure 3.1).  Although the MetS group predominantly had normal 
BMD, this group had more participants with a history of stress fractures (Figure 3.5).  This 
might be due to other contributing factors, but this was not clearly investigated in this study. 
4.5.2 Fasting insulin and BMD 
Not only does mechanical loading increase BMD, but hyperinsulinaemia may also increase 
bone formation.  Hyperinsulinaemia decreases SHBG levels, thereby increasing oestrogen 
bioavailability in obese females and oestrogen is known to increased bone formation (Kinjo, 
2007; Braun et al., 2011; Karsenty, 2012).  Insulin might also regulate bone growth via its 
interaction with the insulin receptors on osteoblasts to stimulate the proliferation of the 
osteoblasts (Reid, 2008).  The MetS group in the current study had elevated FI levels 
(35.9±6.9 mIU/L) (Table 3.2), but none of the bone-related markers differed significantly 
between these two groups, which might explain why there was no significant difference in 
BMD between the MetS and Non-MetS group.  Alternatively, hyperinsulinemic states can 
also stimulate increase androgen production, resulting in decreased synthesis of oestrogens 
(Nestler, 2000). 
4.5.3 Anti-hypertensive and cholesterol lowering medication use and BMD 
The use of certain medications might also alter BMD, and previous studies have reported 
that the use of anti-hypertensive medications (BB’s, diuretics and CCB’s) resulted in 
increased BMD (Ghosh & Majumbar, 2014; Hwang et al., 2015).  A total of 34.1% of the 
MetS participants compared to only 13.9% of the Non-MetS participants reported the use of 
anti-hypertensive medications (Appendix K).  This could potentially have contributed to the 
high percentage of normal BMD observed in both the MetS and Non-MetS groups in this 
study (Figure 3.5).  The use of cholesterol-lowering agents have also been reported to 
increase BMD (Chuengsamarn et al., 2010; Jeong et al., 2014); however, only a limited 
number of participants in both the MetS and Non-MetS groups reported on its use (MetS: 
4.5%; Non-MetS: 5.6%) (Appendix K).  
4.5.4 Physical activity, smoking, alcohol and contraceptive use 
Other confounding factors affecting bone health include physical inactivity, smoking, and 
alcohol consumption (Tamaki et al., 2010; Bolton et al., 2012; Marrone et al., 2012).  
Interestingly, for all the measures of physical activity (work, sport and recreational activities, 
and travelling), the MetS groups appeared to be more physically active than their Non-MetS 
counterparts (Figure 3.10 & 11).  The majority of the participants in the MetS group also 
never smoked before (52.3%) (Figure 3.7), and were not heavy alcohol consumers (8.8%) 
(Figure 3.8).  Smoking has been shown to negatively affect bone health (Shabab, 2012; Ayo-
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Yusuf & Olutoa, 2014), as have heavy alcohol consumption (Kruger et al., 2011; Marrone et 
al., 2012).  However, considering that all confounding factors mentioned here were less 
pronounced in the MetS compared to the Non-MetS group, these factors could have blunted 
the MetS’ effect, as well as that of the individual risk factors on the bone health status, and 
therefore contributed to the high prevalence of normal BMD observed in the MetS group.   
The use of contraceptives, which have been linked to improved bone health (Elkazaz & 
Salama, 2015; Scholes et al., 2011), was also more prevalent in the MetS group (Figure 
3.9).  Although the effect of an increased physical activity status, lower number of smokers, 
less heavy alcohol consumption and increased contraceptive use in the MetS group could 
indicate increased bone health status, no differences were observed between the MetS and 
Non-MetS groups in any of the measures of bone health.  Apart from the negative effect of 
the MetS itself on BMD, a possible reason for this might include the fact that no differences 
were observed in any of the bone markers, as well as no difference in E2 between these two 
groups (Table 3.2).  Although oestrogen is known to decrease osteoclast formation and 
activity and increase osteoclast apoptosis via decreasing the production of cytokines (for 
example IL-1, IL-6 and TNF-α) that will ultimately increase BMD, its role in the regulation of 
osteoblast is less clear (Karsenty, 2012).   
4.5.5 Vitamin D 
Vitamin D deficiency is detrimental to bone health (Pérez-Lopez et al., 2011; Cauley et al., 
2015) and was present in both the MetS and Non-MetS groups.  Brenner et al. (2011), Baker 
et al. (2012) and Barchetta et al. (2013) reported an association between low 25(OH)D 
levels and the occurrence of the MetS.  In obese individuals, sequestering of 25(OH)D may 
decrease the bioavailability of this vitamin (Wortsman et al., 2000), which can account for the 
vitamin D deficiency in the current study.   
In contrast to this, several studies reported no association between 25(OH)D levels and the 
prevalence of the MetS (Kim et al., 2012; George et al., 2013; Chon et al., 2014; Gradillas-
García et al., 2015).  Navarro et al. (2013) also reported similar results, with no association 
noticeable between vitamin D, PTH and the MetS.  The differences in results obtained from 
these studies may be due to differences in ethnicity, the levels of obesity, BMI and WC in 
these populations, as well as the levels of vitamin D used to classify an individual with 
vitamin D deficiency.   
4.6 Menopausal distribution of study population 
The menopausal transition is accompanied by a variety of physiological changes, the most 
common being the changes in body fat distribution and hormonal imbalances (Sowers et al., 
2007; Al-Safi & Polotsky, 2015; Sapkota et al., 2015).  In the current study, a significant 
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decrease in E2 was observed in the PostM group compared to the PreM group (168.5±46.7 
pmol/L vs. 299.3±36.4 pmol/L; p<0.05) (Table 3.3), which is not unexpected since less 
oestrogen is secreted during menopause.  In PreM women, fat deposition occurs in the 
gluteo-femoral region due to oestrogen secretion, whereas the loss of ovarian oestrogen 
secretion during menopause is associated with increased abdominal fat deposition (Carr, 
2003; Goyal et al., 2013).  The current study failed to show any significant differences in BMI 
and WC between the PreM and PostM groups to suggest increased abdominal fat in PostM 
women; however, a trend towards significance was noted for the W:H (p=0.063).  This 
difference might have been significant if the samples size was larger, or if the distribution 
between PreM and PostM was more equal, since n=57 participants were included in the 
PreM group and only n=23 in the PostM group (Table 3.3). 
Increased abdominal fat is usually associated with a higher risk of diabetes, 
hypertriglyceridemia, small dense LDL particles, hypertension and CVD (Carr, 2003; Goyal 
et al., 2013).  A study by Bade et al., (2014) reported increases in TC, TG, LDL-c and a 
decrease in HDL-c levels between PreM and PostM women, independent of BMI, but stated 
that these differences was possibly due to hormonal differences.  Although the current study 
indicated hormonal differences between PreM and PostM women (mentioned above), none 
of the other makers except for SBP differed significantly between the PreM and PostM 
groups.  This can possibly be explained by the lack of significant differences in any of the 
measures of obesity (BMI, WC & W:H) between these two groups (Figure 3.14 & 3.15; Table 
3.3).  In agreement, a study by Sapkota et al. (2015) also found SBP, but not BDP, to differ 
between PreM and PostM females, and further reported that the decline in the oestrogen: 
androgen ratio dilutes the vasorelaxant effects of oestrogens on endothelium.  This 
promotes the production of vasoconstrictive factors such as endothelin that ultimately 
increases BP (Sapkota et al., 2015).   
4.7 Bone health and menopausal status 
The menopausal transition is associated with a decrease in BMD (Al-Safi & Polotsky, 2015; 
AlDughaither et al., 2015).  Parathyroid hormone and the primary female sex hormone, E2, 
both play crucial roles in bone health and are the most important predictors of BMD after 
menopause (Lu et al., 2009; Karsenty, 2012; Starup-Linde, 2013; Taie & Rasheed, 2014).  
Parathyroid hormone was significantly higher in the PostM group than in the PreM group 
(4.5±0.5 pg/mL vs. 3.3±0.2 pg/mL; p<0.001) (Table 3.3), which is comparable to evidence 
reported by Ardawi et al. (2011).  Here, it is suggested that PTH levels increase with age 
(Van Ballegooijen et al., 2014), and since the females in the PostM group were significantly 
older, it could explain the increase in PTH.  Studies have also reported increased PTH levels 
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in hypertensive participants (Garcia et al., 2013; Yagi et al., 2014), which might also have 
contributed here, since the PostM group was indeed hypertensive (Table 3.3).  Calcium is 
known to influence PTH levels, with PostM women usually presenting with low circulating 
Ca2+ levels due to decreased intestinal Ca2+ absorption that will stimulate increased 
secretion of PTH (Nordin et al., 2004; Drake et al., 2015).  Calcium concentrations were 
however not assessed in this study population to support these statements. 
Sowers et al. (2006) reported that the annual E2 concentration of women in the menopausal 
transition was not predictive of BMD loss; however, if E2 levels were below 128.5 pmol/L, it 
might be associated with BMD loss.  Considering that both the PreM and PostM groups in 
the current study population had higher E2 levels than mentioned above (299.3±36.4 pmol/L, 
and 168.5±46.7 pmol/L respectively, Table 3.3), it suggests overall normal bone health 
status, as observed here.  In contrast to the observation by Sowers et al. (2006), studies 
have reported that oestrogens influence BMD via inhibition of osteoclasts and promotion of 
apoptosis (Karsenty, 2012; Taie & Rasheed, 2014; Biason et al., 2015).  Since oestradiol 
was significantly lower in the PostM group (168.5±46.7 pmol/L vs. 299.3±36.4 pmol/L; 
p<0.05), it may suggest that the inhibiting effect of oestradiol on osteoclasts will be 
diminished, allowing osteoclast survival and increased bone resorption, which was not 
evident in the current study.  Here, more women in the PostM group had normal BMD 
(87.0%) than in the PreM group (75.4%) (Figure 3.12), an observation which is more in line 
with the results reported by Sowers et al. (2006). However, these results still warrant further 
investigation since other risk factors are also known to affect BMD. 
Studies have shown that during menopause, increased levels of ALP are also evident due to 
increased bone turnover (Menezes et al., 2015; Mukaiyama et al., 2015).  In agreement, 
Bhattarai et al. (2015), reported ALP levels to be significantly lower in PreM women 
(82.4±78.5 U/L) compared to PostM women (111.9±66.6 U/L; p=0.046).  Although the 
current study indicated no significant difference in ALP between the PreM (75.9±4.2 U/L) 
and PostM groups (90.1±4.9 U/L), a trend was noted (p=0.056) (Table 3.3), which would 
probably have been significant if the sample sizes were larger, and would therefore be able 
to corroborate the findings of Bhattarai et al. (2015).  Furthermore, Menezes et al. (2015) 
reported higher levels of ALP in PostM women who had fractures, than those who did not 
have any fractures.  Despite the aforementioned fact, fractures and stress fractures were 
more prevalent in the PreM group than the PostM group of the current study population 
(Appendix L), which could have contributed to the lack of a significant difference in ALP 
between these two groups. 
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The BMD data (Table 3.3) indicated a significant difference in only the Z-score between the 
PreM (0.1±0.2) and the PostM group (0.9±0.2; p<0.05).  Since this is an age-matched 
measure of BMD, the Z-score is not considered useful to detect low BMD and osteoporosis 
(National Osteoporosis Foundation, 2015).  However, it is rather thought to be indicative of 
other conditions instead, such as hyperparathyroidism or diabetes affecting BMD (NIH, 
2012; National Osteoporosis Foundation, 2015).  Thus, considering that PTH was indeed 
higher in the PostM females (4.5±0.5 pg/mL) than the PreM females (3.3±0.2 pg/mL; 
p<0.001) (Table 3.3), it could suggest that the increased levels thereof might have affected 
BMD.   
In the current study population, 75.4% of PreM woman had normal BMD, whereas Mishra et 
al. (2015) and Silva et al. (2015) reported that lower percentages (12.5% and 71.0%) of 
PreM women had normal BMD (Figure 3.12).  In the PostM group, 87.0% of the current 
study population had normal BMD in comparison to the findings by Mishra et al. (2015) and 
Silva et al. (2015), which reported 0.0% and 29.0% respectively.  Although we did not 
observe any of the PostM women to have osteoporosis, Mishra et al. (2015) and Silva et al. 
(2015) reported that 80.0% and 92.5% of their PostM women respectively, were classified as 
osteoporotic.  It is important to note that neither of the compared studies investigated 
physical activity levels in their study participants, whereas the current study indicated that 
PostM women were more physically active than the PreM group (Appendix L).  This could 
have possibly contributed to the high percentage of normal BMD in the PostM group of the 
current study.  In addition, the small number of study participants in the PostM group might 
have contributed to the different results (n=23).   
Differences in smoking habits (Kruger et al., 2011; Øyen et al., 2014, Ayo-Yusuf & Otula, 
2014) and alcohol consumption (Kruger et al., 2011; Maurel et al., 2012; Marrone et al., 
2012; Sritara et al., 2015) might also help explain the differences in bone health between the 
PreM and PostM groups.  For example, a total of 26.3% of the PreM women indicated that 
they were current smokers, whereas more females in the PostM group were current smokers 
(39.1%) (Appendix L).  In the current study, more PreM women were current (63.2%) and 
heavy alcohol consumers (12.3%) compared to the women in the PostM group (current: 
43.5%; heavy: 0.0%) (Appendix L).  Therefore, the 63.2% of the PreM women who were 
current alcohol consumers might put them at a lower risk of having osteopenia or 
osteoporosis.  Despite these differences in alcohol consumption between the PreM and 
PostM women, more of the PreM group’ women had osteopenia (21.1% vs. 13.0%) and 
osteoporosis (3.5% vs. none) and less of them had normal BMD (75.4% vs. 87.0%) (Figure 
3.12).   
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The use of certain medications might also affect the status of BMD in the PreM and PostM 
groups, since almost half (47.8%) of the PostM women were on anti-hypertensive treatment 
(Appendix L) compared to 15.8% of PreM women.  The use of cholesterol-lowering agents 
was also more common in the PostM (8.7%) than in the PreM group (3.5%).  Both these 
medications are known to increase BMD (Chuengsamarn et al., 2010; Ghosh & Majumbar, 
2014; Jeong et al., 2014; Hwang et al., 2015), which could account for the BMD results 
observed in the PostM group.  
Although menopausal status can play a significant role in the overall health and bone health 
of individuals, one should consider the fact that the MetS and its individuals risk factors, in 
combination with menopausal status, might also be important to consider. 
4.8 Metabolic syndrome and menopausal status 
The changing metabolic status and fat pattern distribution that accompanies the menopausal 
transition is one of the theories which might explain the increased prevalence of the MetS in 
PostM women (Carr, 2003; Goyal et al., 2013; Seif et al., 2015).  In agreement, the current 
study also found that more PostM women were classified with the MetS (n=15) compared to 
their Non-MetS (n=8) counterparts (Figure 3.13).  Figueiredo-Neto et al. (2010) reported that 
the increased prevalence of the MetS in PostM women was due to age.  Although it is not 
unexpected for PostM women to be older than PreM women, as seen in the current study 
(Table 3.3), no significant age differences were observed between the PostM MetS and Non-
MetS groups (Figure 3.14A).  This might possibly be due to the smaller number of PostM 
participants, since only 28.8% of the study participants were classified as being PostM 
(Table 3.3).   
4.8.1 Neither metabolic nor menopausal status had an effect on BMD  
Studies have shown that the presence of the MetS, as well as menopause, both affect BMD 
(Jeon et al., 2011; Nóbrega da Silva et al., 2014; Al-Safi & Polotsky, 2015).  None of the 
BMD measures yielded any significant differences between any of the sub-groups in the 
current study (Figure 3.18).  Since none of these markers differed significantly when the 
MetS and Non-MetS groups were compared (Table 3.2), or when the PreM and PostM 
groups were compared (except for the Z-score, Table 3.3), the division of the PreM group 
into two separate PreM age groups could potentially further have contributed to the “no 
effect” observed.  Furthermore, none of the bone-specific markers (PTH & ALP) differed 
significantly between any of the subgroups (Figure 3.17).  In addition, the primary female sex 
hormone E2, also did not differ significantly between any of the subgroups (Figure 3.17A & 
B).  Since none of these aforementioned biochemical markers differed significantly between 
the Mets and Non-MetS groups, while differences were observed in all three between the 
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PreM and PostM groups, the same explanation as that used for BMD could be used here.  
Furthermore, five of the six sub-groups had a BMI higher than 25 kg/m2 with only a 
significant difference between the PreM (20-39 years) MetS and Non-MetS groups (Figure 
3.14).  This could have further contributed to the lack of significant differences in ALP and E2 
(Figure 3.17B & C), since obesity is known to alter both E2 and ALP concentrations (Green et 
al., 2012; Jones et al., 2013; Pradhan, 2014; Lowe et al., 2011). 
When using BMI as a measure of obesity, the association between BMD and BM can be 
validated by the increased AT, which results in increased conversion of androgens to 
oestrogens (Green et al., 2012; Jones et al., 2013).  Since the current study only revealed 
significant differences in BM and BMI between the PreM (20-39 years) MetS and Non-MetS 
groups, without differences in E2 levels, we tried to explain our results by correlating BM, 
BMI and E2 in the different subgroups.  In the current study, when BM and BMI were 
correlated with E2, a strong and significant association was only observed in the PreM (20-
39 years) MetS group (Figure 3.19A & B), which suggests that the increased BM and BMI, 
increased the oestrogen concentration.  Furthermore, studies by Puntus et al. (2011) and 
Bredella et al. (2011) on PreM women (25-59 years old) and PostM women (40-72 years 
old), and obese PreM women (18-45 years old) respectively, reported no association 
between BMI and E2.  Ali & Al-Zaidi (2011) reported an inverse (negative) association 
between serum E2 levels and BMI in PreM diabetic women (20-45 years old, mean 29.7±4.3 
years).  The inconsistent results found by the different studies, might be due to the presence 
or absence of the MetS in the respective groups, since none of the studies used to 
corroborate or disprove our findings, considered the MetS. 
When investigating the factors affecting BMD in a PostM study populations, Gourlay et al. 
(2014) noted that BM is the most important modifiable determinant of BMD in younger PostM 
(<65 years) women, since it determines the rate of bone loss during the menopausal 
transition (Finkelstein et al., 2008).  In PostM women, AT is the primary source of oestrogens 
and therefore an increased BMI will result in increased levels of oestrogen, via the increased 
conversion of androgens to oestrogens in (Braun et al., 2011; Migliaccio et al., 2011; Chan 
et al., 2014).  Al safi & Polotsky (2015) and Randolph et al. (2011) further explained that 
differences in E2 levels across the menopausal transitions was less pronounced in obese 
compared to non-obese women.  This change in the source of E2 across the menopausal 
transition provides obese PostM women with a non-ovarian reservoir of oestrogen, which is 
not the case in normal weight women, which may blunt the increase in E2, and diminish 
ovarian oestrogen loss with menopause (Randolph et al., 2011).  However, in the current 
study the correlations between BM and E2, and BMI and E2 in the PostM group were 
insignificant in both the MetS and Non-MetS groups, suggesting that in the PostM groups of 
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the current study, BM and BMI may not have influenced the E2 concentrations.  This can 
possibly be due to all participants being obese, since Al safi & Polotsky (2015) and Randolph 
et al. (2011) found that changes in E2 levels are less pronounced in obese women.  In the 
PostM Non-MetS group, a negative but insignificant correlation was noted between both BM 
and BMI with E2 (Figure 3.19E & F).  This can be explained by Jones et al. (2013) who 
reported that in PostM women, a decreased BMI would result in a decrease in oestrogen 
levels.  
4.8.2 Correlation analysis between BMD, BMI and SOS 
Further analyses were conducted to investigate the associations between BMD, BMI and 
SOS.  Strong positive associations were noted in the PreM (20-39 years) MetS groups 
(Figure 3.20A & B), suggesting that as BM and BMI increase, SOS increases, which 
indicates denser bone tissue or increased BMD.  The presence of obesity might increase 
BMD via the increased mechanical loading (Kruger et al., 2011; Xue et al., 2012; El 
Maghraoui et al., 2014).  However, Steinschneider et al. (2003) and Beerhorst et al. (2013) 
explained that SOS travels slower through soft tissue, therefore, increased AT around the 
site of measurements will result in a higher SOS and is not necessarily indicative of 
increased BMD.  The use of the SOS might therefore not be that predictive of increased 
BMD in overweight individuals, as reported in all of the groups except the PreM (20-39 
years) Non-MetS group in the current study that had a BMI below 25 kg/m2 indicating normal 
weight.  In the aforementioned group, there was no correlation between BM and SOS, and 
BMI and SOS (Figure 3.20A & B), possibly due to the normal weight of this group.  
Bullo et al. (2011) reported that BM was the strongest predictor of BMD, which is in 
agreement with the strong and very strong, significant associations that were noted in the 
PreM (≥40 years) MetS and Non-MetS groups between BM and SOS, respectively (Figure 
3.20C & D).  Another study reported that the relationship between BMD and BM was 
stronger than the relationship between BMD and BMI (Salamat et al., 2013).  This may help 
explain why BMI and SOS correlated strongly and significantly in only the Non-MetS, PreM 
(≥40 years) group, and in both MetS and Non-MetS groups between BM and SOS in this 
age group (Figure 3.20C & D).   
Furthermore, studies in PostM women reported significant, positive correlations between 
BM, BMI, and SOS (Brunner et al., 2011; Sun et al., 2014; Sohl et al., 2015).  Although 
positive correlations were also noted in the PostM groups of the current study, all 
correlations were weak and moderate (Figure 3.20E & F).  Here, the effect of ageing and the 
accompanying decrease in height (also noted in the current study) might alter BMI, and 
might be responsible for the results (Canning et al., 2013).  In a study by Yoldemir & Erenus 
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(2012), a similar BMD in PostM MetS and Non-MetS women was reported, and it was 
proposed that the MetS had no effect on BMD in the PostM years.  Some studies even 
suggest that obesity could be considered a protective factor against excessive bone loss 
during ageing (Zillikens et al., 2010; Jeon et al., 2011; Chantler et al., 2012; Alissa et al., 
2014). 
Although the findings of the current study are similar to those previously reported, these 
results raise the question of whether BM and/or BMI really affect BMD in a positive way.  It 
was suggested by Brunner et al. (2011) that the changes in SOS was mainly due to age.  
Migliacco et al. (2011) made an important statement suggesting that when using BMI as a 
measure of obesity, it appears to act as a protective factor in bone health.  In contrast, when 
increased WC (central obesity) is used to define obesity, it is regarded as a risk factor for 
bone loss due to the secretion of inflammatory cytokines (Migliacco et al., 2011).  Thus, care 
should be taken when interpreting results using either BMI or WC.  
4.8.3 Differences in anthropometric and metabolic parameters restricted to 
the PreM group 
4.8.3.1 Measures of obesity 
When investigating both metabolic and menopausal status in the separate PreM (20-39 
years), PreM (≥40 years) and PostM groups, several observations were made.  The PreM 
(20-39 years) MetS group showed increased BM and BMI compared to their Non-MetS 
counterparts (Figure 3.14C & D), possibly due to the PreM (20-39 years) Non-MetS group 
being the only group with a BMI below 25kg/m2, indicating a normal BMI.  Jeon et al. (2011) 
also found significant differences between the BMI of the PreM MetS and Non-MetS women, 
but their study population were slightly older (PreM MetS: 49.3±8.5; PreM Non-MetS: 
55.4±8.3), compared to this study’s PreM (20-39 years) group.  The findings by Jeon et al. 
(2011) could be more comparable to the PreM (≥40 years) group of the current study; 
however, no significant difference was noted between the MetS and Non-MetS individuals in 
this age group.   
The timing of the age of menopause depends on several factors, such as smoking and BMI 
(AlDughaither et al., 2015); however, only 26.3% of the PreM participants were current 
smokers, but more of them have never smoked before (54.4%) (Figure L.4), and the BMI 
also did not differ significantly between the PreM and PostM groups (Table 3.3).  Al-Safi & 
Polotsky (2015) stated that women undergo physiological changes associated with 
menopause in the three to five years prior to the final menstrual period.  According to this 
statement by Al-Safi & Polotsky (2015), participants in the PreM (≥40 years) group in the 
current study, might already be experiencing some age-related metabolic changes, although 
this was not evident here, except for the difference in WC and HDL-c.   
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Waist circumference, which is a better predictor of fat deposition in the abdominal 
extremities, was significantly different between both the PreM MetS and Non-MetS groups 
(Figure 3.15A).  In individuals with the MetS, increased WC is usually accompanied by lipid 
abnormalities and in addition, the presence of menopause also results in changes in lipid 
metabolism (Derby et al., 2009; Bodea & Popa, 2015).   
4.8.3.2 Lipid abnormalities 
In the current study only HDL-c differed significantly between the MetS and Non-MetS 
groups of both PreM age groups (Figure 3.15B), whereas the other two markers indicating 
dyslipidaemia measured here, TG and LDL-c, did not differ significantly between any of the 
groups (Figure 3.15F & 3.16B).   
Although increased LDL-c is not one of the MetS-associated risk factors, increased levels 
thereof are commonly reported in individuals with increased abdominal AT (Han & Lean, 
2014) as noted in all the groups except the PreM (20-39 years) Non-MetS group (Figure 
3.15A).  Han & Lean (2014) explained that although elevated LDL-c is common in individuals 
with increased abdominal fat, it is mainly related to saturated fat consumption and not as 
strongly to weight gain and obesity, although these factors were not investigated in this 
study.  Even though TG’s concentrations did not differ significantly between any groups, the 
increased levels thereof in the MetS groups might be due to increased hepatic production of 
TG’s due to hyperglycaemia as reported by Miranda et al. (2005).  Furthermore, insulin 
levels also affect the synthesis of TG’s (Bodea & Popa, 2015). 
4.8.3.3 Glucose and insulin 
Although insulin concentrations were elevated in five of the six groups (Figure 3.16A), only 
two of the six subgroups presented with increased FG concentrations (>5.6 mmol/L; Figure 
3.15E).  However, no significant differences were noted between any of the subgroups for 
FG and FI in the current study (Figure 3.15E & 3.16A).  The fact that this study population 
were largely obese and overweight, might be one of the major contributors to elevated 
insulin concentrations via increased production of lipoproteins by the liver and the inability of 
the AT to store this excess lipoproteins (Han & Lean, 2014; Bodea & Popa, 2015). 
4.8.3.4 Blood pressure 
During ageing, there is a natural increase in BP, mostly due to changes in arterial stiffness 
and increased peripheral vascular resistance, and the radical decrease in oestrogen levels 
during menopause is also suggested to contribute to alternations in the control of BP (Pinto, 
2006; Cannoletta & Cagnacci, 2014).  A study by Mungreiphy et al. (2011) also reported that 
increased BP was associated with increased age, and also that a higher BMI was associated 
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with increases in both SBP and DBP.  Although clear age groups were set aside for the 
study, it was expected that BP would increase with increased age; however, since none of 
the sub-groups’ ages differed significantly (Figure 3.14A), the significant difference in both 
SBP and DBP between the MetS and Non-MetS PreM (20-39 years) group (Figure 3.15C & 
D) could be explained by the significant differences in BMI observed here (Figure 3.14D).   
According to the abovementioned statement by Mungreiphy et al. (2011) it is expected that 
BP will not differ between the MetS and Non-MetS groups in the older participants of the 
current study, since no difference in age was observed.  Canning et al. (2013) also explained 
that the increase in abdominal tissue is not entirely captured by BMI and may explain why 
there is a weakened association between BMI and health complications with age, since the 
age-related losses in height will also increase the BMI.  The higher WC present in the MetS 
PreM (20-39 years) group (Figure 3.15A) might be partially responsible for the significant 
differences in the BP (Figure 3.15C & D) since an increased WC was previously suggested 
to contribute to the development of hypertension via the secretion of adipokines and 
alterations in lipid levels (Bodea & Popa, 2015).  
4.9 Further investigation: Significant correlations between ALP 
and FI, FG and TG limited to the PreM (≥40 years) group 
To further investigate the relationship between some of the metabolic markers and bone 
health markers, correlation analyses were performed between FI, FG, TG and ALP.  In 
addition to being a marker of bone formation, a study by Webber et al. (2010) reported that 
ALP is an indicator of cardiometabolic risk and ALP was also previously classified as a 
marker of visceral adiposity (Lowe et al., 2011).  Furthermore, Krishnamurthy et al. (2011) 
reported associations between ALP and the increased prevalence of the MetS.   
Although inconsistent results regarding these parameters have been published, correlation 
analysis of the current study yielded interesting results.  Significant associations were limited 
to the PreM (≥40 years) group (Figure 3.21D, E & F) and this might be due to significant 
differences in the WC and HDL-c levels between the MetS and Non-MetS groups in this age 
group.  Studies reported that abdominal obesity is correlated with changes in lipid levels 
(increased TG’s, LDL-c and decreased HDL-c) and that increased WC is commonly 
associated with IR due to increased visceral AT (Robinsin et al., 2013; Taverne et al., 2013; 
Bodea & Popa, 2015).   
4.9.1 Alkaline phosphatase and TG 
Serum ALP levels are known to be higher in obese individuals and may play a role in the 
process of adipogenesis (Ali et al., 2015).  In agreement, a very strong correlation was noted 
between TG’s and ALP in the PreM (≥40 years) MetS group (r=0.82, p=0.00) (Figure 3.21F), 
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which was classified as an obese group.  The hypothesis by Kim et al. (2013b) that 
intracellular lipid accumulation and ALP activity increase simultaneously during 
adipogenesis, might explain this result in the current study.  This is in agreement with what 
Krishnamurhty et al. (2011) reported, where the levels of TG increased with increased ALP 
levels.  Hernández-Mosqueria et al. (2015) hypothesised that changes in the activity of ALP 
might correlate with changes in lipid metabolism.  However, in the Non-MetS groups of the 
current study, no significant associations were noted between TG and ALP (Figure 3.21C, F 
& I), whereas Webber et al. (2010) and Kim et al. (2013b) reported positive, but weak 
correlation between ALP and TG (r=0.17, p<0.001 and r=0.068, p<0.001 respectively).   
4.9.2 Alkaline phosphatase, FI and FG 
Krishnamurthy et al. (2011) reported that the levels of both FG and FI increased with 
increasing levels of ALP.  It is hypothesised that ALP present in adipocytes might regulate 
systemic signalling, related to glucose metabolism and insulin sensitivity, via adipokine 
synthesis and secretion (Hernández-Mosqueria et al., 2015).  In agreement with this 
hypothesis, a very strong and significant positive association was noted between FI and 
ALP, but only in the PreM (≥40 years) Non-MetS group (Figure 3.21D).  Contrasting results 
have also been published, where Kim et al. (2013b) correlated HOMA-IR and ALP and found 
a weak, but significant association between these two parameters (r=0.045, p<0.0001).   
Furthermore, when correlating FG and ALP, a study by Webber et al. (2010) and Kim et al. 
(2013) reported a weak positive correlation between ALP and FG in Non-MetS females and 
a mixed gender population, irrespective of MetS status, respectively (r=0.14, p<0.001 and 
r=0.039, p<0.001 respectively).  Cheung et al. (2013) reported no association between FG 
and BAP.  The current study however found a very strong correlation between FG and ALP 
in the PreM participants (≥40 years) with the MetS (r=0.89, p=0.00) (Figure 3.21E).  
Although the abovementioned studies correlating FG and ALP, investigated the MetS, none 
of these studies except for Webber et al. (2010) performed their correlation analysis in the 
specific MetS and Non-MetS groups (Webber et al., 2010; Kim et al., 2013b, Cheung et al., 
2013), which complicates comparison between different studies. 
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5.1  Introduction 
The final chapter of this thesis summarise the major findings, highlight study limitations and 
provide future recommendations. 
5.2  Major findings 
One of the major findings of this study was the relatively high prevalence of the MetS 
(55.0%), which was higher than that reported in previous South African studies.  The 
prevalence of the different MetS risk factors was similar to that noted by other researchers, 
with increased BP being the most prevalent, followed closely by increased WC and low HDL-
c levels. Although this specific combination was also evident when the sample population 
was divided into the MetS and Non-MetS groups, the order in which the risk factors where 
ranked differed. When comparing the ages of the MetS and Non-MetS groups, no significant 
difference was evident, although literature suggests that participants with the MetS are 
normally older (Hernández et al., 2011; El Maghraoui et al., 2014).  Body mass, BMI, SBP 
and DBP differed significantly between the MetS and Non-MetS groups, but only for the 
PreM (20-39 years) age group, whereas WC and HDL-c differed in both PreM age groups.  
Furthermore, previous studies suggested an increased prevalence of the MetS in PostM 
women in comparison to PreM women (Carr, 2003; Goyal et al., 2013; Seif et al., 2015), 
which was could not be confirmed in the current study population.   
Another major finding was that, irrespective of metabolic and menopausal status, the 
majority of the participants in the current study displayed normal BMD.  Although the 
presence of the MetS seems to be protective against bone loss, this is possibly as a result of 
the increased BMI noted in five of the six subgroups, which resulted in increased mechanical 
loading.  The MetS participants were generally more physically active, have never smoked 
before, whilst fewer of them were heavy alcohol consumers.  All of these factors could have 
contributed to a healthier bone status.  In addition, more of the MetS participants used 
contraceptives, which also increase BMD. 
The low 25(OH)D levels observed in the current study population might be due to the 
ethnicity of the study population, since similar results were found by studies using dark-
skinned participants (Gutiérrez et al., 2011; Van Ballegooijen et al., 2014).  Albeit so, the low 
25(OH)D observed here did not appear to result in low BMD.  The other markers related to 
BMD, PTH and ALP, also did not differ significantly between the MetS and Non-MetS 
groups; however, these two markers are rarely mentioned in the literature, possibly due to 
the fact that no association was evident between these parameters.  When menopausal 
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status was taken into consideration, the increased E2 levels in the PreM groups and 
decreased PTH levels in the PostM groups were in agreement with that found by other 
studies.  Some factors that might also have influenced BMD in the separate PreM and 
PostM groups include smoking status, alcohol consumption and medication use.  More of 
the PostM women were current smokers, whereas more of the PreM were heavy alcohol 
consumers.  Furthermore, both anti-hypertensive and cholesterol lowering treatment were 
more common in the PostM women, which are known to increase BMD.   
Although both BM and BMI were associated with E2, this correlation was only significant in 
the PreM (20-39 years) MetS group, possibly as a result of the increased abdominal fat 
(increased WC) causing increased conversion of androgens to oestrogens.  The correlations 
between BM, BMI, and SOS were significant and positive in only the PreM (20-39 years) 
group with the MetS and the PreM (≥40 years) Non-MetS group.  Interestingly, significant 
correlations between FI, FG and ALP were restricted to the PreM (≥40 years) groups.   
We are aware that some parameters yielded contradicting and inconclusive results, for 
example, the effect of BMI and WC on BMD, and the effect of menopausal stage or age on 
the prevalence of MetS.  This warrants further investigation in order to determine the exact 
mechanisms or effects of the MetS and menopausal status on BMD. 
5.3 Contributions 
This study is one of the first to investigate BMD and the MetS in a farm working community 
in the Western Cape.  The high prevalence of the MetS among these farm working women 
raises reason for concern and further investigation to improve the health of this community.  
Since no BMD database exists for the South African population, and the Sonost 3000 is not 
routinely used in a clinical setting to assess BMD, this study proved useful in starting such a 
database that can be used as a reference framework for future studies where the use of 
DEXA is not possible.   
5.4 Limitations and recommendations 
The use of a larger sample size will result in a more evenly distribution of participants 
between the different subgroups, and might allow stronger statistical power.  The MetS 
definition used in this study is not specific to the South African population, since ethnic-
specific WC cut-off values are non-existent for South Africans, irrespective of the 
suggestions made by some researchers (91.5 cm) (Crowther & Norris, 2012).  These 
suggested cut-off values need to be further studied as well as validated in a much larger 
sample to prove useful. 
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Since most of the information were gathered by means of questionnaires, it is possible that 
reporting bias could have influenced the results.  The researcher also assumed that all 
participants were truthful in their responses when interviewed.  It was unknown whether the 
women who used contraceptives, used it due to abnormal hormone profiles, but in the future, 
this should be included in the questionnaires.  A further limitation is that BMD was only 
measured using the dominant foot, and since differences in BMD can occur between the 
right and left foot (Mergler et al., 2010), it is suggested that both feet be measured in future 
studies.  Furthermore, no reference values exists for BMD measurements for people from 
African and Mixed ancestry decent. 
To complement our BMD data further, a more specific isoenzyme of ALP can be used, 
namely bone-specific ALP (BAP), since the ALP measured in the current study could 
possibly be from other sources including the liver or intestinal tissue.  It would also be 
beneficial to measure both a bone formation and bone resorption marker, rather than just a 
single bone formation marker.  For example, osteocalcin and CTx, used as reference bone 
resorption marker.  Furthermore, the measurement of free radicals and oxidative stress can 
help to contextualise the effects of smoking on BMD.   
Although nutritional assessments were initially included, the low response rate required us to 
excluded dietary data from statistical analysis.  These data might have been beneficial since 
the measurement of macro- and micronutrients can also impact on bone health.  Even 
though the physical activity questionnaire, the GPAQ were reported to be validated in the 
South African population, it is quite possible that there might be either an over, or under 
reporting (Bull et al., 2009).  In order to minimize this, it is suggested for future studies to 
validate physical activity against using a pedometer or accelerometer.   
Although the high prevalence of the MetS did not appear to negatively affect BMD, an 
exercise intervention could prove beneficial to lower the high rates of overweight and obesity 
and thus contribute to lower the prevalence of the MetS, and concurrently positively affect 
the general bone health of these women.  Although the use of a more sensitive vitamin D 
ELISA would be more beneficial, this was not true for this population, since dark-skinned 
people have low vitamin D concentrations (Sharp, 2011; Johnson, 2013).  
Another, and probably the most important limitation is the use of a cross-sectional study 
design, as it is difficult to determine cause and effect of the MetS, and menopausal status 
with respect to BMD.  The use of a longitudinal study design rather than a cross-sectional 
study design will allow the researcher to investigate changes over time and more accurate 
conclusions can be made.  Furthermore, with the use of a longitudinal study design, an 
exercise and/or supplementation intervention can be applied.  The very low levels of vitamin 
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D in this study population could also then be improved by a nutritional and/or a 
supplementation intervention. 
Collectively, this study provides evidence of the relatively high prevalence of the MetS in a 
female farmworker population.  Participants should be encouraged to maintain a healthier 
lifestyle, including a healthier diet and increased physical activity levels.  Although the study 
population had generally normal BMD, the very low levels of vitamin D must be further 
investigated and care must be taken to ensure proper supplementation with vitamin D.   
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APPENDIX B: Participant information and consent form 
 
PARTICIPANT INFORMATION LEAFLET AND CONSENT FORM 
 
 
 
Id Code:___________________ 
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APPENDIX C: Data collection sheet 
CANSA Study: Data Collection Sheet 
 
Gender MALE FEMALE 
Age  
Body Mass (kg)  
Blood Pressure (mmHg)  Heart Rate 
Height (m)  
BMI (kg/m2)  
Waist Circumference (cm)  
Hip Circumference (cm)  
SAD (cm)  
VAT   
Impedance (Ohms)  
Phase Angle   
SAT  
Impedance (Ohms)  
Phase Angle   
Body Shape 
 
 
 
 
 
 
Id Code:___________________ 
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APPENDIX D: PTH ELISA 
Human Parathyroid Hormone ELISA kit (BioVendor, RIS003R) 
Before the ELISA was performed, the plate layout was planned as indicated in the example, 
96-well plate below.  
 
The steps that were followed to perform this ELISA are listed below: 
Preparation of samples: 
 Samples were transferred from the -80°C to the -20°C bio-freezer one day prior to 
the analyses.  
 All samples were allowed to equilibrate at room temperature (22°C), and mixed by a 
vortex mixer prior to the assay procedure.  
Preparation of reagents: 
 The zero calibrator was reconstituted with three mL of distilled water, whereas all 
other calibrators, as well as the controls were reconstituted with one mL of distilled 
water.  
 The wash solution was prepared by adding one volume of wash solution (20x) to 19 
of distilled water.  
S1 S1 
S2 S2 
S3 S3 
S4 S4 
S5 S5 
S6 S6 
C1 C1 
C2 C2 
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Assay procedure:  
1. 50 µl of incubation buffer were added to all wells. 
2. The calibrators (standard one to six, S1-S6), controls (two, C1 and C2) and samples 
were then added in duplicate to the appropriate wells as indicated in the plate layout 
above (200 μL). 
3. The plate, with the aforementioned added contents, were allowed to incubate for two 
hours at room temperature (22 °C) on a horizontal shaker (The Belly Dancer, Stovall 
Life Science Incorporated, Greensboro NC USA) set at 700 ± 100 rpm.  
4. The liquid was aspirated from the wells and tapped on a paper towel to ensure that 
all contents were removed. 
5. The plate was then washed four times by adding 0.4 mL of wash solution to each 
well and aspirating the solution from the wells. 
6. 100 µl of anti-PTH-HRP was then added to each well. 
7. After this addition, the plate was incubated for another hour at room temperature on a 
horizontal shaker set at 700 ± 100 rpm.  
8. The liquid was aspirated from the wells, inverted and patted on absorbent paper to 
ensure that all contents were removed. 
9. Within 15 minutes from the last wash step, 100 μL of Chromogenic solution was 
added to all wells. 
10. The plate was incubated for 30 minutes at room temperature on a horizontal shaker 
set at 700 ± 100 rpm, this time avoiding direct sunlight. 
11. Lastly, 200 μL of Stop Solution was added to all wells. 
12. The absorbencies were read at 450 and 490 nm, within one hour after the stop 
solution was added with a Universal Microplate Reader (EL800). 
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APPENDIX E: Vitamin D ELISA 
Vitamin D ELISA kit (Elabscience, E-EL-0012) 
Before the ELISA was performed, the plate layout was planned as indicated in the example 
96-well plate below.  
 
The steps that were followed to perform this ELISA are listed below: 
Preparation of samples: 
 Samples were moved from the -80 °C to the -20 °C bio-freezer one day prior to the 
analyses.  
 Samples were kept at room temperature prior to the assay procedure. 
Preparation of reagents: 
 The wash buffer was made by diluting 30 mL of Concentrated (25X) Wash Buffer 
with 750 mL of distilled water.  
 The standard was prepared 15 minutes before the assay procedure. The Reference 
Standard was centrifuged at 10 000xg for one minute and reconstituted with one 
millilitre of Reference Standard and Sample Diluent. After standing for ten minutes, it 
was mixed thoroughly by turning it upside down several times and mixing with a 
S1 S1 
S2 S2 
S3 S3 
S4 S4 
S5 S5 
S6 S6 
S7 S7 
S8 S8 
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pipette. This produced a stock solution of 400 ng/mL, used to make serial dilutions to 
render the following concentrations: 200, 100, 50, 25, 12.5, 6.25 and 0 ng/mL.  
 The biotinylated detection Ab was made by using the Concentrated Biotinylated 
Detection Ab and Biotinylated Detection Ab Diluent. Similarly the HRP Conjugate 
was made by using the Concentrated HRP Conjugate and HRP Conjugate Diluent.   
Assay procedure:  
1. 50 μL of Standard, Blank or Sample was added to each well (in duplicate). The 
Blank well contained Reference Standard & Sample Diluent. Immediately 
thereafter, 50 μL of Biotinylated Detection Ab was also added to each well. The 
plate was covered with a Plate sealer and tapped to ensure thorough mixing, 
where after the plate was incubated for 45 minutes at 37 °C (Orbital Shaker 
Incubator, MRC). 
2. The contents was aspirated from the wells and washed three times with 350 μl of 
the Wash Buffer with the use of a multi-channel pipette. The solution was then 
removed by inverting the plate and patted on absorbent paper to ensure that all 
contents were removed. 
3. Next, 100 μL of HRP Conjugate working solution was added to each well, the 
plate covered with the plate sealer and incubated for 30 minutes at 37 °C (Orbital 
Shaker Incubator, MRC). 
4. The plate was then washed five times with the washing buffer as described in 
step 2.  
5. Then, 90 μL of the Substrate Solution was added, covered with a plate sealer and 
incubated for 15 minutes at 37 °C (Orbital Shaker Incubator, MRC). This step 
required protection from light. The reaction was followed and checked to see 
when colour gradients appeared in the standard wells, but this time was limited to 
30 minutes. 
6. Thereafter, 50 μL of the Stop solution was added to each well, which allowed for 
a colour change of blue to yellow.  
7. The optical density of each well was then read with a microplate reader at 450 
nm (EL800 Universal Microplate Reader). 
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APPENDIX F: Procedure for the measurement of BMD with the 
Sonost Osteosys 3000 
 
Pre-test procedure 
For quality control purposes the bone densitometer was calibrated each day. This 
was done by adding ultrasound gel to the calibrator and adding it to the heel bath in 
the same orientation as a participant’s heel in the bath. The surfaces of the coupling 
pad or probe were cleaned with alcohol between each participant.  
 
[To note: The ultrasound gel aids in the progression of the ultrasound wave between the 
probe and the participant’s heel, as illustrated in Figure G1: A, B.] 
   
Figure G: A: Cleaning of probes with alcohol and application of ultrasound gel, and B: Application of 
ultrasound gel to the ankle. 
Testing procedure 
1) The participants were asked to remove all footwear and socks.  
2) Alcohol pads (70% v/v) were used to clean both sides of the participant’s calcaneus 
bones, followed by the application of ultrasound gel (Figure G2: B, G2: A and B). [To 
note: It is important to apply enough gel, as well as to the correct area, since this 
allows for a proper reading – see Figure G2: A, B.]  
3) The participant was asked to place their foot between the probes, with their calf 
resting on the calf support. The heel, toes and calf of the individual had to be flat 
against the surface, as indicated in Figures G3: A and B. 
 
A B 
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Figure G2: A: Correct position to apply the ultrasound gel, B: incorrect position of the ultrasound gel. 
  
 
 
 
 
Figure G3: A: Placement of the foot between the two probes and B: Calf, heel and toes should be in 
contact with the surface. 
4) The participant’s body should also be correctly positioned, with the body and 
foot in line with one another. The incorrect and correct alignment is shown in 
Figure G4: A and B.  
 
Figure G4: The participant’s body and the OsteoSys should be in a straight line. A: Correct, B: Incorrect. 
A B 
A B 
A B 
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5) The year of birth, gender, ethnicity, foot support level, weight and height were 
recorded in the QUS machine, where after the scan was performed. 
6) After the scan was completed, a detailed on-screen result appeared, 
indicating the T-score, Z-score, bone quality index (BQI), speed of sound 
(SOS) and broadband ultrasound attenuation (BUA). This information was 
printed out and attached to the data collection sheets.  
 
An example of a detailed QUS report is shown in Figure G5, with A from a person 
with osteopenia and B from a person with a normal BMD.  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure G5: Example of an osteopenic (A) and normal (B) participant printout. 
 
 
 A  B 
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APPENDIX G: Demographic questionnaire 
    DEMOGRAPHIC QUESTIONNAIRE 
Study title: Cancer risk during urbanisation: metabolic syndrome and cancer  
Do you have a cell phone or land line? YES ___NO:___ 
If YES, can we call you on a specific nr?_________________ 
Participant Information 
Date of interview: Visit 1 Visit 2 Visit 3 
Household (Brick house, 
shack other dwelling) 
 
Total household 
income/week/month 
 
Total in household MALE FEMALE 
Children 0-6 yrs   
Children 7-12 yrs   
Children 13-18 yrs   
Adults 18-30   
Adults 31-45   
Adults 46-60   
Adults 61+   
LANGUAGE AND ACCULTURATION 
Home language of 
respondent 
Afrikaans Xhosa Zulu English Sotho Other 
 
Household head 
speaks 
Home language only 
Home language + 
Afr/Eng 
English/Afrikaans only 
Can you read and 
understand a 
newspaper in your 
home language 
easily, difficult or 
not at all? 
Easily 1 
 
With difficulty 2 
Not at all 3 
Can you read and 
understand a 
newspaper in the 
English language 
easily, difficult or 
not at all? 
Easily 1  
With difficulty 2 
Not at all 3 
NEAREST CLINIC/HOSPITAL 
Name of clinic/hospital Walk  
(minutes) 
Mode of transport 
Walk = 1 ; Taxi = 2 ; Own car = 3; Bicycle = 4 
   
   
 
 
Id Code:___________________ 
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FAMILY CANCER HISTORY 
Immediate family cancer diagnosis? Mother Father Brother Sister 
What type of cancer:  
When diagnosed  
Current status of 
cancer 
Newly 
diagnosed 
Living with 
cancer 
Remission Deceased 
Treatment Chemotherapy Radiotherapy Combination No treatment 
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APPENDIX H: GPAQ 
GPAQ 
 
Physical Activity 
Next I am going to ask you about the time you spend doing different types of physical activity in a typical week. Please 
answer these questions even if you do not consider yourself to be a physically active person.  
Think first about the time you spend doing work.  Think of work as the things that you have to do such as paid or 
unpaid work, study/training, household chores, harvesting food/crops, fishing or hunting for food, seeking employment. 
[Insert other examples if needed].  In answering the following questions 'vigorous-intensity activities' are activities that 
require hard physical effort and cause large increases in breathing or heart rate, 'moderate-intensity activities' are 
activities that require moderate physical effort and cause small increases in breathing or heart rate. 
Questions Response Code 
Activity at work 
1 Does your work involve vigorous-intensity activity 
that causes large increases in breathing or heart 
rate like [carrying or lifting heavy loads, digging or 
construction work] for at least 10 minutes 
continuously?  
[INSERT EXAMPLES]  (USE SHOWCARD) 
Yes 1 
P1 
No 2     If No, go to P 4 
2 In a typical week, on how many days do you do 
vigorous-intensity activities as part of your work? 
Number of days └─┘ 
P2 
3 How much time do you spend doing vigorous-
intensity activities at work on a typical day? 
Hours : minutes 
└─┴─┘: └─┴─┘ 
    hrs                mins 
P3  
(a-b) 
4 Does your work involve moderate-intensity activity 
that causes small increases in breathing or heart 
rate such as brisk walking [or carrying light loads] 
for at least 10 minutes continuously?  
[INSERT EXAMPLES]   (USE SHOWCARD) 
Yes 1 
P4 
No 2      If No, go to P 7 
5 In a typical week, on how many days do you do 
moderate-intensity activities as part of your work? 
Number of days 
└─┘ 
P5 
6 How much time do you spend doing moderate-
intensity activities at work on a typical day? 
Hours : minutes 
└─┴─┘: └─┴─┘ 
    hrs                mins 
P6  
(a-b) 
Travel to and from places 
 
Id Code: ___________________ 
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The next questions exclude the physical activities at work that you have already mentioned. 
Now I would like to ask you about the usual way you travel to and from places.  For example to work, for shopping, to 
market, to place of worship. [insert other examples if needed] 
7 Do you walk or use a bicycle (pedal cycle) for at 
least 10 minutes continuously to get to and from 
places? 
Yes 1 P7 
 No 2      If No, go to P 10 
8 In a typical week, on how many days do you walk or 
bicycle for at least 10 minutes continuously to get to 
and from places? 
Number of 
days └─┘ 
P8 
9 How much time do you spend walking or bicycling 
for travel on a typical day? Hours : 
minutes 
└─┴─┘: └─┴─┘ 
     hrs               mins 
P9  
(a-b) 
Recreational activities 
The next questions exclude the work and transport activities that you have already mentioned. 
Now I would like to ask you about sports, fitness and recreational activities (leisure), [insert relevant terms]. 
10 Do you do any vigorous-intensity sports, fitness or 
recreational (leisure) activities that cause large 
increases in breathing or heart rate like [running or 
football,] for at least 10 minutes continuously?  
[INSERT EXAMPLES]   (USE SHOWCARD) 
Yes   1  
P10 
 
No 2      If No, go  to P 13 
11 In a typical week, on how many days do you do 
vigorous-intensity sports, fitness or recreational 
(leisure) activities? 
Number of days 
└─┘ 
P11 
12 How much time do you spend doing vigorous-
intensity sports, fitness or recreational activities on a 
typical day? 
Hours : minutes 
└─┴─┘: └─┴─┘ 
    hrs                mins 
P12 
(a-b) 
13 Do you do any moderate-intensity sports, fitness or 
recreational (leisure) activities that causes a small 
increase in breathing or heart rate such as brisk 
walking,(cycling, swimming, volleyball)for at least 10 
minutes continuously? 
[INSERT EXAMPLES]   (USE SHOWCARD) 
Yes   1 
P13 
No 2      If No, go to P16 
14 In a typical week, on how many days do you do 
moderate-intensity sports, fitness or recreational 
(leisure) activities? 
Number of days 
└─┘ 
P14 
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15 How much time do you spend doing moderate-
intensity sports, fitness or recreational (leisure) 
activities on a typical day? 
Hours : minutes 
└─┴─┘: └─┴─┘ 
    hrs                mins 
P15 
(a-b) 
Sedentary behaviour 
The following question is about sitting or reclining at work, at home, getting to and from places, or with friends including 
time spent [sitting at a desk, sitting with friends, travelling in car, bus, train, reading, playing cards or watching 
television], but do not include time spent sleeping. 
[INSERT EXAMPLES]   (USE SHOWCARD) 
16 How much time do you usually spend sitting or 
reclining on a typical day? 
Hours : minutes 
└─┴─┘: └─┴─┘ 
    hrs                min s 
P16  
(a-b) 
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APPENDIX I: Bone health questionnaire 
BONE HEALTH QUESTIONNAIRE 
 
Project title: Cancer risk during urbanisation: metabolic syndrome and cancer 
IDENTIFICATION CODE: 
Date of interview:  
Interviewer:  
Health District Site: 
 
Pebbles 
(Villiera) 
Neethlingshoff Solms-Delta 
OWN BONE HISTORY 
Fracture/broken bone? 
 
Yes: No 
What bone & when? 
 
Bone: When: 
Stress fracture? 
 
Yes No 
What bone & when? 
 
Bone: When: 
Treatment for stress fracture? 
 
Immobilisation: Activity: 
Medications: Bone stimulator: 
Pain during activity: 
 
During activity After activity All the time 
Medication associated with 
osteoporosis: 
Anticoagulants (heparin) 
 
Anticonvulsants 
 
Cyclosporine A and tacrolimus 
 
Cancer chemotherapy drugs 
 
Glucocorticoids (and adrenocorticotrophic hormone [ACTH]) 
 
Gonadotropin-releasing hormone agonists 
 
Lithium 
 
Methotrexate 
 
Parenteral nutrition 
 
Thyroxine 
 
 
 
 
 
 
 
 
 
 
  
 
Id Code: ___________________ 
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MENSTRUAL HISTORY 
Age at first menstrual cycle (years):  
Menses start date:  
Menses end date:  
Regular monthly menstrual cycles: 
 
Yes No 
If no, how many days btw cycles:  
Number of cycles in last 12 months:  
Birth control or IUD: 
 
Birth control IUD 
How long: 
 
Irregular cycles in past: 
 
Yes No 
If yes, describe:  
Ever been pregnant: 
 
Yes No 
Number of live births:  
Breastfeeding time (years):  
Menopausal status:  
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DIET HISTORY 
Ever dieted: 
 
Yes No 
Anything you avoid eating: 
 
Yes: No 
Ever taken diet pills or laxatives: 
 
Yes No 
Ever made yourself vomit: 
 
Yes No 
Binge eating: 
 
Yes No 
Excessive exercise to lose weight: 
 
Yes No 
Weight fluctuations over last 5 yrs: 
 
Yes No 
Highest weight in last 5 yrs:  
Lowest weight in last 5 yrs:  
Average days food intake: 
 
Breakfast: 
Lunch: 
Dinner: 
Snacks: 
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MEDICAL HISTORY 
Celiac disease: 
 
Yes No 
Do you not tolerate or avoid certain 
foods: 
 
Yes: No 
Stomach or digestion problems: 
 
Yes No 
Thyroid problems: 
 
Yes No 
Kidney stones: 
 
Yes No 
Prescription medications: 
 
Yes: No 
Over the counter medications or 
vitamins or supplements, including 
pain medications: 
 
Yes: No 
Calcium and/or vitamin D pills or 
chews: 
 
Yes: No 
Which kind and how often: 
 
Type: How often: 
Osteopenia or osteoporosis: 
 
Yes: No 
Bone density test (DEXA): 
 
Yes No 
If yes, when:  
Smoker or heavy drinker: 
 
Yes: No 
If yes, how many and for how long: 
 
How many: How long: 
Amount of time exposed to sunlight:  
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FAMILY HISTORY (maternal, paternal or siblings) 
Osteoporosis: 
 
Yes: No 
Hip fracture: 
 
Yes: No 
Bone disease: 
 
Yes: No 
Kyphosis (round back/hunchback): 
 
Yes: No 
Kidney stones: 
 
Yes: No 
Parathyroid disease: 
 
Yes: No 
Eating disorder: 
 
Yes: No 
Ethnic background: 
 
 
TRAINING HISTORY 
Typical exercise routine including 
duration or distance of each activity 
per week: 
 
Rest days per week:  
How long have you had your current 
running shoes: 
 
Do you wear orthics/shoe inserts:  
How long have you had these:  
Ever had gait analysis: 
 
Yes No 
Do you experience more fatigue than 
normal: 
 
Yes No 
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APPENDIX J: Vitamin D concentrations in study population 
 
Since only a small number of participants (n=29) presented with detectable vitamin D 
concentrations, the vitamin D data could not be compared between the six respective 
groups. Therefore, vitamin D concentrations were only compared between the MetS and 
Non-MetS (Figure J1), and the PreM and PostM groups (Figure J2).   There was no 
significant difference between the MetS (0.70 pg/mL) and Non-MetS (0.84 pg/mL) groups 
(p=0.57). 
   
Figure J.1: Vitamin D concentrations in MetS vs. Non-MetS groups. 
When comparing the vitamin D levels of PreM and PostM women, no significant difference 
was noted between the PreM (0.65 pg/mL) and PostM (0.92 pg/mL) women (p=0.28).  
 
Figure J.2: Vitamin D concentrations in PreM vs. PostM groups. 
Stellenbosch University  https://scholar.sun.ac.za
 
 
155 
 
APPENDIX K: Additional information on menstrual history between 
the MetS and Non-MetS groups 
 
Table K.1: Basic menstrual, pregnancy and breastfeeding history in the MetS and Non-MetS groups. 
 Total (n=80) MetS (n=44) Non-MetS (n=36) 
Age of first menstrual cycle 
(years) 
14 14 14 
History of irregular cycles 28.8% (n=23) 27.3% (n=12) 30.6% (n=11) 
Regular monthly cycles 77.5% (n=62) 77.3% (n=34) 77.8% (n=28) 
Previous pregnancies 86.3% (n=69) 93.2% (n=41) 77.8% (n=28) 
Average time of 
breastfeeding (months) 
40.5 48.7 34.7 
 
Table K.2: The use of several types of medications in the MetS and Non-MetS groups. 
 MetS (n=44) Non-MetS (n=36) 
 Anti-hypertensive 34.1% (n=15) 13.9% (n=5) 
Blood glucose medications 13.6% (n=6) 0.0% (n=0) 
Cholesterol lowering agents 4.5% (n=2) 5.6% (n=2) 
Thyroid medications 4.5% (n=2) 11.1% (n=4) 
Anti-retroviral therapy 4.5% (n=2) 2.8% (n=1) 
Hormone replacement 
therapy 
2.3% (n=1) 0.0% (n=0) 
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APPENDIX L: Additional analyses in the PreM and PostM women 
 
Figure L.1: Percentage of participants with zero, one and two risk factors in the PreM (20-39 years), PreM 
(≥40 years) and PostM groups. 
 
Figure L.2: Classification of participant’s bone health in (A) the PreM group, (B) the PostM group. 
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Figure L.3: Prevalence of fractures and stress fractures in the PreM vs PostM groups. 
 
Figure L.4: Frequency of participants who were previous, current and non-smokers in (A) the PreM, (B) 
the PostM groups. 
 
 
Figure L.5: Frequency of participants who were previous, current, non-consumers and heavy consumers 
of alcohol in (A) the PreM, (B) the PostM participants. 
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Figure L.6: The frequency of previous, current and non-contraceptive users in (A) the total sample 
population, and (B) the PreM vs PostM groups. 
 
Figure L.7:  The number of participants engaging in vigorous- and moderate-intensity activities at work in 
PreM and PostM groups (A), and in sport or recreational physical activities in PreM and PostM groups 
(B). 
 
Figure L.8: The percentage of participants walking or riding a bicycle for more than ten minutes a day for 
travelling purposes in (A) the PreM group, and (B) the PostM group. 
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Table L.1: The use of several types of medications in the PreM and PostM groups. 
 PreM (n=57) PostM (n=23) 
 Anti-hypertensive 15.8% (n=9) 47.8% (n=11) 
Blood glucose medications 5.3% (n=3) 13.0% (n=3) 
Cholesterol lowering agents 3.5% (n=2) 8.7% (n=2) 
Thyroid medications 8.8% (n=5) 4.3% (n=1) 
Anti-retroviral therapy 3.5% (n=2) 4.3% (n=1) 
Hormone replacement 
therapy 
1.8% (n=1)  0.0% (n=0) 
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APPENDIX M: Additional correlation analysis 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure M.1: Correlation between age and body mass index in (A) PreM (20-39 years), (B) PreM (≥40 years) 
and (C) PostM groups. 
 
 
 
 
 
 
 
 
 
 
 
Figure M.2: Correlation between age and diastolic blood pressure in (A) the PreM (20-39 years), (B) the 
PreM (≥40 years), and (C) the PostM groups. 
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Figure M.3: Correlation between body mass and diastolic blood pressure in (A) the PreM (20-39 years), 
(B) the PreM (≥40 years), and (C) the PostM groups. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure M.4: Correlation between body mass index and diastolic blood pressure in (A) the PreM (20-39 
years), (B) the PreM (≥40 years), and (C) the PostM group. 
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Figure M.5: Correlation between fasting insulin and fasting glucose in (A) the PreM (20-39 years), (B) the 
PreM (≥40 years), and (C) the PostM groups. 
 
Stellenbosch University  https://scholar.sun.ac.za
